0001140361-21-037345.txt : 20211110 0001140361-21-037345.hdr.sgml : 20211110 20211110071609 ACCESSION NUMBER: 0001140361-21-037345 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 57 CONFORMED PERIOD OF REPORT: 20210930 FILED AS OF DATE: 20211110 DATE AS OF CHANGE: 20211110 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PDS Biotechnology Corp CENTRAL INDEX KEY: 0001472091 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 264231384 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-37568 FILM NUMBER: 211394385 BUSINESS ADDRESS: STREET 1: 25B VREELAND ROAD STREET 2: SUITE 300 CITY: FLORHAM PARK STATE: NJ ZIP: 07932 BUSINESS PHONE: 800-208-3343 MAIL ADDRESS: STREET 1: 25B VREELAND ROAD STREET 2: SUITE 300 CITY: FLORHAM PARK STATE: NJ ZIP: 07932 FORMER COMPANY: FORMER CONFORMED NAME: Edge Therapeutics, Inc. DATE OF NAME CHANGE: 20090911 10-Q 1 brhc10030652_10q.htm 10-Q

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

(Mark One)


QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2021


 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____________ to _____________

Commission file number 001-37568

 
PDS Biotechnology Corporation
 
 
(Exact name of registrant as specified in its charter)
 

Delaware
 
26-4231384
(State or other jurisdiction of incorporation or organization)
 
(IRS Employer Identification No.)

 
25B Vreeland Road, Suite 300, Florham Park, NJ 07932
 
 
(Address of principal executive offices)
 

 
(800) 208-3343
 
 
(Registrant’s telephone number)
 

     
 
(Former name, former address and former fiscal year, if changed since last report)
 

Securities registered pursuant to Section 12(b) of the Act:

Title of each class
 
Trading symbol(s)
 
Name of each exchange on which registered
Common Stock, par value $0.00033 per share
 
PDSB
 
Nasdaq Capital Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Section 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐
Accelerated filer ☐
Non-accelerated filer
Smaller Reporting Company

Emerging growth company
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes   No ☒

The number of shares of the registrant’s Common Stock, par value $0.00033 per share, outstanding as of November 3, 2021 was 28,435,067.



PDS BIOTECHNOLOGY CORPORATION

FORM 10-Q FOR THE QUARTER ENDED SEPTEMBER 30, 2021

INDEX

     
Page
Part I — Financial Information
 
       
 
Item 1.
Financial Statements (Unaudited):
 
       
   
3
       
   
4
       
   
5
       
   
7
       
   
8
       
 
Item 2.
16
       
 
Item 3.
28
       
 
Item 4.
28
       
Part II — Other Information

       
 
Item 1.
29
       
 
Item 1A.
29
       
 
Item 2.
29
       
 
Item 3.
29
       
 
Item 4.
29
       
 
Item 5.
29
       
 
Item 6.
29
       
30
   
31


PART 1.   
 FINANCIAL INFORMATION

ITEM 1.
FINANCIAL STATEMENTS

PDS BIOTECHNOLOGY CORPORATION AND SUBSIDIARIES

Condensed Consolidated Balance Sheets


 
September 30, 2021
   
December 31, 2020
 
ASSETS
 
(unaudited)
       
Current assets:
           
Cash and cash equivalents
 
$
69,744,004
   
$
28,839,565
 
Prepaid expenses and other
   
1,596,810
     
1,497,665
 
Total current assets
   
71,340,814
     
30,337,230
 
                 
Property and equipment, net
   
1,037
     
5,443
 
Operating lease right-to-use asset
   
406,171
     
547,706
 
                 
Total assets
 
$
71,748,022
   
$
30,890,379
 
                 
LIABILITIES AND STOCKHOLDERS’ EQUITY
               
LIABILITIES
               
Current liabilities:
               
Accounts payable
 
$
1,445,585
   
$
1,415,224
 
Accrued expenses
   
1,923,846
     
1,735,322
 
Operating lease obligation-short term
   
207,717
     
119,904
 
Total current liabilities
   
3,577,148
     
3,270,450
 
                 
Noncurrent liability:
               
Operating lease obligation-long term
   
313,976
     
490,353
 
                 
Total Liabilities
 
$
3,891,124
   
$
3,760,803
 
                 
STOCKHOLDERS’ EQUITY
               
Common stock, $0.00033 par value, 75,000,000 shares authorized at September 30, 2021 and December 31, 2020, 28,435,067 shares and 22,261,619 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively
   
9,383
     
7,346
 
Additional paid-in capital
   
122,231,115
     
70,907,315
 
Accumulated deficit
   
(54,383,600
)
   
(43,785,085
)
Total stockholders’ equity
   
67,856,898
     
27,129,576
 
                 
Total liabilities and stockholders’ equity
 
$
71,748,022
   
$
30,890,379
 

See accompanying notes to the condensed consolidated financial statements.

PDS BIOTECHNOLOGY CORPORATION AND SUBSIDIARIES

Condensed Consolidated Statements of Operations and Comprehensive Loss

(Unaudited)

   
Three Months Ended September 30,
   
Nine Months Ended September 30,
 
   
2021
   
2020
   
2021
   
2020
 
Operating expenses:
                       
Research and development expenses
 
$
3,687,999
   
$
2,060,815
   
$
7,865,249
   
$
5,446,718
 
General and administrative expenses
   
3,274,325
     
1,846,214
     
7,252,371
     
5,428,098
 
Total operating expenses
   
6,962,324
   
3,907,029
     
15,117,620
     
10,874,816
 
                                 
Loss from operations
   
(6,962,324
)
   
(3,907,029
)
   
(15,117,620
)
   
(10,874,816
)
                                 
Other income:
                               
Interest income
   
1,358
     
1,207
     
2,617
     
54,242
 
                                 
Loss before income taxes
   
(6,960,966
)
   
(3,905,822
)
   
(15,115,003
)
   
(10,820,574
)
Benefit from income taxes
   
     
     
4,516,488
     
 
Net loss and comprehensive loss
   
(6,960,966
)
   
(3,905,822
)
   
(10,598,515
)
   
(10,820,574
)
                                 
Per share information:
                               
Net loss per share, basic and diluted
 
$
(0.24
)
 
$
(0.21
)
 
$
(0.43
)
 
$
(0.73
)
                                 
Weighted average common shares outstanding, basic and diluted
   
28,425,850
     
18,961,619
     
24,639,299
     
14,892,764
 

See accompanying notes to the condensed consolidated financial statements.

PDS BIOTECHNOLOGY CORPORATION AND SUBSIDIARIES

Condensed Consolidated Statements of Changes in Stockholders’ Equity

(Unaudited)

   
Common Stock
   
Additional
   

   
Total
 
   
Shares
Issued
   
Amount
   
Paid-in
Capital
   
Accumulated
Deficit
   
Equity
(Deficit)
 
Balance - June 30, 2020
   
15,361,619
   
$
5,064
   
$
52,861,882
   
$
(35,852,457
)
 
$
17,014,489
 
Stock based compensation expense
   
     
     
129,792
     
     
129,792
 
Issuance of common stock from equity transaction     6,900,000
      2,282
      17,784,218
            17,786,500
 
Net loss
   
     
     
     
(3,905,822
)
   
(3,905,822
)
Balance - September 30, 2020
   
22,261,619
   
$
7,346
   
$
70,775,892
   
$
(39,758,279
)
 
$
31,024,959
 

   
Common Stock
   
Additional
   

   
Total
 
   
Shares
Issued
   
Amount
   
Paid-in
Capital
   
Accumulated
Deficit
   
Equity
(Deficit)
 
Balance - June 30, 2021
   
28,417,909
   
$
9,377
   
$
120,405,851
   
$
(47,422,634
)
 
$
72,992,594
 
Stock based compensation expense
   
     
     
1,701,763
     
     
1,701,763
 
Issuance of common stock, from exercise of stock options
   
17,158
     
6
     
123,501
           
123,507
 
Net loss
   
     
     
     
(6,960,966
)
   
(6,960,966
)
Balance - September 30, 2021
   
28,435,067
   
$
9,383
   
$
122,231,115
   
$
(54,383,600
)
 
$
67,856,898
 

See accompanying notes to the condensed consolidated financial statements.

PDS BIOTECHNOLOGY CORPORATION AND SUBSIDIARIES

Condensed Consolidated Statements of Changes in Stockholders’ Equity

(Unaudited)

   
Common Stock
   
Additional
   

   
Total
 
   
Shares
Issued
   
Amount
   
Paid-in
Capital
   
Accumulated
Deficit
   
Equity
(Deficit)
 
Balance - December 31, 2019
   
5,281,237
   
$
1,742
   
$
40,633,670
   
$
(28,937,705
)
 
$
11,697,707
 
Stock based compensation expense
   
     
     
300,898
     
     
300,898
 
Issuance of common stock, net of issuance costs
   
16,900,000
     
5,581
     
29,750,921
     
     
29,756,502
 
Issuance of warrant exercise
   
65,240
     
22
     
70,437
     
     
70,459
 
Issuance of common stock from 401K match
   
15,142
     
1
     
19,966
     
     
19,967
 
Net loss
   
     
     
     
(10,820,574
)
   
(10,820,574
)
Balance - September 30, 2020
   
22,261,619
   
$
7,346
   
$
70,775,892
   
$
(39,758,279
)
 
$
31,024,959
 

   
Common Stock
   
Additional
   

   
Total
 
   
Shares
Issued
   
Amount
   
Paid-in
Capital
   
Accumulated
Deficit
   
Equity
(Deficit)
 
Balance - December 31, 2020
   
22,261,619
   
$
7,346
   
$
70,907,315
   
$
(43,785,085
)
 
$
27,129,576
 
Stock based compensation expense
   
     
     
2,400,980
     
     
2,400,980
 
Issuances of common stock, net of issuance costs
   
6,088,235
     
2,009
     
48,542,989
     
     
48,544,998
 
Issuances of common stock, from exercise of stock options
   
68,571
     
23
     
344,089
     
     
344,112
 
Issuance of common stock from 401K match
   
16,642
     
5
     
35,742
     
     
35,747
 
Net loss
   
     
     
     
(10,598,515
)
   
(10,598,515
)
Balance - September 30, 2021
   
28,435,067
   
$
9,383
   
$
122,231,115
   
$
(54,383,600
)
 
$
67,856,898
 

See accompanying notes to the condensed consolidated financial statements.

PDS BIOTECHNOLOGY CORPORATION AND SUBSIDIARIES

Condensed Consolidated Statements of Cash Flows

(Unaudited)

   
Nine Months Ended September 30,
 
   
2021
   
2020
 
Cash flows from operating activities:
           
Net loss
 
$
(10,598,515
)
 
$
(10,820,574
)
Adjustments to reconcile net loss to net cash used in operating activities:
               
Stock-based compensation expense
   
2,400,980
     
300,898
 
Stock-based 401K company common match
   
35,747
     
19,967
 
Depreciation expense
   
4,406
     
11,706
 
Operating lease expense
   
180,775
     
106,949
 
Changes in operating assets and liabilities:
               
Prepaid expenses and other assets
   
(99,145
)
   
1,935,067
Accounts payable
   
30,361
     
361,871
Accrued expenses
   
188,524
   
125,133
 
Restructuring reserve
   
     
(498,185
)
Operating lease liabilities
   
(127,804
)
   
(62,597
)
Net cash used in operating activities
   
(7,984,671
)
   
(8,519,765
)
                 
Cash flows from financing activities:
               
Proceeds from exercise of warrants
   
     
70,459
 
Proceeds from exercise of stock options
    344,112        
Proceeds from issuances of common stock, net of issuance costs
   
48,544,998
     
29,756,502
 
Net cash provided by financing activities
    48,889,110      
29,826,961
 
                 
Net increase in cash and cash equivalents
   
40,904,439
     
21,307,196
 
Cash and cash equivalents at beginning of period
   
28,839,565
     
12,161,739
 
                 
Cash and cash equivalents at end of period
 
$
69,744,004
   
$
33,468,935
 

See accompanying notes to the condensed consolidated financial statements.

PDS BIOTECHNOLOGY CORPORATION AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements (Unaudited)

Note 1 – Nature of Operations


PDS Biotechnology Corporation, a Delaware corporation (the “Company” or “PDS”), is a clinical-stage immunotherapy company developing a growing pipeline of cancer immunotherapies and infectious disease vaccines designed to overcome the well-established limitations of current immunotherapy technologies. PDS owns Versamune®, a proprietary T-cell activating platform designed to train the immune system to better attack and destroy disease. When paired with an antigen, which is a disease-related protein that is recognizable by the immune system, Versamune® has been shown to induce, in vivo, large quantities of high-quality, highly potent polyfunctional CD8+ killer T-cells, a specific sub-type of CD8+ killer T-cell that is more effective at killing infected or target cells.



The Company’s immuno-oncology products can potentially be used as a component of combination products with other leading technologies to provide effective treatments across a range of advanced cancer types. Currently, the Company believes its product candidates are of interest for potential combination treatments in relation to Human Papillomavirus (HPV)-associated cancers, melanoma, colorectal, lung, breast and prostate cancers and potentially as monotherapies in early-stage cancers. In addition, PDS is working to progress its infectious disease development program, which includes novel vaccines for COVID-19 and universal influenza.



From the Company’s inception, it has devoted substantially all of its efforts to drug development, business planning, engaging regulatory, manufacturing and other technical consultants, acquiring operating assets, planning and executing clinical trials and raising capital.


In December 2019, a novel (new) coronavirus known as SARS-CoV-2 was first detected in Wuhan, Hubei Province, People’s Republic of China, causing outbreaks of the coronavirus disease, known as COVID-19, that has now spread globally. On January 30, 2020, the World Health Organization (WHO) declared COVID-19 a public health emergency. The Secretary of Health and Human Services declared a public health emergency on January 31, 2020, under section 319 of the Public Health Service Act (42 U.S.C. 247d), in response to the COVID-19 outbreak. On March 11, 2020, the WHO declared COVID-19 a pandemic and on March 13 the President declared a national emergency in response to the pandemic. PDS continues to learn more about the full impact of the COVID-19 pandemic which has continued to evolve due to the emergence of variants of concern, resulting in new waves of infection regionally and globally. The COVID-19 pandemic has and could continue to negatively affect the Company’s liquidity and operations.  To date, the start of two of the three initiated PDS0101 clinical trials were delayed, specifically as a result of the adverse impact the COVID-19 pandemic has had on clinical trial operations for cancer indications in the United States. The FDA has continued to update its guidance assisting sponsors in assuring the safety of trial participants, maintaining compliance with Good Clinical Practice (GCP) and minimizing risks to trial integrity.  Clinical trial sites have implemented institution-specific measures securing the safety of patients and staff to ensure the integrity of the trials in the face of the ongoing pandemic. All three studies have since been initiated despite the pandemic challenges; however, the evolving COVID-19 pandemic has impacted the pace of enrollment in clinical trials in general and the Company may be negatively affected with its trials. COVID-19 related travel and other restrictions may also impact the potential for on-site monitoring visiting and audits and inspections by Company personnel, third parties, and government regulators. There may be shortages of site personnel and equipment necessary for the timely completion of the clinical trials. The Company is providing support to address these challenges, but these mitigation measures may not overcome the obstacles that the pandemic has wrought which continue to impede progress of clinical trials.



Although there is uncertainty related to the anticipated impact of the COVID-19 pandemic on the Company’s future results, management believes the Company’s current cash reserves leave us well-positioned to manage the business through this crisis as it continues to unfold. However, the impacts of the COVID-19 pandemic and its variants are broad-reaching and continuing and the financial impacts associated with the COVID-19 pandemic are still uncertain.

Note 2 – Summary of Significant Accounting Policies

(A)
Unaudited interim financial statements:


The interim balance sheet at September 30, 2021, the statements of operations and comprehensive loss and changes in stockholders’ equity for the three and nine months ended September 30, 2021 and 2020, and cash flows for the nine months ended September 30, 2021 and 2020 are unaudited. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. GAAP, in accordance with the requirements of the Securities and Exchange Commission (“SEC”) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. These condensed consolidated financial statements have been prepared on the same basis as the Company’s annual financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments that are necessary for a fair statement of its financial information. The results of operations for the three and nine months ended September 30, 2021 are not necessarily indicative of the results to be expected for the year ending December 31, 2021 or for any other future annual or interim period. The balance sheet as of December 31, 2020 included herein was derived from the audited condensed consolidated financial statements as of that date. These condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto as of and for the year ended December 31, 2020, filed by the Company with the SEC in its Annual Report on Form 10-K on March 18, 2021.

(B)
Use of estimates:


The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of expenses at the date of the consolidated financial statements and during the reporting periods, and to disclose contingent assets and liabilities at the date of the consolidated financial statements. Actual results could differ from those estimates.

(C)
Significant risks and uncertainties:


The Company’s operations are subject to a number of factors that may affect its operating results and financial condition. Such factors include, but are not limited to: the clinical and regulatory development of its products, the Company’s ability to preserve its cash resources, the Company’s review of strategic alternatives, the Company’s ability to add product candidates to its pipeline, the Company’s intellectual property, the ability to efficiently and effectively conduct its clinical trials, competition from products manufactured and sold or being developed by other companies, the price of, and demand for, Company products if approved for sale, the Company’s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products, the Company’s ability to raise capital, and the effects of health epidemics, pandemics, or outbreaks of infectious diseases, including the recent COVID-19 pandemic and its variants.


The Company currently has no commercially approved products. As such, there can be no assurance that the Company’s future research and development programs will be successfully commercialized. Developing and commercializing a product requires significant time and capital and is subject to regulatory review and approval as well as competition from other biotechnology and pharmaceutical companies. The Company operates in an environment of rapid change and is dependent upon the continued services of its employees and consultants and obtaining and protecting its intellectual property.

(D)
Cash equivalents and concentration of cash balance:


The Company considers all highly liquid securities with a maturity weighted average of less than three months to be cash equivalents. The Company’s cash and cash equivalents in bank deposit accounts, at times, may exceed federally insured limits.

(E)
Research and development:


Costs incurred in connection with research and development activities are expensed as incurred. These costs include licensing fees to use certain technology in the Company’s research and development projects as well as fees paid to consultants and entities that perform certain research and testing on behalf of the Company.


Costs for certain development activities, such as clinical trials, are recognized based on an evaluation of the progress to completion of specific tasks using data, such as patient enrollment, clinical site activations or information provided by vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred.

(F)
Patent costs:


The Company expenses patent costs as incurred and classifies such costs as general and administrative expenses in the accompanying statements of operations and comprehensive loss.

(G)
Stock-based compensation:


The Company accounts for its stock-based compensation in accordance with ASC Topic 718, Compensation—Stock Compensation (“ASC 718”). ASC 718 requires all stock-based payments to employees, directors and non-employees to be recognized as expense in the consolidated statements of operations and comprehensive loss based on their grant date fair values. In order to determine the fair value of stock options on the date of grant, the Company uses the Black-Scholes option-pricing model. Inherent in this model are assumptions related to expected stock-price volatility, option term, risk-free interest rate and dividend yield. While the risk-free interest rate and dividend yield are less subjective assumptions that are based on factual data derived from public sources, the expected stock-price volatility and option term assumptions require a greater level of judgment. The Company expenses the fair value of its stock-based compensation awards to employees and directors on a straight-line basis over the requisite service period, which is generally the vesting period. The Company recognizes forfeitures as they occur.

(H)
Net loss per common share:


Basic and diluted net loss per common share is determined by dividing net loss attributable to common stockholders by the weighted average common shares outstanding during the period. For all periods presented, the common shares underlying the stock options and warrants have been excluded from the calculation because their effect would be anti-dilutive. Therefore, the weighted average shares outstanding used to calculate both basic and diluted loss per common share are the same.


The potentially dilutive securities excluded from the determination of diluted loss per share as their effect is antidilutive, are as follows:


 
As of September 30,
 
   
2021
   
2020
 
Stock options to purchase Common Stock
   
2,951,852
     
1,639,753
 
Warrants to purchase Common Stock
   
197,518
     
197,518
 
Total
   
3,149,370
     
1,837,271
 

Note 3 – Liquidity


As of September 30, 2021, the Company had $69.7 million of cash and cash equivalents. The Company’s primary uses of cash are to fund operating expenses, primarily research and development expenditures. Cash used to fund operating expenses is impacted by the timing of when the Company pays these expenses, as reflected in the change to the Company’s outstanding accounts payable and accrued expenses.


On July 29, 2019, the Company entered into a common stock purchase agreement, or the Aspire Purchase Agreement, with Aspire Capital pursuant to which, the Company has the right, in its sole discretion, to present Aspire Capital Fund, LLC, or Aspire Capital, with a purchase notice, directing Aspire Capital (as principal) to purchase up to 100,000 shares of the Company’s common stock per business day, in an aggregate amount of up to $20.0 million of its common stock, or the Purchased Shares, over the term of the Aspire Purchase Agreement. The Company may sell an aggregate of 1,034,979 shares of its common stock (which represented 19.99% of its outstanding shares of common stock on the date of the Aspire Purchase Agreement) without stockholder approval. The Company may sell additional shares of its common stock above the 19.99% limit provided that (i) the Company obtains stockholder approval or (ii) stockholder approval has not been obtained at any time the 1,034,979 share limitation is reached and at all times thereafter the average price paid for all shares issued under the Aspire Purchase Agreement, is equal to or greater than $5.76, which was the consolidated closing bid price of the Company’s common stock on July 26, 2019. The minimum price at which the Company can sell shares under the Aspire Purchase Agreement is $0.50. On July 29, 2019, the Company issued 100,654 shares of its common stock to Aspire Capital, as consideration for entering into the Aspire Purchase Agreement, which the Company refers to as the Commitment Shares. The Company recorded the fair value of the shares at July 29, 2019 of $603,924 as an expense in the third quarter of 2019. Concurrently with the Aspire Purchase Agreement, the Company entered into a registration rights agreement with Aspire Capital, or the Registration Rights Agreement. In accordance with the Registration Rights Agreement, on August 20, 2019, the Company filed a Registration Statement on Form S-1 (File No. 333-232988) to cover the resale of the Commitment Shares and any Purchased Shares issuable to Aspire Capital under the Aspire Purchase Agreement. There is market uncertainty regarding the utilization of financing associated from the Aspire Purchase Agreement. As of September 30, 2021, no Purchase Shares have been sold to Aspire Capital under the Aspire Purchase Agreement.


In February 2020, the Company completed an underwritten public offering, in which it sold 10,000,000 shares of common stock at a public offering price of $1.30 per share. The shares sold included 769,230 shares issued upon the exercise by the underwriter of its option to purchase additional shares at the public offering price, minus underwriting discounts and commissions. The Company received gross proceeds of approximately $13 million and net proceeds of approximately $11.9 million after deducting underwriting discounts and commissions.


In July 2020, the Company filed a shelf registration statement, or the 2020 Shelf Registration Statement, with the SEC, for the issuance of common stock, preferred stock, warrants, rights, debt securities and units, which the Company refers to collectively as the Shelf Securities, up to an aggregate amount of $100 million. The 2020 Shelf Registration Statement was declared effective on July 31, 2020.



In August 2020, the Company sold 6,900,000 shares of its common stock at a public offering price of $2.75 per share pursuant to the 2020 Shelf Registration Statement, which includes 900,000 shares issued upon the exercise by the underwriter of its option to purchase additional shares at the public offering price, minus underwriting discounts and commissions. The Company received gross proceeds of approximately $19.0 million and net proceeds of approximately $17.1 million, after deducting underwriting discounts and offering expenses.

10


In May 2021, the Company received approximately $4.5 million from the net sale of tax benefits through 2019 to an unrelated, profitable New Jersey corporation pursuant the Company’s participation in the New Jersey Technology Business Tax Certificate Transfer Net Operating Loss (NOL) program for State Fiscal Year 2020.



In June 2021, the Company completed an underwritten public offering in which it sold 6,088,235 shares of common stock at a public offering price of $8.50 per share pursuant to the 2020 Shelf Registration Statement, which includes 794,117 shares issued upon the exercise by the underwriter of its option to purchase additional shares at the public offering price, minus underwriting discounts and commissions. the Company received gross proceeds of approximately $51.7 million and net proceeds of approximately $48.5 million, after deducting underwriting discounts and offering expenses. Approximately $29,300,000 of Shelf Securities remain available for future sale under the 2020 Shelf Registration Statement.


The Company’s primary uses of cash are to fund operating expenses, primarily research and development expenditures. Cash used to fund operating expenses is impacted by the timing of when the Company pays these expenses, as reflected in the change in its outstanding accounts payable and accrued expenses.


The Company evaluated whether there are any conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern within one year beyond the filing of this Quarterly Report on Form 10-Q.  The Company’s budgeted cash requirements in 2021 and beyond include expenses related to continuing development and clinical studies.  Based on its available cash resources and cash flow projections as of the date the consolidated financial statements were available for issuance, management believes there are sufficient funds to continue operations and research and development programs for at least 12 months from the date of this report.


The Company plans to continue to fund its operations and capital funding needs through equity and/or debt financings. However, the Company cannot be certain that additional financing will be available when needed or that, if available, financing will be obtained on terms favorable to the Company or its existing stockholders.  The Company may also enter into government funding programs and consider selectively partnering for clinical development and commercialization. The sale of additional equity would result in additional dilution to the Company’s stockholders. Incurring debt financing would result in debt service obligations, and the instruments governing such debt could provide for operating and financing covenants that would restrict its operations. If the Company is unable to raise additional capital in sufficient amounts or on acceptable terms, we may be required to delay, limit, reduce, or terminate its product development or future commercialization efforts or grant rights to develop and market immunotherapies that the Company would otherwise prefer to develop and market itself. Any of these actions could harm its business, results of operations and prospects. Failure to obtain adequate financing also may adversely affect the Company’s ability to operate as a going concern.

Note 4 – Fair Value of Financial Instruments


There were no transfers among Levels 1, 2, or 3 during 2021 or 2020.

   
Fair Value Measurements at Reporting Date Using
 
   
Total
   
Quoted Prices in
Active Markets
(Level 1)
   
Quoted Prices in
Inactive Markets
(Level 2)
   
Significant
Unobservable Inputs
(Level 3)
 
As of September 30, 2021: (unaudited)
                       
Cash and cash equivalents
 
$
69,744,004
   
$
69,744,004
   
$
   
$
 
                                 
As of December 31, 2020:
                               
Cash and cash equivalents
 
$
28,839,565
   
$
28,839,565
   
$
   
$
 

Note 5 – Leases


On July 8, 2019, the Company entered into a lease termination agreement for its office space located at 300 Connell Drive, Suite 4000, Berkeley Heights, NJ 07922 effective August 31, 2019 (the “Lease Termination Agreement”). Pursuant to the Lease Termination Agreement, the Company was required to pay 50 percent of the remaining lease payments of $665,802 over three installments on September 1, 2019, December 1, 2019, and March 1, 2020, which was recorded as lease termination costs in the third quarter of 2019. The Company entered into a temporary month-to-month lease as of September 1, 2019 for office space located at 830 Morris Turnpike, Short Hills, NJ 07078 until the Company entered into a new lease for permanent office space. This lease was terminated on May 31, 2020.


Effective March 5, 2020, the Company entered into a sublease for approximately 11,200 square feet of office space located at 25B Vreeland Road, Suite 300, Florham Park, NJ. The sublease commenced on May 1, 2020 and will continue for a term of forty (40) months with an option to renew through October 31, 2027. As of September 30, 2021, there are twenty-three (23) months remaining in the lease term. Upon inception of the lease, the Company recognized approximately $0.7 million of a ROU asset and operating lease liabilities. The discount rate used to measure the operating lease liability as of May 1, 2020 was 9.15%. Throughout the period described above the Company has maintained, and continues to maintain, a month-to-month lease for its research facilities at the Princeton Innovation Center BioLabs located at 303A College Road E, Princeton NJ, 08540.

11


Supplemental cash flow information related to operating leases is as follows:

   
As of September 30,
 
   
2021
   
2020
 
Cash paid for operating lease liabilities
 
$
127,804
   
$
62,597
 
Right-of use assets recorded in exchange for lease obligations
 
$
   
$
638,831
 


Maturity of the Company’s operating lease liability is as follows:

Year ended December 31,
     
2021 (remaining three months)
 
$
43,035
 
2022
   
294,986
 
2023
   
239,469
 
2024
   
 
2025 and after
   
 
Total future minimum lease payments
   
577,490
 
Less imputed interest
   
(55,797
)
   
$
521,693
 

Note 6 – Accrued Expenses

Accrued expenses and other liabilities consist of the following:

   
As of
September 30, 2021
   
As of
December 31, 2020
 
Accrued research and development costs
 
$
19,500
   
$
204,780
 
Accrued professional fees
   
277,555
     
219,822
 
Accrued compensation
   
1,626,791
     
1,310,720
 
Total
 
$
1,923,846
   
$
1,735,322
 

Note 7 – Stock-Based Compensation


The Company has three equity compensation plans: the 2009 Stock Option Plan, 2014 Equity Incentive Plan and the 2018 Stock Incentive Plan (the “Plans”).


In 2014, the Company’s stockholders approved the 2014 Equity Incentive Plan pursuant to which the Company may grant up to 91,367 shares as ISOs, NQs and restricted stock units (“RSUs”), subject to increases as hereafter described (the “Plan Limit”). In addition, on January 1, 2015 and each January 1 thereafter and prior to the termination of the 2014 Equity Incentive Plan, pursuant to the terms of the 2014 Equity Incentive Plan, the Plan Limit was and shall be increased by the lesser of (x) 4% of the number of shares of Common Stock outstanding as of the immediately preceding December 31 and (y) such lesser number as the Board of Directors may determine in its discretion. In March 2019, the Plan was amended and restated which removed the annual increase component and was limited to 826,292 shares.



As previously disclosed, on December 8, 2020, the Board of Directors of the Company adopted, subject to stockholder approval, the Second Amended and Restated PDS Biotechnology Corporation 2014 Equity Inventive Plan (the “Restated Plan”), which would amend and restate the Amended and Restated PDS Biotechnology Corporation 2014 Equity Incentive Plan (the “Current Plan”). The Company held its annual meeting of stockholders on June 17, 2021 (the “Annual Meeting”). The stockholders voted to approve the Restated Plan at the Annual Meeting. The Restated Plan is identical to the Current Plan in all material respects, except as follows: (a) the number of shares of Common Stock authorized for issuance under the Restated Plan will increase from 826,292 shares to 3,339,243 shares, plus the total number of shares that remained available for issuance, that are not covered by outstanding awards issued under the Current Plan, immediately prior to December 8, 2020; and (b) the Restated Plan will terminate on December 7, 2030, unless earlier terminated. Please reference the disclosure in Note 9.

12


In 2018, the Company’s stockholders approved the 2018 Stock Incentive Plan pursuant to which the Company may grant up to 558,071 shares as (i) Stock Options, (ii) Stock Appreciation Rights, (iii) Restricted Stock, (iv) Preferred Stock, (v) Stock Reload Options and/or (vi) Other Stock-Based Awards.


 Pursuant to the terms of the Plans, ISOs have a term of ten years from the date of grant or such shorter term as may be provided in the option agreement. Unless specified otherwise in an individual option agreement, ISOs generally vest over a four-year term and NQs generally vest over a  one-to-five-year term. Unless terminated by the Board, the Plans shall continue to remain effective for a term of ten years or until such time as no further awards may be granted and all awards granted under the Plans are no longer outstanding. As of September 30, 2021 there were 190,799 shares available for grant under the 2018 Stock Incentive Plan.


 On June 17, 2019, the Board adopted the 2019 Inducement Plan (the “Inducement Plan”). The Inducement Plan provides for the grant of non-qualified stock options. The Inducement Plan was recommended for approval by the Compensation Committee of the Board and subsequently approved and adopted by the Board without stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.


On December 9, 2020, the Company amended the Inducement Plan solely to increase the total number of shares of Common Stock reserved for issuance under the Inducement Plan from 200,000 shares to 500,000 shares. The 2019 Inducement Plan is administered by the Compensation Committee of the Board. In accordance with Rule 5635(c)(4) of the Nasdaq Listing Rules, non-qualified stock options under the 2019 Inducement Plan may only be made to an employee who has not previously been an employee or member of the Board (or any parent or subsidiary of the Company), or following a bona fide period of non-employment by the Company (or a parent or subsidiary of the Company), if he or she is granted such non-qualified stock options in connection with his or her commencement of employment with the Company or a subsidiary and such grant is an inducement material to his or her entering into employment with the Company or such subsidiary. As of September 30, 2021, there were 362,700 shares available for grant under the 2019 Inducement Plan.


The Company’s stock-based compensation expense related to stock options was recognized in operating expense as follows:


   
Three Months September 30, 2021
   
Nine Months Ended September 30,
 
   
2021
   
2020
   
2021
   
2020
 
   
(unaudited)
   
(unaudited)
 
Stock-Based Compensation
                       
Research and development
 
$
596,762
   
$
61,557
   
$
824,580
   
$
168,083
 
General and administrative
   
1,105,000
     
68,235
   
1,576,401
     
132,815
 
Total
 
$
1,701,763
   
$
129,792
   
$
2,400,980
   
$
300,898
 


The fair value of options granted during the three and nine months ended September 30, 2021 and the three and nine months ended September 30, 2020 was estimated using the Black-Scholes option valuation model utilizing the following assumptions. There were 63,800 options granted during the three-month period ended September 30, 2021.


   
Three Months September 30, 2021
   
Nine Months Ended September 30,
 
   
2021
   
2020
   
2021
   
2020
 
   
Weighted Average
   
Weighted Average
   
Weighted Average
   
Weighted Average
 
   
(unaudited)
   
(unaudited)
 
Volatility
   
100.16
%
   
%
   
100.58
%
   
97.00
%
Risk-Free Interest Rate
   
0.77
%
   
%
   
55.88
%
   
0.38
%
Expected Term in Years
   
6.08
     
     
6.28
     
6.07
 
Dividend Rate
   
     
     
     
 
Fair Value of Option on Grant Date
 
$
11.81
   
$
   
$
7.43
   
$
1.10
 

13


The following table summarizes the number of options outstanding and the weighted average exercise price:


   
Number
of Shares
   
Weighted
Average
Exercise Price
   
Weighted Average
Remaining
Contractual
Life in Years
   
Aggregate
Intrinsic Value
 
Options outstanding at December 31, 2020
   
1,650,897
   
$
11.87
     
7.03
   
$
226,731
 
Granted
   
1,722,730
     
3.34
     
9.28
   
$
8,803,138
 
Exercised
   
(95,737
)
   
7.24
     
   
$
 
Forfeited
   
(326,038
)
   
29.71
     
   
$
 
Options outstanding at September 30, 2021
   
2,951,852
   
$
5.07
     
7.99
   
$
29,754,366
 
Vested and expected to vest at September 30, 2021
   
2,951,852
   
$
5.07
     
7.99
   
$
29,754,366
 
Exercisable at September 30, 2021
   
1,130,039
   
$
7.66
     
5.81
   
$
8,914,003
 


At September 30, 2021 there was approximately $11,300,108 of unamortized stock option compensation expense, which is expected to be recognized over a remaining average vesting period of 2.97 years.

Note 8 – Income Taxes


In assessing the realizability of the net deferred tax assets, the Company considers all relevant positive and negative evidence to determine whether it is more likely than not that some portion or all of the deferred income tax assets will not be realized. The realization of the gross deferred tax assets is dependent on several factors, including the generation of sufficient taxable income prior to the expiration of the net operating loss carryforwards. The Company expects to have a loss for 2021 and there will be no current income tax expense. Additionally, there was a full valuation allowance against the net deferred tax assets as of September 30, 2021 and December 31, 2020. In May 2021, in accordance with the State of New Jersey’s Technology Business Tax Certificate Program, which allowed certain high technology and biotechnology companies to sell unused NOL carryforwards to other New Jersey-based corporate taxpayers, the Company sold New Jersey NOL carryforwards, resulting in the recognition of $4.5 million of income tax benefit, net of transaction costs.


The Company’s U.S. statutory rate is 21%. The effective tax rate, excluding the benefit of the sale of any New Jersey net operating losses, for the three and nine months ended September 30, 2021 is 0%.  The primary factor impacting the effective tax rate is the anticipated full year operating loss which will require a full valuation allowance against any associate deferred tax asset.


Entities are also required to evaluate, measure, recognize and disclose any uncertain income tax provisions taken on their income tax returns. The Company has analyzed its tax positions and has concluded that as of September 30, 2021, there were no uncertain positions. The Company’s U.S. federal and state net operating losses have occurred since its inception and as such, tax years subject to potential tax examination could apply from that date because the utilization of net operating losses from prior years opens the relevant year to audit by the IRS and/or state taxing authorities. The Company did not have any unrecognized tax benefits and has not accrued any interest or penalties for the three and nine months ended September 30, 2021 and for the year ended December 31, 2020.

14

Note 9 – Commitments and Contingencies

Rent


For month-to-month arrangements not impacted by the adoption of ASC 842, rent for the three and nine months ended September 30, 2021 was $52,000 and $130,493, respectively, compared to the three and nine months ended September 30, 2020 of $35,700 and $140,678.


Legal Proceedings
 

On July 23, 2021, David R. Rosener, a purported stockholder of the Company, filed a putative class action and shareholder derivative complaint in the Court of Chancery of the State of Delaware (C.A. No. 2021-0644 JRS)  against the Company and all of its directors and certain of its executive officers. The plaintiff named all current directors of PDS as defendants as well as PDS’s Chief Scientific Officer and PDS’s Chief Medical Officer and also named PDS as a nominal defendant.  The plaintiff claims PDS’s bylaws required tabulation of broker non-votes on Proposal 3 at the Company’s 2021 annual stockholder meeting on June 17, 2021, which sought shareholder approval of the Second Amended and Restated PDS Biotechnology Corporation 2014 Equity Incentive Plan (the “Restated Plan”). The complaint asserts claims for breach of fiduciary duties, declaratory judgment, waste of corporate assets and unjust enrichment in connection with the Restated Plan and the granting of an aggregate award of 1,040,700 stock options to certain executive officers pursuant to the Restated Plan.  The plaintiff seeks unspecified monetary damages, seeks to have the Restated Plan declared void, and seeks recission of the grant of stock options as ultra vires.  Given the early stage of this lawsuit, PDS is unable to reasonably estimate the costs associated with the lawsuit or predict the outcome.  Each of the Company, its directors and the named executives intend to defend this action vigorously.  There can be no guarantee as to the timing of any resolution.

Note 10 – Retirement Plan


The Company has a 401(k) defined contribution plan for the benefit of all employees and permits voluntary contributions by employees subject to IRS-imposed limitations. The 401(k) employer contributions were $25,803 and $71,214 for the three and nine months ended September 30, 2021, respectively, compared to $11,809 and $35,293 for the three and nine months ended September 30, 2020, respectively.

Note 11– Subsequent Events


On October 18, 2021, the Company granted an option to purchase 202,800 shares of common stock to its incoming Chief Financial Officer and 25,400 to other incoming employees with a strike price of $12.03 vesting over a four-year period with one quarter vesting on the first anniversary of the date of the grant and vesting monthly over the 36-month period thereafter and expire ten years from the date of the grant. The aggregate fair value of the options granted was $2.2 million.



Effective as November 5, 2021, the Company entered into a Patent License Agreement (the “Patent License Agreement”) with the U.S. Department of Health and Human Services, as represented by National Cancer Institute (“NCI”) of the National Institutes of Health (“NIH”).  Pursuant to the License Agreement, the Company obtained a nonexclusive license to the patent rights for NCI’s T-cell receptor gamma alternate reading frame protein (“TARP”) to develop and commercialize TARP peptide-based therapies in combination with the Company’s Versamune® technology. The Patent License Agreement includes customary milestone payments and royalties.

15

ITEM 2:
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited interim condensed consolidated financial statements and related notes thereto appearing elsewhere in this Quarterly Report on Form 10-Q (this “Quarterly Report”) and with the audited financial statements and notes thereto of the Company as of and for the year ended December 31, 2020 on Form 10-K, filed with the Securities and Exchange Commission, or SEC, on March 18, 2021.

Cautionary Note Regarding Forward-Looking Statements

This Quarterly Report contains forward-looking statements that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this Quarterly Report, including statements regarding our future results of operations and financial position, strategy and plans, and our expectations for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue” or the negative of these terms or other comparable terminology. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described under the heading “Risk Factors” below.  In light of these risks, uncertainties and assumptions, actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements in this Quarterly Report and you should not place undue reliance on these forward-looking statements.

These forward-looking statements may include, but are not limited to, statements about:


the accuracy of estimates of our expenses, future revenue, capital requirements and our needs for additional financing;


our ability to obtain funding for our operations in the event we determine the need to raise additional capital;


our ability to retain key management personnel;


the accuracy of our estimates regarding expenses, future revenues and capital requirements;


Our ability to efficiently and effectively conduct our clinical trials;


our ability to maintain our listing on the Nasdaq Stock Market;


regulatory developments in the United States and foreign countries;


unforeseen circumstances or other disruptions to normal business operations arising from or related to COVID-19;


our expectations regarding the time during which we will be an emerging growth company under the Jumpstart Our Business Startups Act of 2012 (“JOBS Act”); and


other risks and uncertainties, including those listed under Part II, Item 1A. Risk Factors.

Any forward-looking statements in this Quarterly Report reflect our views and assumptions only as of the date that this report is signed with respect to future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements.  Given these uncertainties, you should not place undue reliance on these forward-looking statements. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.

We qualify all of our forward-looking statements by these cautionary statements. In addition, with respect to all of our forward-looking statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

16

Company Overview

We are a clinical-stage immunotherapy company developing a growing pipeline of cancer immunotherapy and infectious disease vaccine candidates designed to overcome the limitations of current immunotherapy technologies. Our Versamune® technology is a proprietary T-cell activating platform designed to treat diseases such as cancer by training the immune system to better recognize, attack and destroy diseased cells. When paired with an antigen (which is a disease-related protein that is recognizable by the immune system), in pre-clinical studies, Versamune® has been shown to induce, in vivo, large quantities of high-quality, highly potent polyfunctional CD8+ killer T-cells, a specific sub-type of T-cell that is more effective at killing infected or targeted cancer cells. Versamune® has also been shown in pre-clinical studies to induce antigen-specific highly potent polyfunctional CD4+ helper T-cells as well as neutralizing antibodies. PDS0101 in its first human clinical trial provided data supporting the previously reported preclinical study results and demonstrated the unique in vivo induction of high levels of active HPV-specific CD8+ T-cells in humans.  Positive preliminary clinical results of PDS0101 in combination with investigational immune-modulating agents Bintrafusp alfa (M7824), and NHS-IL12 (M9241), discussed in more detail below, suggest that PDS0101 induction of in vivo highly active tumor-attacking HPV16 killer (CD8+) T-cells even in advanced, refractory cancer patients who have failed multiple treatments, who may be immunologically limited patients presents the potential for effective disease reduction and prolonged survival.

We believe that the Versamune® platform has the potential to become an industry-leading immuno-oncology technology. It is currently being applied to the development of a robust pipeline of high-value, novel and first-in-class immunotherapies, potentially as single agents and also as part of combination therapies with other leading immuno-oncology technologies and standard of care therapies. To date, Versamune® based therapies have not been linked to any dose limiting toxicities in any human clinical trial. Based upon the promising efficacy data and the positive safety data so far, PDS is preparing to move at least one additional product into Phase 1/2 clinical trials in 2022. We believe our product candidates could be of interest for use in combination with other cancer therapies in the treatment of several advanced, metastatic, and recurrent cancers including HPV-associated cancers, colorectal, lung, breast and prostate cancers or potentially as monotherapies in earlier-stage disease.

PDS0101 in Combination with KEYTRUDA® Clinical Trial (VERSATILE-002):

In November 2020, our VERSATILE-002 Phase 2 clinical trial evaluating the combination of PDS0101 (Versamune® plus a mixture of HPV16 antigens) in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) for treatment of recurrent/ metastatic HPV16-positive head and neck cancer opened and is actively recruiting patients. The clinical trial is evaluating the efficacy and safety of this therapeutic combination as a treatment in patients with recurrent or metastatic head and neck cancer caused by high-risk HPV16 infection.

In this sponsored trial, patients whose cancer has returned or spread following initial treatment, will take this combination of two immuno-therapy drugs in lieu of chemotherapy. Enrolling patients with more functional immune systems earlier in disease recurrence that have not been compromised by extensive chemotherapy may allow improved efficacy of the combination. Patients in the study will receive a total of 5 cycles of combination therapy in the context of standard of care KEYTRUDA™ therapy administered every three weeks until disease progression or intolerance to therapy.
 
The original study design for this combination trial was restricted to patients who have not been treated with a checkpoint inhibitor and are therefore naïve to checkpoint inhibitor (CPI) therapy. PDS amended the protocol in May 2021 to expand this study to include patients with advanced head and neck cancer who have failed multiple treatments, including CPI therapy (CPI refractory patients), a treatment refractory population with extremely high unmet medical need. The amended study design is a Simon two stage design. The primary efficacy endpoint in both CPI naïve and CPI refractory subjects will be the best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 of the combination of pembrolizumab and PDS0101.  Objective response is measured by radiographic tumor responses according to RECIST 1.1.   The lead-in cohort of the initial twelve (12) patients to assess the safety of the combination was successfully enrolled in September 2021. The Data Monitoring Committee assessed the safety data from 13 patients on September 15, 2021 and observed no dose limiting toxicities.  On October 4, 2021, we announced that full enrollment of 17 patients was achieved in the first stage of the CPI naïve arm of the study. If an objective response is achieved among at least four (4) of these seventeen (17) patients, then the study will advance to the second stage of enrollment of the planned 54 patients in this arm. In the expansion CPI refractory arm, the first twenty-one (21) patients will be evaluated for efficacy with a minimum of two (2) or more patients with objective response required to progress to full enrollment of this arm.
 
If the endpoints are achieved, this study may serve as confirmation that PDS0101 enhances the therapeutic benefit of checkpoint inhibitors and could expand evaluation of Versamune®-based therapies in multiple cancer indications.  Total enrollment of both study arms is expected to be approximately ninety-five (95) patients, essentially unchanged from the accrual target of ninety-six (96) patients in the original study design. Preliminary data is expected between the fourth quarter of 2021 and the first quarter of 2022.

17

PDS0101 in Combination with Bintrafusp alfa (M7824) and NHS-IL12 Clinical Trial:

 
In June 2020, the first patient was dosed under a PDS0101 Cooperative Research and Development Agreement, which we refer to as the CRADA, in a National Cancer Institute, or NCI, led Phase 2 clinical study evaluating PDS0101, in combination with two investigational immune-modulating agents Bintrafusp alfa (M7824), a bifunctional “trap” fusion protein targeting TGF-β and PD-L1, and NHS-IL12 (M9241), a tumor-targeting immune-cytokine. Both bintrafusp alfa and NHS-IL12 are owned by and are being developed by Merck KGaA, Darmstadt, Germany.  The NCI-led trial is evaluating the novel triple combination for the treatment of both CPI naïve and refractory patients with advanced HPV-associated cancers that have progressed or returned after treatment. Almost all types of HPV-related cancers (anal, cervical, head and neck, vaginal and vulvar cancers) are represented among the study subjects to date.  Objective response (tumor reduction > 30%) is measured by radiographic tumor responses according to RECIST 1.1.  Full enrollment of a total of 56 patients is expected to be completed during the first quarter of 2022. The recruitment in the trial was temporarily suspended for administrative reasons on October 20, 2021.  The pause in recruitment was unrelated to safety or efficacy of the combination and we continue to communicate with the NCI regarding enrollment. The treatment of already enrolled patients has continued without interruption. At this time, this pause is not expected to affect the timing of clinical data from the trial.
 
The study was accepted for oral presentation at the 2021 meeting of the American Society of Clinical Oncology (ASCO) held June 4-8, 2021. On May 20, 2021, we announced the abstract summarizing interim data of 14 patients from the study. Objective responses were observed in 83% (5 of 6) of HPV16-positive checkpoint inhibitor naïve patients with advanced disease. Objective responses were observed in 63% (5 of 8) of HPV16-positive advanced cancer patients who had also failed checkpoint inhibitor therapy.

On June 7, 2021, updated interim data (Abstract 2501) was presented at ASCO by the study’s Principal Investigator Dr. Julius Strauss. This data included an update on the initial 14 patients with an additional four (4) subsequently recruited CPI refractory HPV16-positive patients whose data became available after the abstract submission as well as an additional seven (7) HPV16-negative patients (patients whose cancer was not caused by HPV16 infection) who were not discussed in the abstract. Tumor reduction and objective response was seen in 83% (5/8) of CPI naïve patients with one (1) achieving a complete response. After a median of eight (8) months of follow-up, 100% (6/6) of these patients were alive, compared to the historical median survival of 7-11 months. In the CPI refractory arm, tumor reduction was observed in 58% (7/12) patients. These 12 patients included the initial 8 patients reported in the abstract where 5 of 8, or 63% had tumor reduction. Of the 4 additional patients in this updated data set, 2 patients already had ongoing tumor reduction but had not yet met the criteria for objective response. Objective response was achieved in 42% (5/12) patients with one (1) achieving a complete response in this refractory arm. The objective response rates reported in checkpoint refractory, advanced HPV-cancer patients are lower than those naïve to checkpoint inhibitors, generally only 5-12%. Importantly, 83% (10/12) of all checkpoint inhibitor refractory patients were still alive at median eight (8) months of follow-up; historic average median survival for this patient population is 3-4 months. Overall, tumor reduction occurred in 67% (12/18) of the HPV16-positive patients, including both CPI naïve and CPI refractory patients. Of note, in the 7 HPV16-negative patients- those with an HPV type other than HPV16 that do not express the molecular target of PDS0101, zero (0) of seven (7) patients experienced tumor reduction or an objective response, providing insight into the potential role of PDS0101 in the observed activity of the triple combination. These data suggest that HPV16-specific CD8+ and CD4+ T-cell induction by PDS0101 as demonstrated in preclinical studies and phase 1 clinical studies, may promote tumor reduction and enhanced clinical benefit of the triple combination.

Moreover, PDS0101 did not appear to compound the toxicities already reported to be induced by Bintrafusp alfa and NHS-IL12. This is an important consideration for combination oncology treatment regimens where a key goal is to avoid additional or excess toxicity associated with limited anti-tumor activity. As would be expected with both PDS0101 and M9241 being delivered subcutaneously, injection site reactions were seen in 20% of patients. No new or additional toxicities have been observed to date from the addition of PDS0101 to the combination of the other two immunotherapies.

PDS0101 in Combination with Chemo-Radiotherapy Clinical Trial (IMMUNOCERV):
 
In October 2020, a third PDS0101 Phase 2 clinical trial was initiated with The University of Texas MD Anderson Cancer Center and is actively recruiting patients. This clinical trial is investigating the safety and preliminary anti-tumor efficacy of PDS0101 in combination with standard-of-care chemo-radiotherapy, or CRT, and their correlation with critical immunological biomarkers in patients with locally advanced cervical cancer. The study goals include evaluation of the rate of regression in patients with a primary tumor that is greater than or equal to 5cm among approximately thirty-five (35) patients. The rate of complete metabolic response is measured by PET-CT at day 170 and the rate of > 90% tumor volume reduction evaluated by MRI at 30-40 days from the start of treatment. Preliminary data is expected from this study in 2022. We believe that Versamune®’s strong T-cell induction has the potential to meaningfully enhance efficacy of the current standard of care CRT treatment in this indication.
 
18

Other Versamune® -Based Products in Development:

PDS0102 – Versamune® + TARP antigens
 
The TARP antigen is over-expressed in acute myelogenous leukemia (AML), prostate and breast cancers. In the U.S. 450,000 patients are projected to be diagnosed with prostate or breast cancer this year and 19,900 patients are projected to be diagnosed with AML. One hundred percent of adult and pediatric AML overexpress the TARP tumor antigen while approximately 90% of prostate cancers and 50% of breast cancers overexpress TARP, providing a potentially significant therapeutic opportunity to impact these diseases. In an early human clinical study, the National Cancer Institute demonstrated that its proprietary TARP antigens (TARP mix) were recognized by the immune system in prostate cancer patients with PSA biochemical recurrence leading to a notable reduction in tumor growth rates. In preclinical studies, a dramatically enhanced TARP-specific CD8+ killer T-cell response was observed when our designed TARP antigens were combined with Versamune® (PDS0102). Preclinical development is ongoing. On November 5, 2021 PDS and NCI entered into a Patent License Agreement to develop and commercialize a product including TARP antigens.  The patent for the TARP antigens extends through 2034. This license agreement is an important step to the further development and commercialization of PDS0102 and plans for a Phase 1/2 clinical trial to start in the second half of 2022.
 
PDS0103 – Versamune® + MUC1 antigens
 
In April 2020, the PDS-NCI CRADA was expanded beyond PDS0101 to include clinical and preclinical development of PDS0103.  PDS0103 is an investigational immunotherapy owned by PDS and designed to treat cancers associated with the mucin-1, or MUC1, oncogenic protein.  PDS0103 combines Versamune® with novel highly immunogenic agonist epitopes of MUC1 developed by the NCI and licensed by PDS.  MUC1 is highly expressed in multiple solid tumors and has been shown to be associated with drug resistance and poor disease prognosis in breast, colorectal, lung and ovarian cancers, for which PDS0103 is being developed. In preclinical studies, and similarly to PDS0101 and PDS0102, PDS0103 demonstrated the ability to generate powerful MUC1-specific CD8+ killer T-cells.  PDS0103 is currently in late preclinical development, and we requested a pre-IND meeting with the FDA to align on a clinical development plan. We are planning to initiate a Phase 2 clinical trial in mid- 2022.
 
PDS0104 – Versamune® + TRP-2 and melanoma antigens

Rates of melanoma have been rising rapidly over the past few decades and approximately 96,480 new melanomas will be diagnosed this year alone. More than 7,000 of these will prove fatal. PDS0104 combines Versamune ® with various melanoma antigens including the Tyrosinase-related protein 2 (TRP2) antigen which is highly expressed in melanoma. In pre-clinical B16 animal models of aggressive melanoma, PDS0104 has been shown to have unique and significant anti-tumor activity as a monotherapy and has also demonstrated strong anti-tumor synergy in combination with checkpoint inhibitors. As the first approval indications for checkpoint inhibitors occurred in melanoma, there is a growing unmet medical need to identify combination regimens with potential activity in checkpoint inhibitor refractory patients with this disease. Preclinical development is ongoing.

Infectious Diseases

Our focus remains on developing our oncology products and progressing the clinical trials described above. However, we are also developing preventive vaccines to address several infectious diseases. Based on the key characteristics of Versamune® we are progressing preclinical development of PDS0202, a universal influenza vaccine candidate, which combines Versamune® with COBRA (Computationally Optimized Broadly Reactive Antigen) antigens.  These COBRA antigens were designed by renowned influenza expert Dr. Ted Ross at the University of Georgia. PDS0202 leverages Versamune®’s ability to induce the immune system to generate high levels of flu-specific neutralizing antibodies, CD4 helper and CD8 killer T-cells, as well as long-acting memory T-cells to potentially provide broad and long-term protection against multiple influenza strains. PDS0202 pre-clinical development is being supported by an agreement with the National Institute of Allergy and Infectious Diseases Collaborative Influenza Vaccine Innovation Centers, or CIVIC program.  We have completed pre-clinical formulation and we have entered into an agreement to license COBRA antigens with the University of Georgia initially to progress into a human clinical trial in 2022.
 
19

PDS0203 is being designed with the goal to potentially provide long-term and broad protection against infection from COVID-19 and its potential mutations, based on the understood potential of Versamune® to prime the immune system to generate both antibodies for near term protection and T-cell responses for immune memory and long-term protection against pathogens. Farmacore Biotechnology has licensed Versamune® in Latin America to develop PDS0203 in Brazil.  Farmacore is developing and manufacturing the antigen component of the vaccine, leads all regulatory and clinical trial efforts in Brazil and has selected a top clinical research organization to conduct clinical trials.

On March 11, 2021, we announced that the COVID-19 vaccine consortium consisting of PDS, Farmacore Biotechnology and Blanver Farmoquímica, received a commitment from the Secretary for Research and Scientific Training of The Ministry of Science, Technology and Innovation of Brazil (“MCTI”) to fund up to approximately US$60 million to support the clinical development and commercialization of a Versamune®-based COVID-19 vaccine in Brazil.  All funding is contingent on the availability of financial resources within the MCTI and subject to negotiations among Farmacore, Blanver and MCTI. We are monitoring the evolving political and public health situation in Brazil that may pose challenges to developing PDS0203, such as the Brazilian Senate’s vote for compulsory licensing for COVID-19 vaccine technology (legislative process is ongoing).
 
MCTI indicated that it intends to make the funding available to perform a combined Phase 1/2 clinical trial, upon authorization by the Brazilian regulatory agency, Agência Nacional de Vigilância Sanitária (ANVISA) to initiate the proposed clinical program in Brazil.  Additional capital planned to be provided by MCTI will fund the manufacturing process scale up, production and the Phase 3 trial, pending the results of the Phase 1/2 trial. We plan to contribute Versamune® scientific expertise and operational support. Blanver Farmoquímica is expected to manufacture, promote, distribute, and commercialize the Versamune®-based COVID-19 vaccine in Latin America. We have not received confirmation of the availability of financial resources within the MCTI to support the clinical development and commercialization of a Versamune®-based COVID-19 vaccine in Brazil.  Clinical development and commercialization of a Versamune®-based COVID-19 vaccine in Brazil has not been initiated. As part of our strategic assessment of the program, Farmacore provided a comprehensive update on its efforts to develop a cGMP ready manufacturing plan and product for the antigen component of the vaccine. Farmacore has presented a proposal to meet certain development milestones in order to continue development of a COVID-19 vaccine containing Versamune®.  We have performed a program review and are in discussions with Farmacore to define the upcoming milestones for further development.
 
 Our current pipeline of Versamune®-based therapies is as follows:

graphic

20

Corporate Information

From the Company’s inception, it has devoted substantially all of its efforts to drug development, business planning, engaging regulatory, manufacturing and other technical consultants, acquiring operating assets, planning and executing clinical trials and raising capital.  We currently operate the existing business of Private PDS (as defined below) as a publicly traded company under the name PDS Biotechnology Corporation. We were incorporated as Edge Therapeutics, Inc., or Edge, on January 22, 2009. On March 15, 2019, privately held PDS Biotechnology Corporation, or Private PDS, completed a reverse merger, or the Merger, with Edge, pursuant to which Private PDS survived as a wholly owned subsidiary of Edge. Under the terms of the Merger, Edge changed its name to PDS Biotechnology Corporation and Private PDS changed its name to PDS Biotechnology Corporation.

We have never been profitable and have incurred net losses in each year since inception. Our net losses were $10.6 million, and $10.8 million for the nine months ended September 30, 2021 and 2020, respectively. As of September 30, 2021, we had an accumulated deficit of $54.4 million. Substantially all of our net losses have resulted from costs incurred in connection with its research and development programs and from general and administrative costs associated with these operations.

As of September 30, 2021, we had $69.7 million in cash and cash equivalents.

Our future funding requirements will depend on many factors, including the following:


the timing and costs of our planned clinical trials;


the timing and costs of our planned preclinical studies of our Versamune® platform;


the outcome, timing and costs of seeking regulatory approvals;


the terms and timing of any future collaborations, licensing, consulting or other arrangements that we may enter into;


the amount and timing of any payments we may be required to make in connection with the licensing, filing, prosecution, maintenance, defense and enforcement of any patents or patent applications or other intellectual property rights; and


the extent to which we license or acquire other products and technologies.

21

KEY COMPONENTS OF OUR STATEMENT OF OPERATIONS

Revenue

We have not generated any revenues from commercial product sales and do not expect to generate any such revenue in the near future. We may generate revenue in the future from a combination of research and development payments, license fees and other upfront payments or milestone payments.

Research and Development Expenses

Research and development expenses include employee-related expenses, licensing fees to use certain technology in our research and development projects, costs of acquiring, developing and manufacturing clinical trial materials, as well as fees paid to consultants and various entities that perform certain research and testing on our behalf. Costs for certain development activities, such as clinical trials, are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations or information provided by vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the consolidated financial statements as prepaid or accrued expenses. Costs incurred in connection with research and development activities are expensed as incurred.

We expect that our research and development expenses will increase significantly over the next several years as we advance our Versamune®-based immuno-oncology, or I-O, candidates into and through clinical trials, pursues regulatory approval of our investigational Versamune® candidates and prepare for a possible commercial launch, all of which will also require a significant investment in contract and internal manufacturing and inventory related costs.

The process of conducting human clinical trials necessary to obtain regulatory approval is costly and time consuming. We may never succeed in achieving marketing approval for our injectable I-O candidates. The probability of successful commercialization of our I-O candidates may be affected by numerous factors, including clinical data obtained in future trials, competition, manufacturing capability and commercial viability. As a result, we are unable to determine the duration and completion costs of our research and development projects or when and to what extent we will generate revenue from the commercialization and sale of any of our product candidates.

Results of Operations

The following table summarizes the results of our operations for the three months ended September 30, 2021 and 2020:

   
Three Months Ended
September 30,
   
Increase (Decrease)
 
   
2021
   
2020
   
$ Amount
   
%
 
   
(in thousands)
             
Operating expenses:
                       
Research and development expenses
 
$
3,688
   
$
2,061
   
$
1,627
     
79
%
General and administrative expenses
   
3,274
     
1,846
     
1,428
     
77
%
Total operating expenses
   
6,962
     
3,907
     
3,055
     
78
%
Loss from operations
   
(6,962
)
   
(3,907
)
   
(3,055
)
   
78
%
Interest income
   
1
     
1
     
     
 
Net loss and comprehensive loss
 
$
(6,961
)
 
$
(3,906
)
 
$
(3,055
)
   
78
%

Research and Development Expenses

Research and development expenses increased to $3.7 million for the three months ended September 30, 2021 from $2.1 million for the three months ended September 30, 2020. The increase of $1.6 million was primarily attributable to an increase of $0.7 million in personnel costs of which $0.5 million was stock compensation costs, and $0.9 million in costs related to clinical studies.

General and Administrative Expenses

General and administrative expenses increased to $3.2 million for the three months ended September 30, 2021 from $1.8 million for the three months ended September 30, 2020. The increase of $1.4 million is primarily attributable to an increase in personnel costs of $1.6 million, of which $1.0 million was stock compensation costs and $0.4 million was severance, partially offset by a decrease in professional fees of $0.2 million.

22

Comparison of the Nine Months Ended September 30, 2021 and 2020

The following table summarizes the results of our operations for the nine months ended September 30, 2021 and 2020:

   
Nine months ended
September 30,
   
Increase (Decrease)
 
   
2021
   
2020
   
$ Amount
   
%
 
   
(in thousands)
             
Operating expenses:
                       
Research and development expenses
 
$
7,865
   
$
5,447
   
$
2,418
     
44
%
General and administrative expenses
   
7,252
     
5,428
     
1,824
     
34
%
Total operating expenses
   
15,117
     
10,875
     
4,242
     
39
%
Loss from operations
   
(15,117
)
   
(10,875
)
   
(4,242
)
   
39
%
Interest income
   
3
     
54
     
(51
)
   
(94
)%
Benefit from income taxes
   
4,516
     
-
     
4,516
     
100
%
Net loss and comprehensive loss
 
$
(10,598
)
 
$
(10,821
)
 
$
223
     
(2
)%

Research and Development Expenses

Research and development expenses increased to $7.9 million for the nine months ended September 30, 2021 from $5.4 million for the same period in 2020. The increase of $2.5 million was primarily attributable to an increase in personnel costs of $0.9 million, of which 0.7 million was stock compensation costs, clinical studies of $2.1 million, regulatory fees of $0.2 million, facility expenses of $0.1 million offset by a decrease in manufacturing costs of $0.8 million.

General and Administrative Expenses

General and administrative expenses increased to $7.2 million for the nine months ended September 30, 2021 from $5.4 million for the same period in 2020. The $1.8 million increase was primarily attributable to an increase in personnel costs of $2.3 million, of which $1.4 million was stock compensation costs and $0.4 million was severance, facility expenses of $0.1 million offset by a decrease in professional services of $0.6 million.

Benefit from Income Taxes

Income tax benefit was $4.5 million for the nine months ended September 30, 2021 and $0 million for the nine months ended September 30, 2020. In the second quarter of 2021, we recognized approximately $4.5 million as a Benefit from Income Taxes from the sale of our NJ tax benefits pursuant to the New Jersey Technology Business Tax Certificate Transfer Net Operating Loss program. This transaction reduced our reported net loss and comprehensive income for the nine months ended September 30, 2021 to approximately $10.6 million, or approximately $0.2 million less than reported for the same period in 2020 which did not include a similar sale of NJ tax benefits.

23

Liquidity and Capital Resources

Our operations were initially financed from cash of $29.1 million from the consummation of the Merger in March 2019.

In July 2019, we entered into a common stock purchase agreement, or the Aspire Purchase Agreement, with Aspire Capital pursuant to which, we have the right, in our sole discretion, to present Aspire Capital Fund, LLC, or Aspire Capital, with a purchase notice, directing Aspire Capital (as principal) to purchase up to 100,000 shares of our common stock per business day, in an aggregate amount of up to $20.0 million of our common stock, or the Purchased Shares, over the term of the Aspire Purchase Agreement. We may sell an aggregate of 1,034,979 shares of our common stock (which represented 19.99% of our outstanding shares of common stock on the date of the Aspire Purchase Agreement) without stockholder approval. We may sell additional shares of our common stock above the 19.99% limit provided that (i) we obtain stockholder approval or (ii) stockholder approval has not been obtained at any time the 1,034,979 share limitation is reached and at all times thereafter the average price paid for all shares issued under the Aspire Purchase Agreement, is equal to or greater than $5.76, which was the consolidated closing bid price of our common stock on July 26, 2019. The minimum price at which we can sell shares under the Aspire Purchase Agreement is $0.50. On July 29, 2019, we issued 100,654 shares of our common stock to Aspire Capital, as consideration for entering into the Aspire Purchase Agreement, which we refer to as the Commitment Shares. We recorded the fair value of the shares at July 29, 2019 of $603,924 as an expense in the third quarter of 2019. Concurrently with the Aspire Purchase Agreement, we entered into a registration rights agreement with Aspire Capital, or the Registration Rights Agreement. In accordance with the Registration Rights Agreement, on August 20, 2019 we filed a Registration Statement on Form S-1 (File No. 333-232988) to cover the resale of the Commitment Shares and any Purchased Shares issuable to Aspire Capital under the Aspire Purchase Agreement. There is market uncertainty regarding the utilization of financing associated from the Aspire Purchase Agreement. As of September 30, 2021, no Purchase Shares have been sold to Aspire Capital under the Aspire Purchase Agreement.

In February 2020, we completed an underwritten public offering, in which we sold 10,000,000 shares of common stock at a public offering price of $1.30 per share. The shares sold included 769,230 shares issued upon the exercise by the underwriter of its option to purchase additional shares at the public offering price, minus underwriting discounts and commissions. We received gross proceeds of approximately $13 million and net proceeds of approximately $11.9 million after deducting underwriting discounts and commissions.

In July 2020, we filed a shelf registration statement, or the 2020 Shelf Registration Statement, with the SEC, for the issuance of common stock, preferred stock, warrants, rights, debt securities and units, which we refer to collectively as the Shelf Securities, up to an aggregate amount of $100 million. The 2020 Shelf Registration Statement was declared effective on July 31, 2020. On August 13, 2020, we sold 6,900,000 shares of its common stock at a public offering price of $2.75 per share pursuant to the 2020 Shelf Registration Statement, which includes 900,000 shares issued upon the exercise by the underwriter of its option to purchase additional shares at the public offering price, minus underwriting discounts and commissions. We received gross proceeds of approximately $19.0 million and net proceeds of approximately $17.1 million, after deducting underwriting discounts and offering expenses.

In May 2021, we received approximately $4.5 million from the net sale of tax benefits to an unrelated, profitable New Jersey corporation pursuant the Company’s participation in the New Jersey Technology Business Tax Certificate Transfer Net Operating Loss (NOL) program for State Fiscal Year 2020.

In June 2021, we sold 6,088,235 shares of our common stock at a public offering price of $8.50 per share pursuant to the 2020 Shelf Registration Statement, which includes 794,117 shares issued upon the exercise by the underwriter of its option to purchase additional shares at the public offering price, minus underwriting discounts and commissions. We received gross proceeds of approximately $51.7 million and net proceeds of approximately $48.5 million, after deducting underwriting discounts and offering expenses. Approximately $29,300,000 of Shelf Securities remain available for future sale under the 2020 Shelf Registration Statement.

As of September 30, 2021, we had $69.7 million in cash and cash equivalents. Our primary uses of cash are to fund operating expenses, primarily research and development expenditures. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable and accrued expenses.

We evaluated whether there are any conditions and events, considered in the aggregate, that raise substantial doubt about our ability to continue as a going concern within one year beyond the filing of this Quarterly Report on Form 10-Q.  Based on such evaluation and our current plans, which are subject to change, management believes that our existing cash and cash equivalents as of September 30, 2021 will be sufficient to satisfy our operating cash needs for at least one year after the filing of this Quarterly Report on Form 10-Q.

24

We plan to continue to fund our operations and capital funding needs through equity and/or debt financings. However, we cannot be certain that additional financing will be available when needed or that, if available, financing will be obtained on terms favorable to us or our existing stockholders. We may also enter into government funding programs and consider selectively partnering for clinical development and commercialization. The sale of additional equity would result in additional dilution to our stockholders. Incurring debt financing would result in debt service obligations, and the instruments governing such debt could provide for operating and financing covenants that would restrict our operations. If we are unable to raise additional capital in sufficient amounts or on acceptable terms, we may be required to delay, limit, reduce, or terminate our product development or future commercialization efforts or grant rights to develop and market immunotherapies that we would otherwise prefer to develop and market ourselves. Any of these actions could harm our business, results of operations and prospects.

Cash Flows

The following table shows a summary of our cash flows for each of the periods indicated (in thousands):

   
Nine Months Ended September 30,
 
   
2021
   
2020
 
Net cash used in operating activities
 
$
(7,985
)
 
$
(8,520
)
Net cash provided by investing activities
   
     
 
Net cash provided by financing activities
   
48,889
     
29,827
 
Net increase in cash
 
$
40,904
   
$
21,307
 

Net Cash Used in Operating Activities

Net cash used in operating activities was $8.0 million and $8.5 million for the nine months ended September 30, 2021 and 2020, respectively. The decrease in cash used in operating activities of $0.5 million includes the $4.5 million NOL sale. Excluding the NOL sale, net cash used in operating activities would have increased $4.0 million primarily due to the increase in the loss before income taxes of $4.3 million, the change in prepaid expenses and other assets of $2.0 million, accounts payables and accruals of $0.3 million partially offset by an increase in stock-based compensation of $2.1 million, and a decrease in restructuring reserve of $0.5 million.

Net Cash Provided by Financing Activities

Net cash provided by financing activities for the nine months ended September 30, 2021 was primarily due to the receipt of net proceeds from the issuance of common stock of $48.5 million.

Net cash provided by financing activities for the nine months ended September 30, 2020 was primarily due to the receipt of net proceeds from the issuance of common stock of $29.8 million.

Operating Capital Requirements

To date, we have not generated any product revenue. We do not know when, or if, we will generate any product revenue and we do not expect to generate significant product revenue unless and until we obtain regulatory approval and commercialize one of our current or future product candidates. We anticipate that we will continue to generate losses for the foreseeable future, and we expect the losses to increase as we continue the development of, and seek regulatory approvals for, our tablet vaccine candidates, and begin to commercialize any approved vaccine candidates. We are subject to all of the risks incident to the development of new products, and may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may harm our business. We expect to incur additional costs associated with operating as a public company and anticipate that we will need substantial additional funding in connection with our continuing operations.

We evaluated whether there are any conditions and events, considered in the aggregate, that raise substantial doubt about our ability to continue as a going concern within one year beyond the filing of this Quarterly Report. Our budgeted cash requirements in 2021 and beyond include expenses related to continuing development and clinical studies.  We believe that our existing cash and cash equivalents as of September 30, 2021 are sufficient to continue operations and research and development programs for at least the next 12 months from the date of this Quarterly Report. Until we can generate significant cash from our operations, we expect to continue to fund our operations with available financial resources. These financial resources may not be adequate to sustain our operations.

25

We have based our projections of operating capital requirements on assumptions that may prove to be incorrect and we may use all of our available capital resources sooner than we expect. Because of the numerous risks and uncertainties associated with research, development and commercialization of pharmaceutical products, we are unable to estimate the exact amount of our operating capital requirements. Our future funding requirements will depend on many factors, including, but not limited to:


the initiation, progress, timing, costs and results of our planned clinical trials;


the effects of health epidemics, pandemics, or outbreaks of infectious diseases, including the recent COVID-19 pandemic, on our business operations, financial condition, results of operations and cash flows;


the outcome, timing and cost of meeting regulatory requirements established by the U.S. Food and Drug Administration, or FDA, the European Medicines Agency, or EMA, and other comparable foreign regulatory authorities;


the cost of filing, prosecuting, defending and enforcing our patent claims and other intellectual property rights;


the cost of defending potential intellectual property disputes, including patent infringement actions brought by third parties against us now or in the future;


the effect of competing technological and market developments;


the cost of establishing sales, marketing and distribution capabilities in regions where we choose to commercialize our products on our own; and


the initiation, progress, timing and results of our commercialization of our product candidates, if approved, for commercial sale.

Please see the section titled “Risk Factors” elsewhere in the Quarterly Report and Annual Report for additional risks associated with our operations.

Purchase Commitments

We have no material non-cancelable purchase commitments with service providers as we have generally contracted on a cancelable, purchase order basis.

Critical Accounting Polices and Estimates

Our management’s discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenue generated and expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

There have been no material changes to our critical accounting policies and estimates during the nine months ended September 30, 2021 from those disclosed in our Annual Report on - Form 10-K for the year ended December 31, 2020.

26

Impact of the CARES Act

On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act, or the CARES Act, was enacted and signed into law, and GAAP requires recognition of the tax effects of new legislation during the reporting period that includes the enactment date. The CARES Act, among other things, includes changes to the tax provisions that benefits business entities and makes certain technical corrections to the 2017 Tax Cuts and Jobs Act, including, permitting net operating losses, or NOLs, carryovers and carrybacks to offset 100% of taxable income for taxable years beginning before 2021. In addition, the CARES Act allows NOLs incurred in 2018, 2019, and 2020 to be carried back to each of the five preceding taxable years to generate a refund of previously paid income taxes. The CARES Act provides other reliefs and stimulus measures. We have evaluated the impact of the CARES Act, and do not expect that any provision of the CARES Act would result in a material cash benefit to us or have a material impact on our financial statements or internal control over financial reporting.

Operations and Liquidity

While the potential economic impact brought by and over the duration of the COVID-19 pandemic may be difficult to assess or predict, the COVID-19 pandemic has resulted in significant disruption of global financial markets, which could in the future negatively affect our liquidity. In addition, a recession or market volatility resulting from the COVID-19 pandemic could affect our business. We have taken proactive, aggressive action throughout the COVID-19 pandemic to protect the health and safety of our employees and expect to continue to implement these measures until we determine that the COVID-19 pandemic is adequately contained for purposes of our business. We may take further actions as government authorities require or recommend or as we determine to be in the best interests of our employees. Given the nature and type of our short-term investments, we do not believe that the COVID-19 pandemic will have a material impact on our current investment liquidity.

Outlook and Impact of COVID-19 on our Business

In December 2019, a novel (new) coronavirus known as SARS-CoV-2 was first detected in Wuhan, Hubei Province, People’s Republic of China, causing outbreaks of the coronavirus disease, known as COVID-19, that has now spread globally. On January 30, 2020 the World Health Organization (WHO) declared COVID-19 a public health emergency. The Secretary of Health and Human Services declared a public health emergency on January 31, 2020, under section 319 of the Public Health Service Act (42 U.S.C. 247d), in response to the COVID-19 outbreak. On March 11, 2020, the WHO declared COVID-19 a pandemic. The full impact of the COVID-19 pandemic is unknown and rapidly evolving. The COVID-19 pandemic has and could continue to negatively affect the Company’s liquidity and operations. To date, two of the three currently planned PDS0101 clinical trials have been delayed, specifically as a result of the adverse impact the COVID-19 pandemic has had on clinical trial operations for cancer indications in the United States.  Even though both of these studies have since been initiated despite the pandemic challenges, the evolving COVID-19 pandemic has also impacted the pace of enrollment in clinical trials and we may be affected by similar delays as patients may avoid or may not be able to travel to healthcare facilities and physicians’ offices unless due to a health emergency and clinical trial staff can no longer get to the clinic.

Although there is uncertainty related to the anticipated impact of the COVID-19 pandemic on our future results, we believe our current cash reserves, leave us well-positioned to manage our business through this crisis as it continues to unfold. However, the impacts of the COVID-19 pandemic are broad-reaching and continuing and the financial impacts associated with the COVID-19 pandemic are still uncertain.

Despite the economic uncertainty resulting from the COVID-19 pandemic, we intend to continue to focus on the development of our product candidates and we have expanded our infectious disease pipeline since the pandemic brought renewed resources and interest on technologies such as the Versamune® platform in the context of research and development in prevention of COVID-19. We licensed Versamune® to Farmacore in Brazil to develop PDS0203; a vaccine for the prevention of COVID-19.  The Secretary for Research and Scientific Training of The Ministry of Science, Technology and Innovation of Brazil provided a commitment to fund up to approximately US$60 million to support the clinical development and commercialization of a Versamune®-based COVID-19 vaccine in Brazil. We have not received confirmation of the availability of financial resources within the MCTI to support the clinical development and commercialization of a Versamune®-based COVID-19 vaccine in Brazil. Clinical development and commercialization of a Versamune®-based COVID-19 vaccine in Brazil has not been initiated.

27

Off-Balance Sheet Arrangements

We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined in the rules and regulations of the SEC.

Smaller Reporting Company

As of January 1, 2021, we are no longer an “emerging growth company,” as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. However, we remain a “smaller reporting company,” as defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended. We will cease to be a smaller reporting company if we have a non-affiliate public float in excess of $250 million and annual revenues in excess of $100 million, or a non-affiliate public float in excess of $700 million, determined on an annual basis. As a smaller reporting company, we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not smaller reporting companies. We will continue to take advantage of some or all of the available exemptions.

ITEM 3.
QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISK

The primary objectives of our investment activities are to ensure liquidity and to preserve principal, while at the same time maximizing the income we receive from our cash and marketable securities without significantly increasing risk. As of September 30, 2021, we had cash equivalents of $69.7 million that were held in a non-interest-bearing money operating account and an institutional U.S. Treasury money market fund. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates. Due to the short-term maturities of our cash equivalents and the low risk profile of our investments, we do not believe that an immediate 100 basis point change in interest rates would have a material effect on the fair market value of our cash equivalents. To minimize the risk in the future, we intend to maintain our portfolio of cash equivalents and short-term investments in institutional market funds that are comprised of U.S. Treasury and Treasury backed repurchase agreements.

ITEM 4.
CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

An evaluation was carried out, under the supervision of and with the participation of our management, including our Chief Executive Officer and our Chief Financial Officer, of the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15 (e)) under the Securities Exchange Act of 1934, or the Exchange Act, as of the end of the period covered by this report. Based on the evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that our disclosure controls and procedures are effective to ensure that the information required to be disclosed by us in the reports we file or submit under the Exchange Act was recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting (as such term is defined in Rule 13a-15(f) under the Exchange Act) identified in connection with the evaluation identified above that occurred during the quarter ended September 30, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

28

PART II.
OTHER INFORMATION

ITEM 1.
LEGAL PROCEEDINGS

On July 23, 2021, David R. Rosener, a purported stockholder of the Company, filed a putative class action and shareholder derivative complaint in the Court of Chancery of the State of Delaware (C.A. No. 2021-0644 JRS) against the Company and all of its directors and certain of its executive officers. The plaintiff named all current directors of PDS as defendants as well as PDS’s Chief Scientific Officer and PDS’s Chief Medical Officer and also named PDS as a nominal defendant. The plaintiff claims PDS’s bylaws required tabulation of broker non-votes on Proposal 3 at the Company’s 2021 annual stockholder meeting held on June 17, 2021, which sought shareholder approval of the Second Amended and Restated PDS Biotechnology Corporation 2014 Equity Incentive Plan (the “Restated Plan”). The complaint asserts claims for breach of fiduciary duties, declaratory judgment, waste of corporate assets and unjust enrichment in connection with the Restated Plan and the granting of an aggregate award of 1,040,700 stock options to certain executive officers pursuant to the Restated Plan.  The plaintiff seeks unspecified monetary damages, seeks to have the Restated Plan declared void, and seeks recission of the grant of stock options as ultra vires.  Given the early stage of this lawsuit, PDS is unable to reasonably estimate the costs associated with the lawsuit or predict the outcome.  Each of the Company, its directors and the named aforementioned executives intend to defend this action vigorously.  There can be no guarantee as to the timing of any resolution.

PDS may be involved, from time to time, in legal proceedings and claims arising in the ordinary course of its business. Such matters are subject to many uncertainties and outcomes are not predictable with assurance.

ITEM 1A.
RISK FACTORS

There have been no material changes from our risk factors as previously reported in our Annual Report on Form 10-K for the year ended December 31, 2020. However, any investment in our business involves a high degree of risk. Before making an investment decision, you should carefully consider the information we include in this Quarterly Report on Form 10-Q, including our unaudited interim condensed consolidated financial statements and accompanying notes, our Annual Report on Form 10-K for the year ended December 31, 2020 filed on March 18, 2021, including our financial statements and related notes contained therein, and the additional information in the other reports we file with the Securities and Exchange Commission. These risks may result in material harm to our business and our financial condition and results of operations. In this event, the market price of our common stock may decline and you could lose part or all of your investment. Additional risks that we currently believe are immaterial may also impair our business operations. Our business, financial conditions and future prospects and the trading price of our common stock could be harmed as a result of any of these risks.

ITEM 2.
UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

There were no unregistered sales of the Company’s equity securities during the nine months ended September 30, 2021.

ITEM 3.
DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4.
MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5.
OTHER INFORMATION

On September 30, 2021, the Company delivered a notice of termination without cause to Seth Van Voorhees and removed him from his position as the Company’s Chief Financial Officer, principal financial officer and principal accounting officer. The Company and Mr. Van Voorhees are continuing to discuss the terms of Mr. Van Voorhees separation from the Company.

ITEM 6.
EXHIBITS

29

EXHIBIT INDEX

Exhibit
Number
 
Exhibit Description
 
Executive Employment Agreement, dated October 4, 2021, by and between PDS Biotechnology Corporation and Matthew Hill (filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on October 6, 2021, and incorporated by reference herein).
     
 
Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
     
 
Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
     
 
Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (furnished herewith).
     
 
Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (furnished herewith).
     
101.INS*
 
Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)
     
101.SCH*
 
Inline XBRL Taxonomy Extension Schema Document
     
101.CAL*
 
Inline XBRL Taxonomy Extension Calculation Linkbase Document
     
101.DEF*
 
Inline XBRL Taxonomy Extension Definition Linkbase Document
     
101.LAB*
 
Inline XBRL Taxonomy Extension Label Linkbase Document
     
101.PRE*
 
Inline XBRL Taxonomy Extension Presentation Linkbase Document
     
104
 
Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)

*
Filed herewith (unless otherwise noted as being furnished herewith)
**
Certain portions of the Exhibit have been redacted pursuant to Item 601(b)(10)(iv) of Regulation S-K.

30

SIGNATURES

Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 
PDS Biotechnology Corporation
     
November 10, 2021
By:
/s/ Frank Bedu-Addo
   
Frank Bedu-Addo
   
President and Chief Executive Officer
(Principal Executive Officer)
     
     
November 10, 2021
By:
/s/ Matthew Hill
   
Matthew Hill
   
Chief Financial Officer
   
(Principal Financial and Accounting Officer)


31

EX-31.1 2 brhc10030652_ex31-1.htm EXHIBIT 31.1

Exhibit 31.1

CERTIFICATION OF PRINCIPAL EXECUTIVE AND FINANCIAL OFFICER
PURSUANT TO EXCHANGE ACT RULE 13a-14(a)/15d-14(a)
AS ADOPTED PURSUANT TO SECTION 302
OF THE SARBANES-OXLEY ACT OF 2002

I, Frank Bedu-Addo, certify that:

1.
I have reviewed this Quarterly Report on Form 10-Q of PDS Biotechnology Corporation for the period ended September 30, 2021;

2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3
Based on my knowledge, the condensed consolidated financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:


a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;


b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of condensed consolidated financial statements for external purposes in accordance with generally accepted accounting principles;


c)
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and


d)
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.
The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):


a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and


b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Dated: November 10, 2021
/s/ Frank Bedu-Addo
 
 
Frank Bedu-Addo
 
 
President and Chief Executive Officer
 
 
(Principal Executive Officer)
 



EX-31.2 3 brhc10030652_ex31-2.htm EXHIBIT 31.2

Exhibit 31.2

CERTIFICATION OF PRINCIPAL ACCOUNTING OFFICER
PURSUANT TO EXCHANGE ACT RULE 13a-14(a)/15d-14(a)
AS ADOPTED PURSUANT TO SECTION 302
OF THE SARBANES-OXLEY ACT OF 2002

I, Matthew Hill, certify that:

1.
I have reviewed this Quarterly Report on Form 10-Q of PDS Biotechnology Corporation for the period ended September 30, 2021;

2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3
Based on my knowledge, the condensed consolidated financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:


a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;


b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of condensed consolidated financial statements for external purposes in accordance with generally accepted accounting principles;


c)
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and


d)
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.
The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):


a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and


b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Dated: November 10, 2021
/s/ Matthew Hill
 
 
Matthew Hill
 
 
Chief Financial Officer
 
 
(Principal Financial and Accounting Officer)
 



EX-32.1 4 brhc10030652_ex32-1.htm EXHIBIT 32.1

Exhibit 32.1

CERTIFICATION
PURSUANT TO 18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the accompanying Quarterly Report of PDS Biotechnology Corporation (the “Company”), on Form 10-Q for the quarter ended September 30, 2021 (the “Report”), I, Frank Bedu-Addo, President and Chief Executive Officer of the Company, hereby certify pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002 that:


(1)
the Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and


(2)
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: November 10, 2021
/s/ Frank Bedu-Addo
 
 
Frank Bedu-Addo
 
 
President and Chief Executive Officer
 
 
(Principal Executive Officer)
 



EX-32.2 5 brhc10030652_ex32-2.htm EXHIBIT 32.2

Exhibit 32.2
CERTIFICATION
PURSUANT TO 18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the accompanying Quarterly Report of PDS Biotechnology Corporation (the “Company”), on Form 10-Q for the quarter ended September 30, 2021 (the “Report”), I, Matthew Hill, Chief Financial Officer of the Company, hereby certify pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002 that:


(1)
the Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and


(2)
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: November 10, 2021
/s/ Matthew Hill
 
 
Matthew Hill
 
 
Chief Financial Officer
 
 
(Principal Financial and Accounting Officer)
 



EX-101.SCH 6 pdsb-20210930.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 010000 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 010100 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 020000 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 030000 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 040000 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 060100 - Disclosure - Nature of Operations link:presentationLink link:calculationLink link:definitionLink 060200 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 060300 - Disclosure - Liquidity link:presentationLink link:calculationLink link:definitionLink 060400 - Disclosure - Fair Value of Financial Instruments link:presentationLink link:calculationLink link:definitionLink 060500 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 060600 - Disclosure - Accrued Expenses link:presentationLink link:calculationLink link:definitionLink 060700 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 060800 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 060900 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 061000 - Disclosure - Retirement Plan link:presentationLink link:calculationLink link:definitionLink 061100 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 070200 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 080200 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 080400 - Disclosure - Fair Value of Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 080500 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 080600 - Disclosure - Accrued Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 080700 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 090100 - Disclosure - Nature of Operations (Details) link:presentationLink link:calculationLink link:definitionLink 090200 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 090300 - Disclosure - Liquidity (Details) link:presentationLink link:calculationLink link:definitionLink 090400 - Disclosure - Fair Value of Financial Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 090500 - Disclosure - Leases, Operating Leases (Details) link:presentationLink link:calculationLink link:definitionLink 090502 - Disclosure - Leases, Supplemental Cash Flow Information Related to Operating Leases (Details) link:presentationLink link:calculationLink link:definitionLink 090504 - Disclosure - Leases, Future Payments for Operating Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 090506 - Disclosure - Leases, Future Payments for Operating Lease Liabilities (Details) CALC 01 link:presentationLink link:calculationLink link:definitionLink 090600 - Disclosure - Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 090700 - Disclosure - Stock-Based Compensation, Equity Compensation Plans (Details) link:presentationLink link:calculationLink link:definitionLink 090702 - Disclosure - Stock-Based Compensation, Stock-Based Compensation Expense Related to Stock Options (Details) link:presentationLink link:calculationLink link:definitionLink 090704 - Disclosure - Stock-Based Compensation, Assumptions Used to Value Stock Options Granted (Details) link:presentationLink link:calculationLink link:definitionLink 090706 - Disclosure - Stock-Based Compensation, Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 090800 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 090900 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 091000 - Disclosure - Retirement Plan (Details) link:presentationLink link:calculationLink link:definitionLink 091100 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 pdsb-20210930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 pdsb-20210930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 pdsb-20210930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Area of office space under sub-lease Area of Real Estate Property Award Type [Axis] Summary of Significant Accounting Policies [Abstract] Accrued Expenses Accounts Payable and Accrued Liabilities Disclosure [Text Block] Accounts payable Accrued professional fees Total Accrued expenses Accrued Liabilities, Current Additional paid-in capital Additional Paid in Capital Additional Paid-in Capital [Member] Stock-based compensation expense APIC, Share-based Payment Arrangement, Increase for Cost Recognition Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Stock-based compensation expense Share-based Payment Arrangement, Expense Antidilutive Securities [Axis] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive impact to EPS (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Antidilutive Securities, Name [Domain] Total assets Assets ASSETS Assets [Abstract] Total current assets Assets, Current Current assets: Assets, Current [Abstract] Summary of Significant Accounting Policies Unaudited Interim Financial Statements Business Acquisition [Line Items] Liquidity [Abstract] Business Combination, Consideration Transferred [Abstract] Cash and cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Net increase in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect Cash and cash equivalents at end of period Cash and cash equivalents at beginning of period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash Equivalents and Concentration of Cash Balance Cash and Cash Equivalents, Policy [Policy Text Block] Supplemental Cash Flow Information Related to Operating Leases [Abstract] Cash and cash equivalents Commitments and Contingencies [Abstract] Commitments and Contingencies Common stock reserved for issuance (in shares) Common Stock [Member] Common stock, shares issued (in shares) Common stock, par value (in dollars per share) Common stock, $0.00033 par value, 75,000,000 shares authorized at September 30, 2021 and December 31, 2020, 28,435,067 shares and 22,261,619 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively Common stock, shares authorized (in shares) Common stock shares outstanding (in shares) Retirement Plan [Abstract] Comprehensive loss Current income tax expense 401(k) employer contributions Defined Contribution Plan, Employer Discretionary Contribution Amount Depreciation expense Depreciation Stock-Based Compensation [Abstract] Stock-Based Compensation Share-based Payment Arrangement [Text Block] Net Loss per Common Share [Abstract] Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract] Per share information: Net Loss per Common Share Earnings Per Share, Policy [Policy Text Block] Net loss per share, basic (in dollars per share) Net loss per share, diluted (in dollars per share) Federal statutory rate Effective tax rate Effective Income Tax Rate Reconciliation, Percent Period for recognition Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Stock Options [Member] Stock Options to Purchase Common Stock [Member] Share-based Payment Arrangement, Option [Member] Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Unamortized Stock Compensation Expense [Abstract] Stock Options [Abstract] Legal Proceedings [Abstract] Share-based Payment Arrangement, Additional Disclosure [Abstract] Unamortized stock compensation expense Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Equity Component [Domain] Fair Value of Financial Instruments [Abstract] Fair Value, Net Asset (Liability) [Abstract] Fair Value Transfers Between Levels [Abstract] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value Hierarchy and NAV [Axis] Fair Value of Financial Instruments [Abstract] Transfers from Level 1 to Level 2 Fair Value, Assets, Level 1 to Level 2 Transfers, Amount Transfers into Level 3 Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3 Transfers out of Level 3 Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3 Transfers from Level 2 to Level 1 Fair Value, Assets, Level 2 to Level 1 Transfers, Amount Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value Hierarchy and NAV [Domain] Fair Value of Financial Instruments Fair Value of Financial Instruments Fair Value, by Balance Sheet Grouping [Table Text Block] Quoted Prices in Active Markets (Level 1) [Member] Quoted Prices in Inactive Markets (Level 2) [Member] Significant Unobservable Inputs (Level 3) [Member] Grantee Status [Domain] Grantee Status [Axis] General and administrative expenses General and Administrative Expense General and Administrative [Member] Loss before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Income Statement Location [Domain] Income Taxes [Abstract] Income Statement Location [Axis] Condensed Consolidated Statements of Operations and Comprehensive Loss [Abstract] Accrued interest and penalties Income Taxes Benefit from income taxes Benefit from income taxes Income Tax Expense (Benefit) Restructuring reserve Increase (Decrease) in Restructuring Reserve Operating lease liabilities Accounts payable Increase (Decrease) in Accounts Payable Accrued expenses Increase (Decrease) in Accrued Liabilities Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Increase (Decrease) in Stockholders' Equity [Roll Forward] Interest income Investment Income, Interest Issuance of common stock from equity transaction Term of sub-lease agreement Lessor, Operating Lease, Term of Contract Leases Remaining lease term 2022 Lessee, Operating Lease, Liability, to be Paid, Year One Total future minimum lease payments Lessee, Operating Lease, Liability, to be Paid Less imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount 2021 (remaining three months) 2024 Lessee, Operating Lease, Liability, to be Paid, Year Three Future Payments for Operating Lease Liabilities Lessee, Operating Lease, Liability, Maturity [Table Text Block] 2023 Lessee, Operating Lease, Liability, to be Paid, Year Two Leases [Abstract] Lessee, Operating Lease, Description [Abstract] Discount rate used to measure operating lease liability Lessee, Operating Lease, Discount Rate Leases [Abstract] Total Liabilities Liabilities LIABILITIES Liabilities [Abstract] LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities and Equity [Abstract] Total liabilities and stockholders' equity Liabilities and Equity Noncurrent liability: Liabilities, Noncurrent [Abstract] Total current liabilities Liabilities, Current Current liabilities: Nature of Operations Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Net loss Net loss Over-Allotment Option [Member] Operating lease obligation-short term Operating Lease, Liability, Current Operating lease obligation-long term Operating Lease, Liability, Noncurrent Future Payments for Operating Lease Liabilities [Abstract] Lessee, Operating Lease, Liability, Payment, Due [Abstract] Cash paid for operating lease liabilities Right-of-use asset Operating lease right-to-use asset Rent expense Operating lease liability Lease liability Operating Lease, Liability Operating lease expense Operating expenses: Operating Expenses [Abstract] Total operating expenses Operating Expenses Loss from operations Operating Income (Loss) Nature of Operations [Abstract] Other income: Other Income and Expenses [Abstract] Accrued Expenses [Abstract] Retirement Plan Stock-based 401K company common match Plan Name [Domain] Plan Name [Axis] Prepaid expenses and other Prepaid Expense and Other Assets, Current Proceeds from exercise of warrants Proceeds from issuance of shares Proceeds from issuances of common stock, net of issuance costs Proceeds from exercise of stock options Property and equipment, net Property, Plant and Equipment, Net Right-of use assets recorded in exchange for lease obligations Research and Development Research and Development Expense, Policy [Policy Text Block] Research and development expenses Research and Development Expense Research and Development [Member] Accumulated Deficit [Member] Accumulated deficit Retained Earnings (Accumulated Deficit) Liquidity Substantial Doubt about Going Concern [Text Block] Vested and expected to vest, weighted average remaining contractual life Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Expected term Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Term of option Expiration period Options outstanding, weighted average remaining contractual life Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Exercisable, aggregate intrinsic value Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Percentage of options vesting Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Exercisable, weighted average remaining contractual life Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Proceeds from issuance of shares, net of underwriting discounts and commissions Sale of Stock, Consideration Received on Transaction Sale of Stock [Domain] Assumptions Used to Value Stock Options Granted Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Stock Option Activity Antidilutive Securities Accrued Expenses and Other Liabilities Schedule of Accrued Liabilities [Table Text Block] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Stock-Based Compensation Expense Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Patent Costs Selling, General and Administrative Expenses, Policy [Policy Text Block] Vesting period Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Weighted Average Exercise Price [Roll Forward] Options granted (in shares) Granted (in shares) Forfeited (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Remaining Options Granted [Member] Share-based Payment Arrangement, Tranche Two [Member] One Quarter of Options Granted [Member] Share-based Payment Arrangement, Tranche One [Member] Share price (in dollars per share) Share Price Stock-Based Compensation [Abstract] Share-based Payment Arrangement, Noncash Expense [Abstract] Stock-based compensation expense Share-based Payment Arrangement, Noncash Expense Exercised (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Frank Bedu-Addo, Gregory Conn, and Lauren Wood [Member] Other Employees [Member] Share-based Payment Arrangement, Employee [Member] Granted (in dollars per share) Exercise price (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Dividend rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Assumptions Used in Determining Fair Value of Stock Options Granted [Abstract] Risk-free interest rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Number of shares authorized for issuance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Shares available for grant (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Exercisable (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Exercisable (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Exercised, aggregate intrinsic value Weighted Average Remaining Contractual Life and Aggregate Intrinsic Value [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Options outstanding, beginning balance (in shares) Options outstanding, ending balance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Vested and expected to vest (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Options outstanding, ending balance (in dollars per share) Options outstanding, beginning balance (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Options outstanding, aggregate intrinsic value Options outstanding, aggregate intrinsic value Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Fair value of option on grant date (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Number of Shares [Roll Forward] Vested and expected to vest, aggregate intrinsic value Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Vested and expected to vest (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Equity Award [Domain] Stock-Based Compensation Share-based Payment Arrangement [Policy Text Block] Sales price (in dollars per share) Shares Issued, Price Per Share Balance (in shares) Balance (in shares) Shares, Outstanding Condensed Consolidated Balance Sheets [Abstract] Statement [Table] Statement [Line Items] Condensed Consolidated Statements of Cash Flows [Abstract] Equity Components [Axis] Condensed Consolidated Statements of Changes in Stockholders' Equity [Abstract] Issuance of common stock from 401K match (in shares) Stock Issued During Period, Shares, Employee Benefit Plan Issuance of common stock from 401K match Stock Issued During Period, Value, Employee Benefit Plan Exercised (in shares) Issuances of common stock, from exercise of stock options (in shares) Issuance of common stock (in shares) Issuance of common stock, net of issuance costs (in shares) Subsequent Events [Abstract] Shares Granted or Issued, Share-based Payment Arrangement [Abstract] Issuances of common stock, from exercise of stock options Issuance of common stock, net of issuance costs Total stockholders' equity Balance Balance Stockholders' Equity Attributable to Parent STOCKHOLDERS' EQUITY STOCKHOLDERS' EQUITY Subsequent Event [Member] Subsequent Event Type [Domain] Subsequent Event [Line Items] Subsequent Event Type [Axis] Subsequent Events [Abstract] Subsequent Event [Table] Subsequent Events Sale of Stock [Axis] Unrecognized tax benefits Use of Estimates Use of Estimates, Policy [Policy Text Block] Vesting [Axis] Vesting [Domain] Warrants to Purchase Common Stock [Member] Warrant [Member] Weighted average common shares outstanding, diluted (in shares) Weighted average common shares outstanding, basic (in shares) Accrued compensation Chief Financial Officer [Member] Maximum [Member] Minimum [Member] Statistical Measurement [Domain] Statistical Measurement [Axis] Cover [Abstract] Document Type Document Quarterly Report Document Transition Report Entity Interactive Data Current Amendment Flag Document Fiscal Year Focus Document Fiscal Period Focus Document Period End Date Entity Registrant Name Entity Central Index Key Entity File Number Entity Tax Identification Number Entity Incorporation, State or Country Code Current Fiscal Year End Date Entity Current Reporting Status Entity Shell Company Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity Address, Address Line One Entity Address, Address Line Two Entity Address, City or Town Entity Address, State or Province Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security Trading Symbol Security Exchange Name Entity Common Stock, Shares Outstanding Liquidity [Abstract] The number of planned clinical trials. Number of planned clinical trials The number of planned clinical trials that have been delayed, specifically as a result of the adverse impact the COVID-19 Pandemic has had on clinical trial operations for cancer indications in the United States. Number of planned clinical trials delayed Number of planned clinical trials delayed The total current and noncurrent amount recognized for uncertain tax positions as of the balance sheet date. Liability for Uncertain Tax Positions Uncertain tax positions Represents the 2010 Equity Incentive Plan, the 2012 Equity Incentive Plan, and the 2014 Equity Incentive Plan (the Plans). Equity Compensation Plans [Member] The Plans [Member] Refers to the percentage of stock outstanding as of the immediately preceding December 31st used to determine the annual increase in the Plan limit for authorized shares that may be granted as qualified and nonqualified options. Percentage of Common Stock outstanding Percentage of Common Stock outstanding used to determine annual increase in the plan limit Term the Plan shall continue to remain effective, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Share-based Compensation Arrangement by Share-based Payment Award, Term of Plan Term of plan The 2019 Inducement Plan provides for the grant of non-qualified stock options. Inducement Plan 2019 [Member] 2019 Inducement Plan [Member] Number of equity-based compensation plans. Number of Equity-Based Compensation Plans Number of equity compensation plans Incentive stock options (ISOs) under the equity compensation plans that may be granted only to employees. Incentive Stock Options [Member] Incentive Stock Options [Member] Non-qualified stock options (NQs) under the equity compensation plans that may be granted to service providers. Nonqualified Stock Options [Member] Nonqualified Options [Member] Represents the 2018 Equity Incentive Plan. Equity Incentive Plan 2018 [Member] 2018 Equity Incentive Plan [Member] Represents the 2014 Equity Incentive Plan. Equity Incentive Plan 2014 [Member] 2014 Equity Incentive Plan [Member] Number of installments in which the remaining lease payments need to be made in order to terminate the operating lease agreement. Operating Lease, Number of Installments for Remaining Lease Payment Number of installments for remaining lease payment Amount of remaining lease payments under the operating lease agreement. Operating Lease, Remaining lease payments Remaining lease payments The percentage of remaining payments that required to be paid in order to terminate an operating lease agreement. Operating Lease, Percentage of remaining payments required to be paid to terminate lease Percentage of remaining payments required to be paid to terminate lease Percentage of the company's outstanding shares that can be sold under a common stock purchase agreement without stockholder approval. Common Stock Purchase Agreement, Shares that can be sold, Percentage Percentage of shares of common stock that can be sold without shareholder approval Aggregate amount of shares to be purchased under a common stock purchase agreement. Common Stock Purchase Agreement, Shares to be purchased, Value Common stock to be purchased under common stock purchase agreement Aggregate number of shares of company's outstanding shares that can be sold under a common stock purchase agreement without shareholder approval. Common Stock Purchase Agreement, Shares that can be sold, Shares Shares of common stock that can be sold without shareholder approval (in shares) The amount of securities included in a shelf registration statement filed with the Securities and Exchange Commission (the "2020 Shelf Registration Statement") for the issuance of common stock, preferred stock, warrants, rights, debt securities and units (collectively, the "Shelf Securities") that are available for future sale. Shelf Registration Statement, Available for future sale Registered securities in Shelf Registration Statement available for future sale Number of shares issued during the period as consideration for equity transaction. Stock Issued During Period, Shares, Equity Transaction Issuance of common stock from equity transaction (in shares) Cumulative number of shares purchased under a common stock purchase agreement. Common Stock Purchase Agreement, Cumulative shares sold Shares sold under common stock purchase agreement (in shares) Securities that remain available for future sale under a shelf registration statement, or 2020 Shelf Registration Statement, filed with the SEC in July 2020, for the issuance of common stock, preferred stock, warrants, rights, debt securities and units, collectively the "Shelf Securities." Shelf securities available for sale Shelf securities available for sale Amount of cash inflow received from the sale of unused NOL carryforwards pursuant to the State of New Jersey's Technology Business Tax Certificate Program, which allowed certain high technology and biotechnology companies to sell unused NOL carryforwards to other New Jersey-based corporate taxpayers. Proceeds from Sale of Unused Net Operating Loss Carryforwards Proceeds from sale of tax benefits Number of shares to be purchased under a common stock purchase agreement. Common Stock Purchase Agreement, Shares to be purchased, Shares Shares of common stock to be purchased (in shares) Tabular disclosure of supplemental cash flow information related to lessee's operating leases and right-of-use assets and lease liabilities. Lessee, Operating Lease, Supplemental Cash Flow Information Related to Operating Lease [Table Text Block] Supplemental Cash Flow Information Related to Operating Leases Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Accrued Research and Development Costs, Current Accrued research and development costs Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options granted (or share units converted) into shares. Share-based Compensation Arrangement by Share-based Payment Award, Options, Granted in Period, Intrinsic Value Granted, aggregate intrinsic value Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options forfeited (or share units converted) into shares. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeited in Period, Intrinsic Value Forfeited, aggregate intrinsic value Weighted average remaining contractual term for option awards granted, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Share-based Compensation Arrangement by Share-based Payment Award, Options, Granted, Weighted Average Remaining Contractual Term Granted, weighted average remaining contractual life Value of stock issued as a result of the exercise of warrants. Stock Issued During Period, Value, Warrants Exercised Issuance of warrant exercise Number of shares of stock issued from exercise of warrants during the current period. Stock Issued During Period, Shares, Warrants Exercised Issuance of warrant exercise (in shares) Equity impact of the value of new stock issued during the period as consideration for equity transaction. Stock Issued During Period, Value, Equity Transaction Issuance of common stock from equity transaction Disclosure of accounting policy for significant risks and uncertainties. Significant Risks and Uncertainties, Policy [Policy Text Block] Significant Risks and Uncertainties Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year and thereafter following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Lessee, Operating Lease, Liability, to be Paid, Year Four and Thereafter 2025 and after Fair value of options granted. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock. Share-based Compensation Arrangement by Share-based Payment Award, Options, Granted in Period, Fair Value Aggregate fair value of options granted EX-101.PRE 10 pdsb-20210930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 11 image00001.jpg begin 644 image00001.jpg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end XML 12 brhc10030652_10q_htm.xml IDEA: XBRL DOCUMENT 0001472091 2021-01-01 2021-09-30 0001472091 2021-11-03 0001472091 2021-09-30 0001472091 2020-12-31 0001472091 2020-07-01 2020-09-30 0001472091 2021-07-01 2021-09-30 0001472091 2020-01-01 2020-09-30 0001472091 us-gaap:RetainedEarningsMember 2020-12-31 0001472091 us-gaap:RetainedEarningsMember 2021-06-30 0001472091 2019-12-31 0001472091 us-gaap:CommonStockMember 2019-12-31 0001472091 2021-06-30 0001472091 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001472091 us-gaap:CommonStockMember 2020-12-31 0001472091 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001472091 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001472091 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001472091 us-gaap:CommonStockMember 2021-06-30 0001472091 2020-06-30 0001472091 us-gaap:RetainedEarningsMember 2019-12-31 0001472091 us-gaap:RetainedEarningsMember 2020-06-30 0001472091 us-gaap:CommonStockMember 2020-06-30 0001472091 us-gaap:CommonStockMember 2020-01-01 2020-09-30 0001472091 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-09-30 0001472091 us-gaap:RetainedEarningsMember 2020-01-01 2020-09-30 0001472091 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0001472091 us-gaap:RetainedEarningsMember 2021-01-01 2021-09-30 0001472091 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-09-30 0001472091 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0001472091 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0001472091 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0001472091 us-gaap:CommonStockMember 2021-01-01 2021-09-30 0001472091 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0001472091 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0001472091 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001472091 2020-09-30 0001472091 us-gaap:RetainedEarningsMember 2021-09-30 0001472091 us-gaap:CommonStockMember 2020-09-30 0001472091 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001472091 us-gaap:CommonStockMember 2021-09-30 0001472091 us-gaap:RetainedEarningsMember 2020-09-30 0001472091 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-09-30 0001472091 us-gaap:WarrantMember 2020-01-01 2020-09-30 0001472091 us-gaap:WarrantMember 2021-01-01 2021-09-30 0001472091 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-09-30 0001472091 srt:MaximumMember 2019-07-29 0001472091 2019-07-29 0001472091 2019-07-26 0001472091 srt:MinimumMember 2019-07-26 0001472091 2019-07-29 2019-07-29 0001472091 us-gaap:OverAllotmentOptionMember 2021-06-01 2021-06-30 0001472091 us-gaap:OverAllotmentOptionMember 2020-08-01 2020-08-31 0001472091 us-gaap:OverAllotmentOptionMember 2020-02-01 2020-02-29 0001472091 2020-02-01 2020-02-29 0001472091 2021-06-01 2021-06-30 0001472091 2020-08-01 2020-08-31 0001472091 2020-08-31 0001472091 2020-02-29 0001472091 2020-07-31 0001472091 2021-05-01 2021-05-31 0001472091 2020-01-01 2020-12-31 0001472091 us-gaap:FairValueInputsLevel3Member 2021-09-30 0001472091 us-gaap:FairValueInputsLevel1Member 2021-09-30 0001472091 us-gaap:FairValueInputsLevel3Member 2020-12-31 0001472091 us-gaap:FairValueInputsLevel1Member 2020-12-31 0001472091 us-gaap:FairValueInputsLevel2Member 2021-09-30 0001472091 us-gaap:FairValueInputsLevel2Member 2020-12-31 0001472091 2019-07-08 0001472091 2020-05-01 0001472091 pdsb:EquityIncentivePlan2014Member 2019-03-31 0001472091 pdsb:EquityIncentivePlan2018Member 2018-12-31 0001472091 pdsb:EquityIncentivePlan2014Member 2021-06-17 0001472091 pdsb:EquityIncentivePlan2014Member 2014-12-31 0001472091 pdsb:EquityIncentivePlan2014Member 2014-01-01 2014-12-31 0001472091 srt:MaximumMember pdsb:IncentiveStockOptionsMember pdsb:EquityCompensationPlansMember 2021-01-01 2021-09-30 0001472091 srt:MaximumMember pdsb:NonqualifiedStockOptionsMember pdsb:EquityCompensationPlansMember 2021-01-01 2021-09-30 0001472091 srt:MinimumMember pdsb:NonqualifiedStockOptionsMember pdsb:EquityCompensationPlansMember 2021-01-01 2021-09-30 0001472091 pdsb:IncentiveStockOptionsMember pdsb:EquityCompensationPlansMember 2021-01-01 2021-09-30 0001472091 pdsb:EquityCompensationPlansMember 2021-01-01 2021-09-30 0001472091 pdsb:InducementPlan2019Member 2020-12-08 0001472091 pdsb:InducementPlan2019Member 2020-12-09 0001472091 pdsb:EquityIncentivePlan2018Member 2021-09-30 0001472091 pdsb:InducementPlan2019Member 2021-09-30 0001472091 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-09-30 0001472091 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-09-30 0001472091 us-gaap:GeneralAndAdministrativeExpenseMember 2021-07-01 2021-09-30 0001472091 us-gaap:ResearchAndDevelopmentExpenseMember 2020-07-01 2020-09-30 0001472091 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-09-30 0001472091 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-09-30 0001472091 us-gaap:ResearchAndDevelopmentExpenseMember 2021-07-01 2021-09-30 0001472091 us-gaap:GeneralAndAdministrativeExpenseMember 2020-07-01 2020-09-30 0001472091 us-gaap:EmployeeStockOptionMember 2020-12-31 0001472091 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-09-30 0001472091 us-gaap:EmployeeStockOptionMember 2021-09-30 0001472091 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-12-31 0001472091 us-gaap:EmployeeStockOptionMember us-gaap:ShareBasedPaymentArrangementEmployeeMember pdsb:EquityIncentivePlan2014Member 2020-12-08 2020-12-08 0001472091 us-gaap:ShareBasedPaymentArrangementEmployeeMember us-gaap:SubsequentEventMember 2021-10-18 2021-10-18 0001472091 srt:ChiefFinancialOfficerMember us-gaap:SubsequentEventMember 2021-10-18 2021-10-18 0001472091 us-gaap:EmployeeStockOptionMember us-gaap:SubsequentEventMember 2021-10-18 2021-10-18 0001472091 us-gaap:EmployeeStockOptionMember us-gaap:SubsequentEventMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2021-10-18 2021-10-18 0001472091 us-gaap:EmployeeStockOptionMember us-gaap:SubsequentEventMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2021-10-18 2021-10-18 shares iso4217:USD iso4217:USD shares pdsb:ClinicalTrial pure pdsb:Installment utr:sqft pdsb:Plan false --12-31 2021 Q3 0001472091 P1Y P1Y 0.25 10-Q true 2021-09-30 false 001-37568 PDS Biotechnology Corp DE 26-4231384 25B Vreeland Road, Suite 300 Florham Park, NJ 07932 800 208-3343 Common Stock, par value $0.00033 per share PDSB NASDAQ Yes Yes Non-accelerated Filer true false false 28435067 69744004 28839565 1596810 1497665 71340814 30337230 1037 5443 406171 547706 71748022 30890379 1445585 1415224 1923846 1735322 207717 119904 3577148 3270450 313976 490353 3891124 3760803 0.00033 0.00033 75000000 75000000 28435067 28435067 22261619 22261619 9383 7346 122231115 70907315 -54383600 -43785085 67856898 27129576 71748022 30890379 3687999 2060815 7865249 5446718 3274325 1846214 7252371 5428098 6962324 3907029 15117620 10874816 -6962324 -3907029 -15117620 -10874816 1358 1207 2617 54242 -6960966 -3905822 -15115003 -10820574 0 0 -4516488 0 -6960966 -6960966 -3905822 -3905822 -10598515 -10598515 -10820574 -10820574 -0.24 -0.24 -0.21 -0.21 -0.43 -0.43 -0.73 -0.73 28425850 28425850 18961619 18961619 24639299 24639299 14892764 14892764 15361619 5064 52861882 -35852457 17014489 0 129792 0 129792 6900000 2282 17784218 0 17786500 0 0 -3905822 -3905822 22261619 7346 70775892 -39758279 31024959 28417909 9377 120405851 -47422634 72992594 0 1701763 0 1701763 17158 6 123501 0 123507 0 0 -6960966 -6960966 28435067 9383 122231115 -54383600 67856898 5281237 1742 40633670 -28937705 11697707 0 300898 0 300898 16900000 5581 29750921 0 29756502 65240 22 70437 0 70459 15142 1 19966 0 19967 0 0 -10820574 -10820574 22261619 7346 70775892 -39758279 31024959 22261619 7346 70907315 -43785085 27129576 0 2400980 0 2400980 6088235 2009 48542989 0 48544998 68571 23 344089 0 344112 16642 5 35742 0 35747 0 0 -10598515 -10598515 28435067 9383 122231115 -54383600 67856898 -10598515 -10820574 2400980 300898 35747 19967 4406 11706 180775 106949 99145 -1935067 30361 361871 188524 125133 0 -498185 -127804 -62597 -7984671 -8519765 0 70459 344112 0 48544998 29756502 48889110 29826961 40904439 21307196 28839565 12161739 69744004 33468935 <div style="font-weight: bold;"><span style="background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Note 1 – Nature of Operations</span></div> <div><br/> </div> <div style="display:none;"><br/></div> <div style="text-align: justify; text-indent: 36pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">PDS Biotechnology Corporation, a Delaware corporation (the “Company” or “PDS”), is a clinical-stage immunotherapy company developing a growing pipeline of cancer immunotherapies and infectious disease vaccines designed to overcome the well-established limitations of current immunotherapy technologies. PDS owns Versamune®, a proprietary T-cell activating platform designed to train the immune system to better attack and destroy disease. When paired with an antigen, which is a disease-related protein that is recognizable by the immune system, Versamune® has been shown to induce, <i>in vivo,</i> large quantities of high-quality, highly potent polyfunctional CD8+ killer T-cells, a specific sub-type of CD8+ killer T-cell that is more effective at killing infected or target cells. </span></div> <div style="display:none;"><br/></div> <div style="text-indent: 36pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"> <br/> </span></div> <div style="display:none;"><br/></div> <div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: justify; text-indent: 36pt;">The Company’s immuno-oncology products can potentially be used as a component of combination products with other leading technologies to provide effective treatments across a range of advanced cancer types. Currently, the Company believes its product candidates are of interest for potential combination treatments in relation to Human Papillomavirus (HPV)-associated cancers, melanoma, colorectal, lung, breast and prostate cancers and potentially as monotherapies in early-stage cancers. In addition, PDS is working to progress its infectious disease development program, which includes novel vaccines for COVID-19 and universal influenza. </div> <div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div> <div style="display:none;"><br/></div> <div style="text-indent: 36pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"> <span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div> <div style="display:none;"><br/></div> <div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; text-align: justify; text-indent: 36pt;">From the Company’s inception, it has devoted substantially all of its efforts to drug development, business planning, engaging regulatory, manufacturing and other technical consultants, acquiring operating assets, planning and executing clinical trials and raising capital.</div> <div><span style="font-size: 10pt;"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div> <div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><br/> </span> </div> <div><span style="font-size: 10pt;"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div> <div style="display:none;"><br/></div> <div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; text-align: justify; text-indent: 36pt;">In December 2019, a novel (new) coronavirus known as SARS-CoV-2 was first detected in Wuhan, Hubei Province, People’s Republic of China, causing outbreaks of the coronavirus disease, known as COVID-19, that has now spread globally. On January 30, 2020, the World Health Organization (WHO) declared COVID-19 a public health emergency. The Secretary of Health and Human Services declared a public health emergency on January 31, 2020, under section 319 of the Public Health Service Act (42 U.S.C. 247d), in response to the COVID-19 outbreak. On March 11, 2020, the WHO declared COVID-19 a pandemic and on March 13 the President declared a national emergency in response to the pandemic. PDS continues to learn more about the full impact of the COVID-19 pandemic which has continued to evolve due to the emergence of variants of concern, resulting in new waves of infection regionally and globally. The COVID-19 pandemic has and could continue to negatively affect the Company’s liquidity and operations.  To date, the start of two of the three initiated PDS0101 clinical trials were delayed, specifically as a result of the adverse impact the COVID-19 pandemic has had on clinical trial operations for cancer indications in the United States. The FDA has continued to update its guidance assisting sponsors in assuring the safety of trial participants, maintaining compliance with Good Clinical Practice (GCP) and minimizing risks to trial integrity.  Clinical trial sites have implemented institution-specific measures securing the safety of patients and staff to ensure the integrity of the trials in the face of the ongoing pandemic. All three studies have since been initiated despite the pandemic challenges; however, the evolving COVID-19 pandemic has impacted the pace of enrollment in clinical trials in general and the Company may be negatively affected with its trials. COVID-19 related travel and other restrictions may also impact the potential for on-site monitoring visiting and audits and inspections by Company personnel, third parties, and government regulators. There may be shortages of site personnel and equipment necessary for the timely completion of the clinical trials. The Company is providing support to address these challenges, but these mitigation measures may not overcome the obstacles that the pandemic has wrought which continue to impede progress of clinical trials.</div> <div><span style="font-size: 10pt;"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div> <div style="display:none;"><br/></div> <div style="text-indent: 20pt;"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><br/> </span> </div> <div><span style="font-size: 10pt;"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div> <div style="display:none;"><br/></div> <div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; text-align: justify; text-indent: 36pt;">Although there is uncertainty related to the anticipated impact of the COVID-19 pandemic on the Company’s future results, management believes the Company’s current cash reserves leave us well-positioned to manage the business through this crisis as it continues to unfold. However, the impacts of the COVID-19 pandemic and its variants are broad-reaching and continuing and the financial impacts associated with the COVID-19 pandemic are still uncertain.</div> 2 3 <div style="font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Note 2 – Summary of Significant Accounting Policies</div> <div><br/> </div> <div> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 36pt; vertical-align: top; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(A)</td> <td style="width: auto; vertical-align: top;"> <div style="font-weight: bold;">Unaudited interim financial statements:</div> </td> </tr> </table> <div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div style="display:none;"><br/></div> <div style="text-align: justify; text-indent: 36pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The interim balance sheet at September 30, 2021, the statements of operations and comprehensive loss and changes in stockholders’ equity for the three and nine months ended September 30, 2021 and 2020, and cash flows for the nine months ended September 30, 2021 and 2020 are unaudited. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. GAAP, in accordance with the requirements of the Securities and Exchange Commission (“SEC”) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. These condensed consolidated financial statements have been prepared on the same basis as the Company’s annual financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments that are necessary for a fair statement of its financial information. The results of operations for the three and nine months ended September 30, 2021 are not necessarily indicative of the results to be expected for the year ending December 31, 2021 or for any other future annual or interim period. The balance sheet as of December 31, 2020 included herein was derived from the audited condensed consolidated financial statements as of that date. These condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto as of and for the year ended December 31, 2020, filed by the Company with the SEC in its Annual Report on Form 10-K on March 18, 2021.</div> <div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(B)</td> <td style="width: auto; vertical-align: top;"> <div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Use of estimates:</div> </td> </tr> </table> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div style="display:none;"><br/></div> <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of expenses at the date of the consolidated financial statements and during the reporting periods, and to disclose contingent assets and liabilities at the date of the consolidated financial statements. Actual results could differ from those estimates.</div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(C)</td> <td style="width: auto; vertical-align: top;"> <div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Significant risks and uncertainties:</div> </td> </tr> </table> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div style="display:none;"><br/></div> <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The Company’s operations are subject to a number of factors that may affect its operating results and financial condition. Such factors include, but are not limited to: the clinical and regulatory development of its products, the Company’s ability to preserve its cash resources, the Company’s review of strategic alternatives, the Company’s ability to add product candidates to its pipeline, the Company’s intellectual property, the ability to efficiently and effectively conduct its clinical trials, competition from products manufactured and sold or being developed by other companies, the price of, and demand for, Company products if approved for sale, the Company’s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products, the Company’s ability to raise capital, and the effects of health epidemics, pandemics, or outbreaks of infectious diseases, including the recent COVID-19 pandemic and its variants.<br/> </div> <div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div> <div style="display:none;"><br/></div> <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The Company currently has no commercially approved products. As such, there can be no assurance that the Company’s future research and development programs will be successfully commercialized. Developing and commercializing a product requires significant time and capital and is subject to regulatory review and approval as well as competition from other biotechnology and pharmaceutical companies. The Company operates in an environment of rapid change and is dependent upon the continued services of its employees and consultants and obtaining and protecting its intellectual property.</div> <div> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(D)</td> <td style="width: auto; vertical-align: top;"> <div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Cash equivalents and concentration of cash balance:</div> </td> </tr> </table> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div style="display:none;"><br/></div> <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The Company considers all highly liquid securities with a maturity weighted average of less than three months to be cash equivalents. The Company’s cash and cash equivalents in bank deposit accounts, at times, may exceed federally insured limits.</div> <div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div><br/></div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(E)</td> <td style="width: auto; vertical-align: top;"> <div style="font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Research and development:</div> </td> </tr> </table> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div style="display:none;"><br/></div> <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Costs incurred in connection with research and development activities are expensed as incurred. These costs include licensing fees to use certain technology in the Company’s research and development projects as well as fees paid to consultants and entities that perform certain research and testing on behalf of the Company.</div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div style="display:none;"><br/></div> <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Costs for certain development activities, such as clinical trials, are recognized based on an evaluation of the progress to completion of specific tasks using data, such as patient enrollment, clinical site activations or information provided by vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred.</div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(F)</td> <td style="width: auto; vertical-align: top;"> <div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Patent costs:</div> </td> </tr> </table> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div style="display:none;"><br/></div> <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The Company expenses patent costs as incurred and classifies such costs as general and administrative expenses in the accompanying statements of operations and comprehensive loss.</div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(G)</td> <td style="width: auto; vertical-align: top;"> <div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Stock-based compensation:</div> </td> </tr> </table> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div style="display:none;"><br/></div> <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The Company accounts for its stock-based compensation in accordance with ASC Topic 718, Compensation—Stock Compensation (“ASC 718”). ASC 718 requires all stock-based payments to employees, directors and non-employees to be recognized as expense in the consolidated statements of operations and comprehensive loss based on their grant date fair values. In order to determine the fair value of stock options on the date of grant, the Company uses the Black-Scholes option-pricing model. Inherent in this model are assumptions related to expected stock-price volatility, option term, risk-free interest rate and dividend yield. While the risk-free interest rate and dividend yield are less subjective assumptions that are based on factual data derived from public sources, the expected stock-price volatility and option term assumptions require a greater level of judgment. The Company expenses the fair value of its stock-based compensation awards to employees and directors on a straight-line basis over the requisite service period, which is generally the vesting period. The Company recognizes forfeitures as they occur.</div> <div> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(H)</td> <td style="width: auto; vertical-align: top;"> <div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Net loss per common share:</div> </td> </tr> </table> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div style="display:none;"><br/></div> <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Basic and diluted net loss per common share is determined by dividing net loss attributable to common stockholders by the weighted average common shares outstanding during the period. For all periods presented, the common shares underlying the stock options and warrants have been excluded from the calculation because their effect would be anti-dilutive. Therefore, the weighted average shares outstanding used to calculate both basic and diluted loss per common share are the same.</div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div style="display:none;"><br/></div> <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The potentially dilutive securities excluded from the determination of diluted loss per share as their effect is antidilutive, are as follows:</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"><br/> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="6" rowspan="1" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-weight: bold;">As of September 30,</div> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td colspan="1" style="vertical-align: bottom; font-family: &amp; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-family: &amp;amp; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; font-family: &amp;amp; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-weight: bold;"> 2021<br/> </div> </td> <td colspan="1" style="font-family: &amp; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-family: &amp;amp; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; font-family: &amp;amp; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-weight: bold;">2020<br/> </div> </td> <td colspan="1" style="font-family: &amp; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td colspan="1" style="vertical-align: bottom; font-family: &amp;amp; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Stock options to purchase Common Stock</div> </td> <td colspan="1" style="font-family: &amp; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-family: &amp; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div>2,951,852</div> </td> <td colspan="1" style="font-family: &amp; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-family: &amp; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-family: &amp; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div>1,639,753</div> </td> <td colspan="1" style="font-family: &amp; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td colspan="1" style="vertical-align: bottom; font-family: &amp;amp; width: 76%; padding-bottom: 2px;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Warrants to purchase Common Stock</div> </td> <td colspan="1" style="font-family: &amp; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-family: &amp; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div>197,518</div> </td> <td colspan="1" style="font-family: &amp; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-family: &amp; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-family: &amp; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div>197,518</div> </td> <td colspan="1" style="font-family: &amp; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td colspan="1" style="vertical-align: bottom; font-family: &amp;amp; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Total</div> </td> <td colspan="1" style="font-family: &amp; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-family: &amp; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div>3,149,370</div> </td> <td colspan="1" style="font-family: &amp; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-family: &amp; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-family: &amp; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div>1,837,271</div> </td> <td colspan="1" style="font-family: &amp; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> </table> <div> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 36pt; vertical-align: top; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(A)</td> <td style="width: auto; vertical-align: top;"> <div style="font-weight: bold;">Unaudited interim financial statements:</div> </td> </tr> </table> <div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div style="display:none;"><br/></div> <div style="text-align: justify; text-indent: 36pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The interim balance sheet at September 30, 2021, the statements of operations and comprehensive loss and changes in stockholders’ equity for the three and nine months ended September 30, 2021 and 2020, and cash flows for the nine months ended September 30, 2021 and 2020 are unaudited. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. GAAP, in accordance with the requirements of the Securities and Exchange Commission (“SEC”) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. These condensed consolidated financial statements have been prepared on the same basis as the Company’s annual financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments that are necessary for a fair statement of its financial information. The results of operations for the three and nine months ended September 30, 2021 are not necessarily indicative of the results to be expected for the year ending December 31, 2021 or for any other future annual or interim period. The balance sheet as of December 31, 2020 included herein was derived from the audited condensed consolidated financial statements as of that date. These condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto as of and for the year ended December 31, 2020, filed by the Company with the SEC in its Annual Report on Form 10-K on March 18, 2021.</div> <div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(B)</td> <td style="width: auto; vertical-align: top;"> <div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Use of estimates:</div> </td> </tr> </table> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div style="display:none;"><br/></div> <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of expenses at the date of the consolidated financial statements and during the reporting periods, and to disclose contingent assets and liabilities at the date of the consolidated financial statements. Actual results could differ from those estimates.</div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(C)</td> <td style="width: auto; vertical-align: top;"> <div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Significant risks and uncertainties:</div> </td> </tr> </table> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div style="display:none;"><br/></div> <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The Company’s operations are subject to a number of factors that may affect its operating results and financial condition. Such factors include, but are not limited to: the clinical and regulatory development of its products, the Company’s ability to preserve its cash resources, the Company’s review of strategic alternatives, the Company’s ability to add product candidates to its pipeline, the Company’s intellectual property, the ability to efficiently and effectively conduct its clinical trials, competition from products manufactured and sold or being developed by other companies, the price of, and demand for, Company products if approved for sale, the Company’s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products, the Company’s ability to raise capital, and the effects of health epidemics, pandemics, or outbreaks of infectious diseases, including the recent COVID-19 pandemic and its variants.<br/> </div> <div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div> <div style="display:none;"><br/></div> <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The Company currently has no commercially approved products. As such, there can be no assurance that the Company’s future research and development programs will be successfully commercialized. Developing and commercializing a product requires significant time and capital and is subject to regulatory review and approval as well as competition from other biotechnology and pharmaceutical companies. The Company operates in an environment of rapid change and is dependent upon the continued services of its employees and consultants and obtaining and protecting its intellectual property.</div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(D)</td> <td style="width: auto; vertical-align: top;"> <div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Cash equivalents and concentration of cash balance:</div> </td> </tr> </table> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div style="display:none;"><br/></div> <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The Company considers all highly liquid securities with a maturity weighted average of less than three months to be cash equivalents. The Company’s cash and cash equivalents in bank deposit accounts, at times, may exceed federally insured limits.</div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(E)</td> <td style="width: auto; vertical-align: top;"> <div style="font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Research and development:</div> </td> </tr> </table> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div style="display:none;"><br/></div> <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Costs incurred in connection with research and development activities are expensed as incurred. These costs include licensing fees to use certain technology in the Company’s research and development projects as well as fees paid to consultants and entities that perform certain research and testing on behalf of the Company.</div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div style="display:none;"><br/></div> <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Costs for certain development activities, such as clinical trials, are recognized based on an evaluation of the progress to completion of specific tasks using data, such as patient enrollment, clinical site activations or information provided by vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred.</div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(F)</td> <td style="width: auto; vertical-align: top;"> <div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Patent costs:</div> </td> </tr> </table> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div style="display:none;"><br/></div> <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The Company expenses patent costs as incurred and classifies such costs as general and administrative expenses in the accompanying statements of operations and comprehensive loss.</div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(G)</td> <td style="width: auto; vertical-align: top;"> <div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Stock-based compensation:</div> </td> </tr> </table> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div style="display:none;"><br/></div> <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The Company accounts for its stock-based compensation in accordance with ASC Topic 718, Compensation—Stock Compensation (“ASC 718”). ASC 718 requires all stock-based payments to employees, directors and non-employees to be recognized as expense in the consolidated statements of operations and comprehensive loss based on their grant date fair values. In order to determine the fair value of stock options on the date of grant, the Company uses the Black-Scholes option-pricing model. Inherent in this model are assumptions related to expected stock-price volatility, option term, risk-free interest rate and dividend yield. While the risk-free interest rate and dividend yield are less subjective assumptions that are based on factual data derived from public sources, the expected stock-price volatility and option term assumptions require a greater level of judgment. The Company expenses the fair value of its stock-based compensation awards to employees and directors on a straight-line basis over the requisite service period, which is generally the vesting period. The Company recognizes forfeitures as they occur.</div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(H)</td> <td style="width: auto; vertical-align: top;"> <div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Net loss per common share:</div> </td> </tr> </table> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div style="display:none;"><br/></div> <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Basic and diluted net loss per common share is determined by dividing net loss attributable to common stockholders by the weighted average common shares outstanding during the period. For all periods presented, the common shares underlying the stock options and warrants have been excluded from the calculation because their effect would be anti-dilutive. Therefore, the weighted average shares outstanding used to calculate both basic and diluted loss per common share are the same.</div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div style="display:none;"><br/></div> <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The potentially dilutive securities excluded from the determination of diluted loss per share as their effect is antidilutive, are as follows:</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"><br/> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="6" rowspan="1" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-weight: bold;">As of September 30,</div> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td colspan="1" style="vertical-align: bottom; font-family: &amp; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-family: &amp;amp; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; font-family: &amp;amp; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-weight: bold;"> 2021<br/> </div> </td> <td colspan="1" style="font-family: &amp; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-family: &amp;amp; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; font-family: &amp;amp; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-weight: bold;">2020<br/> </div> </td> <td colspan="1" style="font-family: &amp; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td colspan="1" style="vertical-align: bottom; font-family: &amp;amp; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Stock options to purchase Common Stock</div> </td> <td colspan="1" style="font-family: &amp; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-family: &amp; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div>2,951,852</div> </td> <td colspan="1" style="font-family: &amp; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-family: &amp; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-family: &amp; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div>1,639,753</div> </td> <td colspan="1" style="font-family: &amp; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td colspan="1" style="vertical-align: bottom; font-family: &amp;amp; width: 76%; padding-bottom: 2px;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Warrants to purchase Common Stock</div> </td> <td colspan="1" style="font-family: &amp; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-family: &amp; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div>197,518</div> </td> <td colspan="1" style="font-family: &amp; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-family: &amp; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-family: &amp; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div>197,518</div> </td> <td colspan="1" style="font-family: &amp; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td colspan="1" style="vertical-align: bottom; font-family: &amp;amp; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Total</div> </td> <td colspan="1" style="font-family: &amp; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-family: &amp; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div>3,149,370</div> </td> <td colspan="1" style="font-family: &amp; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-family: &amp; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-family: &amp; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div>1,837,271</div> </td> <td colspan="1" style="font-family: &amp; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> </table> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div style="display:none;"><br/></div> <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The potentially dilutive securities excluded from the determination of diluted loss per share as their effect is antidilutive, are as follows:</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"><br/> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="6" rowspan="1" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-weight: bold;">As of September 30,</div> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td colspan="1" style="vertical-align: bottom; font-family: &amp; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-family: &amp;amp; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; font-family: &amp;amp; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-weight: bold;"> 2021<br/> </div> </td> <td colspan="1" style="font-family: &amp; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-family: &amp;amp; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; font-family: &amp;amp; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-weight: bold;">2020<br/> </div> </td> <td colspan="1" style="font-family: &amp; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td colspan="1" style="vertical-align: bottom; font-family: &amp;amp; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Stock options to purchase Common Stock</div> </td> <td colspan="1" style="font-family: &amp; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-family: &amp; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div>2,951,852</div> </td> <td colspan="1" style="font-family: &amp; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-family: &amp; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-family: &amp; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div>1,639,753</div> </td> <td colspan="1" style="font-family: &amp; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td colspan="1" style="vertical-align: bottom; font-family: &amp;amp; width: 76%; padding-bottom: 2px;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Warrants to purchase Common Stock</div> </td> <td colspan="1" style="font-family: &amp; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-family: &amp; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div>197,518</div> </td> <td colspan="1" style="font-family: &amp; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-family: &amp; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-family: &amp; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div>197,518</div> </td> <td colspan="1" style="font-family: &amp; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td colspan="1" style="vertical-align: bottom; font-family: &amp;amp; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Total</div> </td> <td colspan="1" style="font-family: &amp; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-family: &amp; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div>3,149,370</div> </td> <td colspan="1" style="font-family: &amp; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-family: &amp; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-family: &amp; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div>1,837,271</div> </td> <td colspan="1" style="font-family: &amp; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> </table> 2951852 1639753 197518 197518 3149370 1837271 <div style="font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Note 3 – Liquidity</div> <div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div style="display:none;"><br/></div> <div style="text-align: justify; text-indent: 36pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">As of September 30, 2021, the Company had $69.7 million of cash and cash equivalents. The Company’s primary uses of cash are to fund operating expenses, primarily research and development expenditures. Cash used to fund operating expenses is impacted by the timing of when the Company pays these expenses, as reflected in the change to the Company’s outstanding accounts payable and accrued expenses.</div> <div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div style="display:none;"><br/></div> <div style="text-align: justify; text-indent: 36pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">On July 29, 2019, the Company entered into a common stock purchase agreement, or the Aspire Purchase Agreement, with Aspire Capital pursuant to which, the Company has the right, in its sole discretion, to present Aspire Capital Fund, LLC, or Aspire Capital, with a purchase notice, directing Aspire Capital (as principal) to purchase up to 100,000 shares of the Company’s common stock per business day, in an aggregate amount of up to $20.0 million of its common stock, or the Purchased Shares, over the term of the Aspire Purchase Agreement. The Company may sell an aggregate of 1,034,979 shares of its common stock (which represented 19.99% of its outstanding shares of common stock on the date of the Aspire Purchase Agreement) without stockholder approval. The Company may sell additional shares of its common stock above the 19.99% limit provided that (i) the Company obtains stockholder approval or (ii) stockholder approval has not been obtained at any time the 1,034,979 share limitation is reached and at all times thereafter the average price paid for all shares issued under the Aspire Purchase Agreement, is equal to or greater than $5.76, which was the consolidated closing bid price of the Company’s common stock on July 26, 2019. The minimum price at which the Company can sell shares under the Aspire Purchase Agreement is $0.50. On July 29, 2019, the Company issued 100,654 shares of its common stock to Aspire Capital, as consideration for entering into the Aspire Purchase Agreement, which the Company refers to as the Commitment Shares. The Company recorded the fair value of the shares at July 29, 2019 of $603,924 as an expense in the third quarter of 2019. Concurrently with the Aspire Purchase Agreement, the Company entered into a registration rights agreement with Aspire Capital, or the Registration Rights Agreement. In accordance with the Registration Rights Agreement, on August 20, 2019, the Company filed a Registration Statement on Form S-1 (File No. 333-232988) to cover the resale of the Commitment Shares and any Purchased Shares issuable to Aspire Capital under the Aspire Purchase Agreement. There is market uncertainty regarding the utilization of financing associated from the Aspire Purchase Agreement. As of September 30, 2021, no Purchase Shares have been sold to Aspire Capital under the Aspire Purchase Agreement.</div> <div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div style="display:none;"><br/></div> <div style="text-align: justify; text-indent: 36pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">In February 2020, the Company completed an underwritten public offering, in which it sold 10,000,000 shares of common stock at a public offering price of $1.30 per share. The shares sold included 769,230 shares issued upon the exercise by the underwriter of its option to purchase additional shares at the public offering price, minus underwriting discounts and commissions. The Company received gross proceeds of approximately $13 million and net proceeds of approximately $11.9 million after deducting underwriting discounts and commissions.</div> <div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div style="display:none;"><br/></div> <div style="text-align: justify; text-indent: 36pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">In July 2020, the Company filed a shelf registration statement, or the 2020 Shelf Registration Statement, with the SEC, for the issuance of common stock, preferred stock, warrants, rights, debt securities and units, which the Company refers to collectively as the Shelf Securities, up to an aggregate amount of $100 million. The 2020 Shelf Registration Statement was declared effective on July 31, 2020. </div> <div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div style="display:none;"><br/></div> <div style="text-align: justify; text-indent: 36pt;"> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div style="display:none;"><br/></div> <div style="text-align: justify; text-indent: 36pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">In August 2020, the Company sold 6,900,000 shares of its common stock at a public offering price of $2.75 per share pursuant to the 2020 Shelf Registration Statement, which includes 900,000 shares issued upon the exercise by the underwriter of its option to purchase additional shares at the public offering price, minus underwriting discounts and commissions. The Company received gross proceeds of approximately $19.0 million and net proceeds of approximately $17.1 million, after deducting underwriting discounts and offering expenses.</div> <div style="text-align: justify; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <br/> </div> <div style="display:none;"><br/></div> <div style="text-align: justify; text-indent: 36pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">In May 2021, the Company received approximately $4.5 million from the net sale of tax benefits through 2019 to an unrelated, profitable New Jersey corporation pursuant the Company’s participation in the New Jersey Technology Business Tax Certificate Transfer Net Operating Loss (NOL) program for State Fiscal Year 2020. </span> </div> <div style="display:none;"><br/></div> <div style="text-align: justify; text-indent: 36pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span></div> <div><span style="font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div style="display:none;"><br/></div> <div style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 36pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">In June 2021, </span><span style="font-size: 10pt; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">the Company completed an underwritten public offering in which it sold 6,088,235 shares of common stock at a public offering price of $8.50 per share pursuant to the 2020 Shelf Registration Statement, which includes 794,117 shares issued upon the exercise by the underwriter of its option to purchase additional shares at the public offering price, minus underwriting discounts and commissions. the Company received gross proceeds of approximately $51.7 million and net proceeds of approximately $48.5 million, after deducting underwriting discounts and offering expenses. Approximately $29,300,000 of Shelf Securities remain available for future sale under the 2020 Shelf Registration Statement.</span></div> <div style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span></div> <div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div style="display:none;"><br/></div> <div style="text-align: justify; text-indent: 36pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The Company’s primary uses of cash are to fund operating expenses, primarily research and development expenditures. Cash used to fund operating expenses is impacted by the timing of when the Company pays these expenses, as reflected in the change in its outstanding accounts payable and accrued expenses.</div> <div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <div style="display:none;"><br/></div> <div style="text-align: justify; text-indent: 36pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The Company evaluated whether there are any conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern within one year beyond the filing of this Quarterly Report on Form 10-Q.  The Company’s budgeted cash requirements in 2021 and beyond include expenses related to continuing development and clinical studies.  Based on its available cash resources and cash flow projections as of the date the consolidated financial statements were available for issuance, management believes there are sufficient funds to continue operations and research and development programs for at least 12 months from the date of this report.</div> <div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div style="display:none;"><br/></div> <div style="text-align: justify; text-indent: 36pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The Company plans to continue to fund its operations and capital funding needs through equity and/or debt financings. However, the Company cannot be certain that additional financing will be available when needed or that, if available, financing will be obtained on terms favorable to the Company or its existing stockholders.  The Company may also enter into government funding programs and consider selectively partnering for clinical development and commercialization. The sale of additional equity would result in additional dilution to the Company’s stockholders. Incurring debt financing would result in debt service obligations, and the instruments governing such debt could provide for operating and financing covenants that would restrict its operations. If the Company is unable to raise additional capital in sufficient amounts or on acceptable terms, we may be required to delay, limit, reduce, or terminate its product development or future commercialization efforts or grant rights to develop and market immunotherapies that the Company would otherwise prefer to develop and market itself. Any of these actions could harm its business, results of operations and prospects. Failure to obtain adequate financing also may adversely affect the Company’s ability to operate as a going concern.</div> 69700000 100000 20000000.0 1034979 0.1999 0.1999 1034979 5.76 0.50 100654 603924 0 10000000 1.30 769230 13000000 11900000 100000000 6900000 2.75 900000 19000000.0 17100000 4500000 6088235 8.50 794117 51700000 48500000 29300000 <div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Note 4 – Fair Value of Financial Instruments</div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <div style="display:none;"><br/></div> <div style="text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">There were no transfers among Levels 1, 2, or 3 during 2021 or 2020.</div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"> </td> <td colspan="14" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Fair Value Measurements at Reporting Date Using</div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Total</div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Quoted Prices in</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> Active Markets</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(Level 1)</div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Quoted Prices in</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> Inactive Markets</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(Level 2)</div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Significant</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Unobservable Inputs</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(Level 3)</div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; white-space: nowrap;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">As of <span style="text-indent: 0pt;">September 30</span>, <span style="text-indent: 0pt;">2021</span>: (unaudited)</div> </td> <td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> <div> <div style="text-indent: -7.2pt; margin-left: 16.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Cash and cash equivalents</div> </div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">69,744,004</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">69,744,004</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">–</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">–</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">As of </span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">December 31, <span style="text-indent: 0pt;">2020</span>:</span></div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 16.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Cash and cash equivalents</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">28,839,565</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">28,839,565</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">–</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">–</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"> </td> </tr> </table> <div style="display:none;"><br/></div> <div style="text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">There were no transfers among Levels 1, 2, or 3 during 2021 or 2020.</div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"> </td> <td colspan="14" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Fair Value Measurements at Reporting Date Using</div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Total</div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Quoted Prices in</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> Active Markets</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(Level 1)</div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Quoted Prices in</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> Inactive Markets</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(Level 2)</div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Significant</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Unobservable Inputs</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(Level 3)</div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; white-space: nowrap;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">As of <span style="text-indent: 0pt;">September 30</span>, <span style="text-indent: 0pt;">2021</span>: (unaudited)</div> </td> <td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> <div> <div style="text-indent: -7.2pt; margin-left: 16.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Cash and cash equivalents</div> </div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">69,744,004</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">69,744,004</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">–</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">–</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">As of </span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">December 31, <span style="text-indent: 0pt;">2020</span>:</span></div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 16.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Cash and cash equivalents</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">28,839,565</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">28,839,565</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">–</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">–</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"> </td> </tr> </table> 0 0 0 0 0 0 0 0 69744004 69744004 0 0 28839565 28839565 0 0 <div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Note 5 – Leases</div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <div style="display:none;"><br/></div> <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">On July 8, 2019, the Company entered into a lease termination agreement for its office space located at 300 Connell Drive, Suite 4000, Berkeley Heights, NJ 07922 effective August 31, 2019 (the “Lease Termination Agreement”). Pursuant to the Lease Termination Agreement, the Company was required to pay 50 percent of the remaining lease payments of $665,802 over three installments on September 1, 2019, December 1, 2019, and March 1, 2020, which was recorded as lease termination costs in the third quarter of 2019. The Company entered into a temporary month-to-month lease as of September 1, 2019 for office space located at 830 Morris Turnpike, Short Hills, NJ 07078 until the Company entered into a new lease for permanent office space. This lease was terminated on May 31, 2020.</div> <div> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <div style="display:none;"><br/></div> <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Effective March 5, 2020, the Company entered into a sublease for approximately 11,200 square feet of office space located at 25B Vreeland Road, Suite 300, Florham Park, NJ. The sublease commenced on May 1, 2020 and will continue for a term of forty (40) months with an option to renew through October 31, 2027. As of September 30, 2021, there are twenty-three (23) months remaining in the lease term. Upon inception of the lease, the Company recognized approximately $0.7 million of a ROU asset and operating lease liabilities. The discount rate used to measure the operating lease liability as of May 1, 2020 was 9.15%. Throughout the period described above the Company has maintained, and continues to maintain, a month-to-month lease for its research facilities at the Princeton Innovation Center BioLabs located at 303A College Road E, Princeton NJ, 08540.</div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <div style="display:none;"><br/></div> <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Supplemental cash flow information related to operating leases is as follows:</div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="6" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-weight: bold;">As of September 30,</div> </td> <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-weight: bold;">2021<br/> </div> </td> <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; font-weight: bold; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px; font-weight: bold;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-weight: bold;">2020<br/> </div> </td> <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div>Cash paid for operating lease liabilities</div> </td> <td colspan="1" style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div> <div>$</div> </div> </td> <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div> <div>127,804</div> </div> </td> <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div>$</div> </td> <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div>62,597</div> </td> <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 76%;" valign="bottom"> <div>Right-of use assets recorded in exchange for lease obligations</div> </td> <td colspan="1" style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div>$</div> </td> <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div>–</div> </td> <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div>$</div> </td> <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div>638,831</div> </td> <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> </table> <div> <br/> </div> <div style="display:none;"><br/></div> <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Maturity of the Company’s operating lease liability is as follows:</div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; font-family: &amp;amp;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Year ended December 31,</div> </td> <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">2021 (remaining three months)</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">43,035</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">2022</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">294,986</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">2023</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">239,469</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">2024</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">–</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">2025 and after</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">–</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Total future minimum lease payments</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">577,490</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Less imputed interest</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(55,797</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div>)</div> </td> </tr> <tr> <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">521,693</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> </tr> </table> 0.50 665802 3 11200 P40M P23M 700000 700000 0.0915 <div style="display:none;"><br/></div> <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Supplemental cash flow information related to operating leases is as follows:</div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="6" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-weight: bold;">As of September 30,</div> </td> <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-weight: bold;">2021<br/> </div> </td> <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; font-weight: bold; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px; font-weight: bold;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-weight: bold;">2020<br/> </div> </td> <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div>Cash paid for operating lease liabilities</div> </td> <td colspan="1" style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div> <div>$</div> </div> </td> <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div> <div>127,804</div> </div> </td> <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div>$</div> </td> <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div>62,597</div> </td> <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 76%;" valign="bottom"> <div>Right-of use assets recorded in exchange for lease obligations</div> </td> <td colspan="1" style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div>$</div> </td> <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div>–</div> </td> <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div>$</div> </td> <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div>638,831</div> </td> <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> </table> 127804 62597 0 638831 <div style="display:none;"><br/></div> <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Maturity of the Company’s operating lease liability is as follows:</div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; font-family: &amp;amp;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Year ended December 31,</div> </td> <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">2021 (remaining three months)</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">43,035</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">2022</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">294,986</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">2023</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">239,469</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">2024</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">–</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">2025 and after</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">–</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Total future minimum lease payments</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">577,490</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Less imputed interest</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(55,797</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div>)</div> </td> </tr> <tr> <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">521,693</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> </tr> </table> 43035 294986 239469 0 0 577490 55797 521693 <div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Note 6 – Accrued Expenses</div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Accrued expenses and other liabilities consist of the following:</div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"> <tr> <td style="vertical-align: middle; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center;">As of</div> <div style="text-align: center;">September 30, 2021</div> </td> <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px; text-align: center;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center;">As of</div> <div style="text-align: center;">December 31, 2020</div> </td> <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color: #CCEEFF; vertical-align: middle; white-space: nowrap; width: 76%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> <div> <div>Accrued research and development costs</div> </div> </td> <td colspan="1" style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div>$</div> </td> <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div>19,500</div> </td> <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div>$</div> </td> <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div>204,780</div> </td> <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: middle; font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 76%;" valign="bottom"> <div>Accrued professional fees</div> </td> <td colspan="1" style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div> <div>277,555</div> </div> </td> <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div>219,822</div> </td> <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: middle; font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> <div>Accrued compensation</div> </td> <td colspan="1" style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div>1,626,791</div> </td> <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div>1,310,720</div> </td> <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: middle; font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 76%; padding-bottom: 4px;" valign="bottom"> <div style="margin-left: 9pt;">Total</div> </td> <td colspan="1" style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> <div>$</div> </td> <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div>1,923,846</div> </td> <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> <div> <div>$</div> </div> </td> <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div> <div>1,735,322</div> </div> </td> <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> </tr> </table> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Accrued expenses and other liabilities consist of the following:</div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"> <tr> <td style="vertical-align: middle; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center;">As of</div> <div style="text-align: center;">September 30, 2021</div> </td> <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px; text-align: center;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center;">As of</div> <div style="text-align: center;">December 31, 2020</div> </td> <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color: #CCEEFF; vertical-align: middle; white-space: nowrap; width: 76%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> <div> <div>Accrued research and development costs</div> </div> </td> <td colspan="1" style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div>$</div> </td> <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div>19,500</div> </td> <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div>$</div> </td> <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div>204,780</div> </td> <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: middle; font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 76%;" valign="bottom"> <div>Accrued professional fees</div> </td> <td colspan="1" style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div> <div>277,555</div> </div> </td> <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div>219,822</div> </td> <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: middle; font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> <div>Accrued compensation</div> </td> <td colspan="1" style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div>1,626,791</div> </td> <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div>1,310,720</div> </td> <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: middle; font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 76%; padding-bottom: 4px;" valign="bottom"> <div style="margin-left: 9pt;">Total</div> </td> <td colspan="1" style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> <div>$</div> </td> <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div>1,923,846</div> </td> <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> <div> <div>$</div> </div> </td> <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div> <div>1,735,322</div> </div> </td> <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> </tr> </table> 19500 204780 277555 219822 1626791 1310720 1923846 1735322 <div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Note 7 – Stock-Based Compensation</div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><br/> </span> </div> <div style="display:none;"><br/></div> <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">The Company has three equity compensation plans: the 2009 Stock Option Plan, 2014 Equity Incentive Plan and the 2018 Stock Incentive Plan (the “Plans”).</div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><br/> </span> </div> <div style="display:none;"><br/></div> <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">In 2014, the Company’s stockholders approved the 2014 Equity Incentive Plan pursuant to which the Company may grant up to 91,367 shares as ISOs, NQs and restricted stock units (“RSUs”), subject to increases as hereafter described (the “Plan Limit”). In addition, on January 1, 2015 and each January 1 thereafter and prior to the termination of the 2014 Equity Incentive Plan, pursuant to the terms of the 2014 Equity Incentive Plan, the Plan Limit was and shall be increased by the lesser of (x) 4% of the number of shares of Common Stock outstanding as of the immediately preceding December 31 and (y) such lesser number as the Board of Directors may determine in its discretion. In March 2019, the Plan was amended and restated which removed the annual increase component and was limited to 826,292 shares.</div> <div style="display:none;"><br/></div> <div style="text-align: justify; text-indent: 36pt;"> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><br/> </span> </div> <div style="display:none;"><br/></div> <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-align: justify; text-indent: 36pt; text-transform: none;">As previously disclosed, on December 8, 2020, the Board of Directors of the Company adopted, subject to stockholder approval, the Second Amended and Restated PDS Biotechnology Corporation 2014 Equity Inventive Plan (the “Restated Plan”), which would amend and restate the Amended and Restated PDS Biotechnology Corporation 2014 Equity Incentive Plan (the “Current Plan”). The Company held its annual meeting of stockholders on June 17, 2021 (the “Annual Meeting”). The stockholders voted to approve the Restated Plan at the Annual Meeting. The Restated Plan is identical to the Current Plan in all material respects, except as follows: (a) the number of shares of Common Stock authorized for issuance under the Restated Plan will increase from 826,292 shares to 3,339,243 shares, plus the total number of shares that remained available for issuance, that are not covered by outstanding awards issued under the Current Plan, immediately prior to December 8, 2020; and (b) the Restated Plan will terminate on December 7, 2030, unless earlier terminated. Please reference the disclosure in Note 9.</div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><br/> </span> </div> <div style="display:none;"><br/></div> <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">In 2018, the Company’s stockholders approved the 2018 Stock Incentive Plan pursuant to which the Company may grant up to 558,071 shares as (i) Stock Options, (ii) Stock Appreciation Rights, (iii) Restricted Stock, (iv) Preferred Stock, (v) Stock Reload Options and/or (vi) Other Stock-Based Awards.</div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><br/> </span> </div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"> </span></div> <div style="display:none;"><br/></div> <div style="text-align: justify; text-indent: 24.5pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><span class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;"> </span>Pursuant to the terms of the Plans, ISOs have a term of ten years from the date of grant or such shorter term as may be provided in the option agreement. Unless specified otherwise in an individual option agreement, ISOs generally vest over a four-year term and NQs generally vest over a  <span style="-sec-ix-hidden:Fact_20e52b3f4e9448c19213e59036d5133d">one</span>-to-five-year term. Unless terminated by the Board, the Plans shall continue to remain effective for a term of ten years or until such time as no further awards may be granted and all awards granted under the Plans are no longer outstanding. As of September 30, 2021 there were 190,799 shares available for grant under the 2018 Stock Incentive Plan.</div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><br/> </span> </div> <div style="display:none;"><br/></div> <div style="text-align: justify; text-indent: 24.5pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><span class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;"> </span>On June 17, 2019, the Board adopted the 2019 Inducement Plan (the “Inducement Plan”). The Inducement Plan provides for the grant of non-qualified stock options. The Inducement Plan was recommended for approval by the Compensation Committee of the Board and subsequently approved and adopted by the Board without stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.</div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><br/> </span> </div> <div style="display:none;"><br/></div> <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">On December 9, 2020, the Company amended the Inducement Plan solely to increase the total number of shares of Common Stock reserved for issuance under the Inducement Plan from 200,000 shares to 500,000 shares. The 2019 Inducement Plan is administered by the Compensation Committee of the Board. In accordance with Rule 5635(c)(4) of the Nasdaq Listing Rules, non-qualified stock options under the 2019 Inducement Plan may only be made to an employee who has not previously been an employee or member of the Board (or any parent or subsidiary of the Company), or following a bona fide period of non-employment by the Company (or a parent or subsidiary of the Company), if he or she is granted such non-qualified stock options in connection with his or her commencement of employment with the Company or a subsidiary and such grant is an inducement material to his or her entering into employment with the Company or such subsidiary. As of September 30, 2021, there were 362,700 shares available for grant under the 2019 Inducement Plan.</div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><br/> </span> </div> <div style="display:none;"><br/></div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;">The Company’s stock-based compensation expense related to stock options was recognized in operating expense as follows:</div> <div style="display:none;"><br/></div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman', Times, serif; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><br/> </span> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman', Times, serif; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"> <tr> <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Three Months September 30, 2021<br/> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Nine Months Ended September 30,</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: middle; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">2021<br/> </span></div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">2020<br/> </span></div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">2021<br/> </span></div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">2020<br/> </span></div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: middle; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="6" style="vertical-align: bottom;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">(unaudited)</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="6" style="vertical-align: bottom;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">(unaudited)</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: middle;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Stock-Based Compensation</div> </td> <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; vertical-align: bottom;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; vertical-align: bottom;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; vertical-align: bottom;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; vertical-align: bottom;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"> <div> <div style="text-indent: -7.2pt; margin-left: 16.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Research and development</div> </div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div> </div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">596,762</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div> </div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">61,557</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div> </div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">824,580</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div> </div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">168,083</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; padding-bottom: 2px;" valign="bottom"> <div> <div style="text-indent: -7.2pt; margin-left: 16.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">General and administrative</div> </div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">1,105,000</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">68,235</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"/> </div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">1,576,401</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">132,815</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> <div> <div style="text-indent: -7.2pt; margin-left: 25.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Total</div> </div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div> </div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">1,701,763</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div> </div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">129,792</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div> </div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">2,400,980</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div> </div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">300,898</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> </table> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"> <br class="Apple-interchange-newline"/> </span></div> <div style="display:none;"><br/></div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;">The fair value of options granted during the three and nine months ended September 30, 2021 and the three and nine months ended September 30, 2020 was estimated using the Black-Scholes option valuation model utilizing the following assumptions<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">. </span>There were 63,800 options granted during the three-month period ended September 30, 2021.</div> <div style="display:none;"><br/></div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman', Times, serif; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><br/> </span> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman', Times, serif; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"> <tr> <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Three Months September 30, 2021<br/> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Nine Months Ended September 30,</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">2021</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">2020<br/> </span></div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">2021</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">2020</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Weighted Average</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Weighted Average</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Weighted Average</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Weighted Average</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="6" style="vertical-align: bottom;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">(unaudited)</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="6" style="vertical-align: bottom;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">(unaudited)</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: middle; width: 52%; background-color: rgb(204, 238, 255);" valign="bottom"> <div> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Volatility</div> </div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">100.16</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">%</div> </div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">–</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">%</div> </div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">100.58</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">%</div> </div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">97.00</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">%</div> </div> </td> </tr> <tr> <td style="vertical-align: middle; width: 52%;" valign="bottom"> <div> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Risk-Free Interest Rate</div> </div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">0.77</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">%</div> </div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">–</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">%</div> </div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">55.88</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">%</div> </div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">0.38</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">%</div> </div> </td> </tr> <tr> <td style="vertical-align: middle; width: 52%; background-color: rgb(204, 238, 255);" valign="bottom"> <div> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Expected Term in Years</div> </div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">6.08</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">–</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">6.28</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">6.07</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: middle; width: 52%;" valign="bottom"> <div> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Dividend Rate</div> </div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">–</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">–</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">–</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">–</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: middle; width: 52%; background-color: #CCEEFF;" valign="bottom"> <div> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Fair Value of Option on Grant Date</div> </div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div> </div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">11.81</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div> </div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">–</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div> </div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">7.43</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div> </div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">1.10</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> </table> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"> <br/> </span></div> <div style="display:none;"><br/></div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;">The following table summarizes the number of options outstanding and the weighted average exercise price:</div> <div style="display:none;"><br/></div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman', Times, serif; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><br/> </span> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman', Times, serif; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"> <tr> <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Number</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">of Shares</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Weighted</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Average</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Exercise Price</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Weighted Average</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Remaining</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Contractual</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Life in Years</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Aggregate</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Intrinsic Value</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"> <div> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Options outstanding at December 31, <span style="text-indent: 0pt;">2020</span></div> </div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">1,650,897</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div> </div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">11.87</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">7.03</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div> </div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">226,731</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%;" valign="bottom"> <div> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Granted</div> </div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">1,722,730</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">3.34</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">9.28</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div> </div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">8,803,138</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"> <div> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Exercised</div> </div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">(95,737</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0);">)</div> </div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">7.24</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div>–</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div> </div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">–</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; padding-bottom: 2px;" valign="bottom"> <div> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Forfeited</div> </div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">(326,038</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0);">)</div> </div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">29.71</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">–</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div> </div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">–</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"> <div> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Options outstanding at <span style="text-indent: 0pt;">September 30, 2021</span></div> </div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">2,951,852</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div> </div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">5.07</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">7.99</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div> </div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">29,754,366</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px;" valign="bottom"> <div> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Vested and expected to vest at <span style="text-indent: 0pt;">September 30, 2021</span></div> </div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">2,951,852</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div> </div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">5.07</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">7.99</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div> </div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">29,754,366</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> <div> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Exercisable at <span style="text-indent: 0pt;">September 30, 2021</span></div> </div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">1,130,039</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div> </div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">7.66</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">5.81</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div> </div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">8,914,003</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> </table> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><br class="Apple-interchange-newline"/> </span></div> <div style="display:none;"><br/></div> <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">At September 30, 2021 there was approximately $11,300,108 of unamortized stock option compensation expense, which is expected to be recognized over a remaining average vesting period of 2.97 years.</div> 3 91367 0.04 826292 826292 3339243 558071 P10Y P4Y P5Y P10Y 190799 200000 500000 362700 <div style="display:none;"><br/></div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;">The Company’s stock-based compensation expense related to stock options was recognized in operating expense as follows:</div> <div style="display:none;"><br/></div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman', Times, serif; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><br/> </span> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman', Times, serif; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"> <tr> <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Three Months September 30, 2021<br/> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Nine Months Ended September 30,</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: middle; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">2021<br/> </span></div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">2020<br/> </span></div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">2021<br/> </span></div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">2020<br/> </span></div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: middle; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="6" style="vertical-align: bottom;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">(unaudited)</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="6" style="vertical-align: bottom;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">(unaudited)</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: middle;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Stock-Based Compensation</div> </td> <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; vertical-align: bottom;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; vertical-align: bottom;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; vertical-align: bottom;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; vertical-align: bottom;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"> <div> <div style="text-indent: -7.2pt; margin-left: 16.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Research and development</div> </div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div> </div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">596,762</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div> </div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">61,557</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div> </div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">824,580</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div> </div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">168,083</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; padding-bottom: 2px;" valign="bottom"> <div> <div style="text-indent: -7.2pt; margin-left: 16.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">General and administrative</div> </div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">1,105,000</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">68,235</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"/> </div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">1,576,401</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">132,815</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> <div> <div style="text-indent: -7.2pt; margin-left: 25.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Total</div> </div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div> </div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">1,701,763</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div> </div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">129,792</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div> </div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">2,400,980</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div> </div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">300,898</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> </table> 596762 61557 824580 168083 1105000 68235 1576401 132815 1701763 129792 2400980 300898 <div style="display:none;"><br/></div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;">The fair value of options granted during the three and nine months ended September 30, 2021 and the three and nine months ended September 30, 2020 was estimated using the Black-Scholes option valuation model utilizing the following assumptions<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">. </span>There were 63,800 options granted during the three-month period ended September 30, 2021.</div> <div style="display:none;"><br/></div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman', Times, serif; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><br/> </span> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman', Times, serif; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"> <tr> <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Three Months September 30, 2021<br/> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Nine Months Ended September 30,</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">2021</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">2020<br/> </span></div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">2021</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">2020</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Weighted Average</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Weighted Average</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Weighted Average</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Weighted Average</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="6" style="vertical-align: bottom;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">(unaudited)</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="6" style="vertical-align: bottom;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">(unaudited)</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: middle; width: 52%; background-color: rgb(204, 238, 255);" valign="bottom"> <div> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Volatility</div> </div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">100.16</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">%</div> </div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">–</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">%</div> </div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">100.58</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">%</div> </div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">97.00</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">%</div> </div> </td> </tr> <tr> <td style="vertical-align: middle; width: 52%;" valign="bottom"> <div> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Risk-Free Interest Rate</div> </div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">0.77</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">%</div> </div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">–</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">%</div> </div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">55.88</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">%</div> </div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">0.38</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">%</div> </div> </td> </tr> <tr> <td style="vertical-align: middle; width: 52%; background-color: rgb(204, 238, 255);" valign="bottom"> <div> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Expected Term in Years</div> </div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">6.08</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">–</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">6.28</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">6.07</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: middle; width: 52%;" valign="bottom"> <div> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Dividend Rate</div> </div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">–</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">–</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">–</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">–</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: middle; width: 52%; background-color: #CCEEFF;" valign="bottom"> <div> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Fair Value of Option on Grant Date</div> </div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div> </div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">11.81</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div> </div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">–</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div> </div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">7.43</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div> </div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">1.10</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> </table> 63800 1.0016 0 1.0058 0.9700 0.0077 0 0.5588 0.0038 P6Y29D P6Y3M10D P6Y25D 0 0 0 0 11.81 0 7.43 1.10 <div style="display:none;"><br/></div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;">The following table summarizes the number of options outstanding and the weighted average exercise price:</div> <div style="display:none;"><br/></div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman', Times, serif; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><br/> </span> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman', Times, serif; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"> <tr> <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Number</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">of Shares</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Weighted</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Average</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Exercise Price</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Weighted Average</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Remaining</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Contractual</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Life in Years</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Aggregate</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Intrinsic Value</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"> <div> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Options outstanding at December 31, <span style="text-indent: 0pt;">2020</span></div> </div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">1,650,897</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div> </div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">11.87</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">7.03</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div> </div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">226,731</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%;" valign="bottom"> <div> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Granted</div> </div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">1,722,730</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">3.34</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">9.28</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div> </div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">8,803,138</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"> <div> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Exercised</div> </div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">(95,737</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0);">)</div> </div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">7.24</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div>–</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div> </div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">–</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; padding-bottom: 2px;" valign="bottom"> <div> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Forfeited</div> </div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">(326,038</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0);">)</div> </div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">29.71</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">–</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div> </div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">–</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"> <div> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Options outstanding at <span style="text-indent: 0pt;">September 30, 2021</span></div> </div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">2,951,852</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div> </div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">5.07</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">7.99</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div> </div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">29,754,366</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px;" valign="bottom"> <div> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Vested and expected to vest at <span style="text-indent: 0pt;">September 30, 2021</span></div> </div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">2,951,852</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div> </div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">5.07</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">7.99</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div> </div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">29,754,366</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> <div> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Exercisable at <span style="text-indent: 0pt;">September 30, 2021</span></div> </div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">1,130,039</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div> </div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">7.66</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">5.81</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div> </div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"> <div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">8,914,003</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> </table> 1650897 11.87 P7Y10D 226731 1722730 3.34 P9Y3M10D 8803138 95737 7.24 0 326038 29.71 0 2951852 5.07 P7Y11M26D 29754366 2951852 5.07 P7Y11M26D 29754366 1130039 7.66 P5Y9M21D 8914003 11300108 P2Y11M19D <div style="font-weight: bold; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Note 8 – Income Taxes</div> <div><span style="font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <div style="display:none;"><br/></div> <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">In assessing the realizability of the net deferred tax assets, the Company considers all relevant positive and negative evidence to determine whether it is more likely than not that some portion or all of the deferred income tax assets will not be realized. The realization of the gross deferred tax assets is dependent on several factors, including the generation of sufficient taxable income prior to the expiration of the net operating loss carryforwards. The Company expects to have a loss for 2021 and there will be no current income tax expense. Additionally, there was a full valuation allowance against the net deferred tax assets as <span style="font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 48px; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial;">of September 30, 2021 and December 31, 2020. </span><span style="font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 48px; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">In May 2021, in accordance with the State of New Jersey’s Technology Business Tax Certificate Program, which allowed certain high technology and biotechnology companies to sell unused NOL carryforwards to other New Jersey-based corporate taxpayers, the Company sold New Jersey NOL carryforwards, resulting in the recognition of $4.5 million of income tax benefit, net of transaction costs.</span></div> <div><span style="font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <div style="display:none;"><br/></div> <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The Company’s U.S. statutory rate is 21%. The effective tax rate, excluding the benefit of the sale of any New Jersey net operating losses, for the three and nine months ended September 30, 2021 is 0%.  The primary factor impacting the effective tax rate is the anticipated full year operating loss which will require a full valuation allowance against any associate deferred tax asset.</div> <div><span style="font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <div style="display:none;"><br/></div> <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Entities are also required to evaluate, measure, recognize and disclose any uncertain income tax provisions taken on their income tax returns. The Company has analyzed its tax positions and has concluded that as of September 30, 2021, there were no uncertain positions. The Company’s U.S. federal and state net operating losses have occurred since its inception and as such, tax years subject to potential tax examination could apply from that date because the utilization of net operating losses from prior years opens the relevant year to audit by the IRS and/or state taxing authorities. The Company did not have any unrecognized tax benefits and has not accrued any interest or penalties for the three and nine months ended September 30, 2021 and for the year ended December 31, 2020.</div> 0 -4500000 0.21 0 0 0 0 0 0 0 0 0 <div style="font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Note 9 – Commitments and Contingencies</div> <div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <div style="text-align: justify; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Rent</span></div> <div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <div style="display:none;"><br/></div> <div style="text-align: justify; text-indent: 36pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">For month-to-month arrangements not impacted by the adoption of ASC 842, rent for the three and nine months ended September 30, 2021 was $52,000 and $130,493, respectively, compared to the three and nine months ended September 30, 2020 of $35,700 and $140,678.</div> <div><br/> </div> <div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span> <span style="font-size: 10pt;"> </span></div> <div><span style="font-size: 10pt;"> </span></div> <div style="display:none;"><br/></div> <div style="background-color: #FFFFFF; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: justify; text-indent: 0pt; text-transform: none;"> <span style="text-decoration: underline;">Legal Proceedings</span><br/> </div> <div> </div> <div style="display:none;"><br/></div> <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">On July 23, 2021, David R. Rosener, a purported stockholder of the Company, filed a putative class action and shareholder derivative complaint in the Court of Chancery of the State of Delaware (C.A. No. 2021-0644 JRS)  against the Company and all of its directors and certain of its executive officers. The plaintiff named all current directors of PDS as defendants as well as PDS’s Chief Scientific Officer and PDS’s Chief Medical Officer and also named PDS as a nominal defendant.  The plaintiff claims PDS’s bylaws required tabulation of broker non-votes on Proposal 3 at the Company’s 2021 annual stockholder meeting on June 17, 2021, which sought shareholder approval of the Second Amended and Restated PDS Biotechnology Corporation 2014 Equity Incentive Plan (the “Restated Plan”). The complaint asserts claims for breach of fiduciary duties, declaratory judgment, waste of corporate assets and unjust enrichment in connection with the Restated Plan and the granting of an aggregate award of 1,040,700 stock options to certain executive officers pursuant to the Restated Plan.  The plaintiff seeks unspecified monetary damages, seeks to have the Restated Plan declared void, and seeks recission of the grant of stock options as ultra vires.  Given the early stage of this lawsuit, PDS is unable to reasonably estimate the costs associated with the lawsuit or predict the outcome.  <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">Each of the Company, its directors and the named executives intend to defend this action vigorously.  There can be no guarantee as to the timing of any resolution.</span></div> 52000 130493 35700 140678 1040700 <div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Note 10 – Retirement Plan</div> <div><span style="font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <div style="display:none;"><br/></div> <div style="text-indent: 36pt; text-align: justify;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;">The Company has a 401(k) defined contribution plan for the benefit of all employees and permits voluntary contributions by employees subject to IRS-imposed limitations. The 401(k) employer contributions were </span><span style="font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">$25,803 and $71,214 for the three and nine months ended September 30, 2021, respectively, <span style="font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-indent: 48px; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial;">compared </span><span style="font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-indent: 48px; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial;">to</span><span style="font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-indent: 48px; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> $11,809 and $35,293 </span></span><span style="font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><span style="font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-indent: 48px; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><span style="font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-indent: 48px; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial;">for the three and nine months ended September 30, 2020, </span></span>respectively.</span></span></div> 25803 71214 11809 35293 <div style="font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Note 11– Subsequent Events</div> <div><span style="background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div><span style="background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span></div> <div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div style="display:none;"><br/></div> <div style="text-indent: 36pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: justify;">On October 18, 2021, the Company granted an option to purchase 202,800 shares of common stock to its incoming Chief Financial Officer and 25,400 to other incoming employees with a strike price of $12.03 vesting over a four-year period with <span style="-sec-ix-hidden:Fact_0ea4b9b0fe0748d88020a8a6163e898a">one quarter</span> vesting on the <span style="-sec-ix-hidden:Fact_cce204b7c2724959b24f9ffac7001a97">first</span> anniversary of the date of the grant and vesting monthly over the 36-month period thereafter and expire ten years from the date of the grant. The aggregate fair value of the options granted was $2.2 million.</div> <div style="display:none;"><br/></div> <div style="text-indent: 36pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <br/> </div> <div style="display:none;"><br/></div> <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Effective as November 5, 2021, the Company entered into a Patent License Agreement (the “Patent License Agreement”) with the U.S. Department of Health and Human Services, as represented by National Cancer Institute (“NCI”) of the National Institutes of Health (“NIH”).  Pursuant to the License Agreement, the Company obtained a nonexclusive license to the patent rights for NCI’s T-cell receptor gamma alternate reading frame protein (“TARP”) to develop and commercialize TARP peptide-based therapies in combination with the Company’s Versamune<sup>®</sup> technology. The Patent License Agreement includes customary milestone payments and royalties.</div> 202800 25400 12.03 P4Y P36M P10Y 2200000 XML 13 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Document and Entity Information - shares
9 Months Ended
Sep. 30, 2021
Nov. 03, 2021
Cover [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Quarterly Report true  
Document Period End Date Sep. 30, 2021  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2021  
Document Fiscal Period Focus Q3  
Document Transition Report false  
Entity File Number 001-37568  
Entity Registrant Name PDS Biotechnology Corp  
Entity Central Index Key 0001472091  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 26-4231384  
Entity Address, Address Line One 25B Vreeland Road,  
Entity Address, Address Line Two Suite 300  
Entity Address, City or Town Florham Park,  
Entity Address, State or Province NJ  
Entity Address, Postal Zip Code 07932  
City Area Code 800  
Local Phone Number 208-3343  
Title of 12(b) Security Common Stock, par value $0.00033 per share  
Trading Symbol PDSB  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   28,435,067

XML 14 R2.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Balance Sheets - USD ($)
Sep. 30, 2021
Dec. 31, 2020
Current assets:    
Cash and cash equivalents $ 69,744,004 $ 28,839,565
Prepaid expenses and other 1,596,810 1,497,665
Total current assets 71,340,814 30,337,230
Property and equipment, net 1,037 5,443
Operating lease right-to-use asset 406,171 547,706
Total assets 71,748,022 30,890,379
Current liabilities:    
Accounts payable 1,445,585 1,415,224
Accrued expenses 1,923,846 1,735,322
Operating lease obligation-short term 207,717 119,904
Total current liabilities 3,577,148 3,270,450
Noncurrent liability:    
Operating lease obligation-long term 313,976 490,353
Total Liabilities 3,891,124 3,760,803
STOCKHOLDERS' EQUITY    
Common stock, $0.00033 par value, 75,000,000 shares authorized at September 30, 2021 and December 31, 2020, 28,435,067 shares and 22,261,619 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively 9,383 7,346
Additional paid-in capital 122,231,115 70,907,315
Accumulated deficit (54,383,600) (43,785,085)
Total stockholders' equity 67,856,898 27,129,576
Total liabilities and stockholders' equity $ 71,748,022 $ 30,890,379
XML 15 R3.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares
Sep. 30, 2021
Dec. 31, 2020
STOCKHOLDERS' EQUITY    
Common stock, par value (in dollars per share) $ 0.00033 $ 0.00033
Common stock, shares authorized (in shares) 75,000,000 75,000,000
Common stock, shares issued (in shares) 28,435,067 22,261,619
Common stock shares outstanding (in shares) 28,435,067 22,261,619
XML 16 R4.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Operating expenses:        
Research and development expenses $ 3,687,999 $ 2,060,815 $ 7,865,249 $ 5,446,718
General and administrative expenses 3,274,325 1,846,214 7,252,371 5,428,098
Total operating expenses 6,962,324 3,907,029 15,117,620 10,874,816
Loss from operations (6,962,324) (3,907,029) (15,117,620) (10,874,816)
Other income:        
Interest income 1,358 1,207 2,617 54,242
Loss before income taxes (6,960,966) (3,905,822) (15,115,003) (10,820,574)
Benefit from income taxes 0 0 4,516,488 0
Net loss (6,960,966) (3,905,822) (10,598,515) (10,820,574)
Comprehensive loss $ (6,960,966) $ (3,905,822) $ (10,598,515) $ (10,820,574)
Per share information:        
Net loss per share, basic (in dollars per share) $ (0.24) $ (0.21) $ (0.43) $ (0.73)
Net loss per share, diluted (in dollars per share) $ (0.24) $ (0.21) $ (0.43) $ (0.73)
Weighted average common shares outstanding, basic (in shares) 28,425,850 18,961,619 24,639,299 14,892,764
Weighted average common shares outstanding, diluted (in shares) 28,425,850 18,961,619 24,639,299 14,892,764
XML 17 R5.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Changes in Stockholders' Equity - USD ($)
Common Stock [Member]
Additional Paid-in Capital [Member]
Accumulated Deficit [Member]
Total
Balance at Dec. 31, 2019 $ 1,742 $ 40,633,670 $ (28,937,705) $ 11,697,707
Balance (in shares) at Dec. 31, 2019 5,281,237      
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Stock-based compensation expense $ 0 300,898 0 300,898
Issuance of common stock, net of issuance costs $ 5,581 29,750,921 0 29,756,502
Issuance of common stock, net of issuance costs (in shares) 16,900,000      
Issuance of warrant exercise $ 22 70,437 0 70,459
Issuance of warrant exercise (in shares) 65,240      
Issuance of common stock from 401K match $ 1 19,966 0 19,967
Issuance of common stock from 401K match (in shares) 15,142      
Net loss $ 0 0 (10,820,574) (10,820,574)
Balance at Sep. 30, 2020 $ 7,346 70,775,892 (39,758,279) 31,024,959
Balance (in shares) at Sep. 30, 2020 22,261,619      
Balance at Jun. 30, 2020 $ 5,064 52,861,882 (35,852,457) 17,014,489
Balance (in shares) at Jun. 30, 2020 15,361,619      
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Stock-based compensation expense $ 0 129,792 0 129,792
Issuance of common stock from equity transaction $ 2,282 17,784,218 0 17,786,500
Issuance of common stock from equity transaction (in shares) 6,900,000      
Net loss $ 0 0 (3,905,822) (3,905,822)
Balance at Sep. 30, 2020 $ 7,346 70,775,892 (39,758,279) 31,024,959
Balance (in shares) at Sep. 30, 2020 22,261,619      
Balance at Dec. 31, 2020 $ 7,346 70,907,315 (43,785,085) 27,129,576
Balance (in shares) at Dec. 31, 2020 22,261,619      
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Stock-based compensation expense $ 0 2,400,980 0 2,400,980
Issuance of common stock, net of issuance costs $ 2,009 48,542,989 0 48,544,998
Issuance of common stock, net of issuance costs (in shares) 6,088,235      
Issuances of common stock, from exercise of stock options $ 23 344,089 0 344,112
Issuances of common stock, from exercise of stock options (in shares) 68,571      
Issuance of common stock from 401K match $ 5 35,742 0 35,747
Issuance of common stock from 401K match (in shares) 16,642      
Net loss $ 0 0 (10,598,515) (10,598,515)
Balance at Sep. 30, 2021 $ 9,383 122,231,115 (54,383,600) 67,856,898
Balance (in shares) at Sep. 30, 2021 28,435,067      
Balance at Jun. 30, 2021 $ 9,377 120,405,851 (47,422,634) 72,992,594
Balance (in shares) at Jun. 30, 2021 28,417,909      
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Stock-based compensation expense $ 0 1,701,763 0 1,701,763
Issuances of common stock, from exercise of stock options $ 6 123,501 0 123,507
Issuances of common stock, from exercise of stock options (in shares) 17,158      
Net loss $ 0 0 (6,960,966) (6,960,966)
Balance at Sep. 30, 2021 $ 9,383 $ 122,231,115 $ (54,383,600) $ 67,856,898
Balance (in shares) at Sep. 30, 2021 28,435,067      
XML 18 R6.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Cash Flows - USD ($)
9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Cash flows from operating activities:    
Net loss $ (10,598,515) $ (10,820,574)
Adjustments to reconcile net loss to net cash used in operating activities:    
Stock-based compensation expense 2,400,980 300,898
Stock-based 401K company common match 35,747 19,967
Depreciation expense 4,406 11,706
Operating lease expense 180,775 106,949
Changes in operating assets and liabilities:    
Prepaid expenses and other assets (99,145) 1,935,067
Accounts payable 30,361 361,871
Accrued expenses 188,524 125,133
Restructuring reserve 0 (498,185)
Operating lease liabilities (127,804) (62,597)
Net cash used in operating activities (7,984,671) (8,519,765)
Cash flows from financing activities:    
Proceeds from exercise of warrants 0 70,459
Proceeds from exercise of stock options 344,112 0
Proceeds from issuances of common stock, net of issuance costs 48,544,998 29,756,502
Net cash provided by financing activities 48,889,110 29,826,961
Net increase in cash and cash equivalents 40,904,439 21,307,196
Cash and cash equivalents at beginning of period 28,839,565 12,161,739
Cash and cash equivalents at end of period $ 69,744,004 $ 33,468,935
XML 19 R7.htm IDEA: XBRL DOCUMENT v3.21.2
Nature of Operations
9 Months Ended
Sep. 30, 2021
Nature of Operations [Abstract]  
Nature of Operations
Note 1 – Nature of Operations


PDS Biotechnology Corporation, a Delaware corporation (the “Company” or “PDS”), is a clinical-stage immunotherapy company developing a growing pipeline of cancer immunotherapies and infectious disease vaccines designed to overcome the well-established limitations of current immunotherapy technologies. PDS owns Versamune®, a proprietary T-cell activating platform designed to train the immune system to better attack and destroy disease. When paired with an antigen, which is a disease-related protein that is recognizable by the immune system, Versamune® has been shown to induce, in vivo, large quantities of high-quality, highly potent polyfunctional CD8+ killer T-cells, a specific sub-type of CD8+ killer T-cell that is more effective at killing infected or target cells.



The Company’s immuno-oncology products can potentially be used as a component of combination products with other leading technologies to provide effective treatments across a range of advanced cancer types. Currently, the Company believes its product candidates are of interest for potential combination treatments in relation to Human Papillomavirus (HPV)-associated cancers, melanoma, colorectal, lung, breast and prostate cancers and potentially as monotherapies in early-stage cancers. In addition, PDS is working to progress its infectious disease development program, which includes novel vaccines for COVID-19 and universal influenza.



From the Company’s inception, it has devoted substantially all of its efforts to drug development, business planning, engaging regulatory, manufacturing and other technical consultants, acquiring operating assets, planning and executing clinical trials and raising capital.


In December 2019, a novel (new) coronavirus known as SARS-CoV-2 was first detected in Wuhan, Hubei Province, People’s Republic of China, causing outbreaks of the coronavirus disease, known as COVID-19, that has now spread globally. On January 30, 2020, the World Health Organization (WHO) declared COVID-19 a public health emergency. The Secretary of Health and Human Services declared a public health emergency on January 31, 2020, under section 319 of the Public Health Service Act (42 U.S.C. 247d), in response to the COVID-19 outbreak. On March 11, 2020, the WHO declared COVID-19 a pandemic and on March 13 the President declared a national emergency in response to the pandemic. PDS continues to learn more about the full impact of the COVID-19 pandemic which has continued to evolve due to the emergence of variants of concern, resulting in new waves of infection regionally and globally. The COVID-19 pandemic has and could continue to negatively affect the Company’s liquidity and operations.  To date, the start of two of the three initiated PDS0101 clinical trials were delayed, specifically as a result of the adverse impact the COVID-19 pandemic has had on clinical trial operations for cancer indications in the United States. The FDA has continued to update its guidance assisting sponsors in assuring the safety of trial participants, maintaining compliance with Good Clinical Practice (GCP) and minimizing risks to trial integrity.  Clinical trial sites have implemented institution-specific measures securing the safety of patients and staff to ensure the integrity of the trials in the face of the ongoing pandemic. All three studies have since been initiated despite the pandemic challenges; however, the evolving COVID-19 pandemic has impacted the pace of enrollment in clinical trials in general and the Company may be negatively affected with its trials. COVID-19 related travel and other restrictions may also impact the potential for on-site monitoring visiting and audits and inspections by Company personnel, third parties, and government regulators. There may be shortages of site personnel and equipment necessary for the timely completion of the clinical trials. The Company is providing support to address these challenges, but these mitigation measures may not overcome the obstacles that the pandemic has wrought which continue to impede progress of clinical trials.



Although there is uncertainty related to the anticipated impact of the COVID-19 pandemic on the Company’s future results, management believes the Company’s current cash reserves leave us well-positioned to manage the business through this crisis as it continues to unfold. However, the impacts of the COVID-19 pandemic and its variants are broad-reaching and continuing and the financial impacts associated with the COVID-19 pandemic are still uncertain.
XML 20 R8.htm IDEA: XBRL DOCUMENT v3.21.2
Summary of Significant Accounting Policies
9 Months Ended
Sep. 30, 2021
Summary of Significant Accounting Policies [Abstract]  
Summary of Significant Accounting Policies
Note 2 – Summary of Significant Accounting Policies

(A)
Unaudited interim financial statements:


The interim balance sheet at September 30, 2021, the statements of operations and comprehensive loss and changes in stockholders’ equity for the three and nine months ended September 30, 2021 and 2020, and cash flows for the nine months ended September 30, 2021 and 2020 are unaudited. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. GAAP, in accordance with the requirements of the Securities and Exchange Commission (“SEC”) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. These condensed consolidated financial statements have been prepared on the same basis as the Company’s annual financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments that are necessary for a fair statement of its financial information. The results of operations for the three and nine months ended September 30, 2021 are not necessarily indicative of the results to be expected for the year ending December 31, 2021 or for any other future annual or interim period. The balance sheet as of December 31, 2020 included herein was derived from the audited condensed consolidated financial statements as of that date. These condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto as of and for the year ended December 31, 2020, filed by the Company with the SEC in its Annual Report on Form 10-K on March 18, 2021.

(B)
Use of estimates:


The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of expenses at the date of the consolidated financial statements and during the reporting periods, and to disclose contingent assets and liabilities at the date of the consolidated financial statements. Actual results could differ from those estimates.

(C)
Significant risks and uncertainties:


The Company’s operations are subject to a number of factors that may affect its operating results and financial condition. Such factors include, but are not limited to: the clinical and regulatory development of its products, the Company’s ability to preserve its cash resources, the Company’s review of strategic alternatives, the Company’s ability to add product candidates to its pipeline, the Company’s intellectual property, the ability to efficiently and effectively conduct its clinical trials, competition from products manufactured and sold or being developed by other companies, the price of, and demand for, Company products if approved for sale, the Company’s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products, the Company’s ability to raise capital, and the effects of health epidemics, pandemics, or outbreaks of infectious diseases, including the recent COVID-19 pandemic and its variants.


The Company currently has no commercially approved products. As such, there can be no assurance that the Company’s future research and development programs will be successfully commercialized. Developing and commercializing a product requires significant time and capital and is subject to regulatory review and approval as well as competition from other biotechnology and pharmaceutical companies. The Company operates in an environment of rapid change and is dependent upon the continued services of its employees and consultants and obtaining and protecting its intellectual property.

(D)
Cash equivalents and concentration of cash balance:


The Company considers all highly liquid securities with a maturity weighted average of less than three months to be cash equivalents. The Company’s cash and cash equivalents in bank deposit accounts, at times, may exceed federally insured limits.

(E)
Research and development:


Costs incurred in connection with research and development activities are expensed as incurred. These costs include licensing fees to use certain technology in the Company’s research and development projects as well as fees paid to consultants and entities that perform certain research and testing on behalf of the Company.


Costs for certain development activities, such as clinical trials, are recognized based on an evaluation of the progress to completion of specific tasks using data, such as patient enrollment, clinical site activations or information provided by vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred.

(F)
Patent costs:


The Company expenses patent costs as incurred and classifies such costs as general and administrative expenses in the accompanying statements of operations and comprehensive loss.

(G)
Stock-based compensation:


The Company accounts for its stock-based compensation in accordance with ASC Topic 718, Compensation—Stock Compensation (“ASC 718”). ASC 718 requires all stock-based payments to employees, directors and non-employees to be recognized as expense in the consolidated statements of operations and comprehensive loss based on their grant date fair values. In order to determine the fair value of stock options on the date of grant, the Company uses the Black-Scholes option-pricing model. Inherent in this model are assumptions related to expected stock-price volatility, option term, risk-free interest rate and dividend yield. While the risk-free interest rate and dividend yield are less subjective assumptions that are based on factual data derived from public sources, the expected stock-price volatility and option term assumptions require a greater level of judgment. The Company expenses the fair value of its stock-based compensation awards to employees and directors on a straight-line basis over the requisite service period, which is generally the vesting period. The Company recognizes forfeitures as they occur.

(H)
Net loss per common share:


Basic and diluted net loss per common share is determined by dividing net loss attributable to common stockholders by the weighted average common shares outstanding during the period. For all periods presented, the common shares underlying the stock options and warrants have been excluded from the calculation because their effect would be anti-dilutive. Therefore, the weighted average shares outstanding used to calculate both basic and diluted loss per common share are the same.


The potentially dilutive securities excluded from the determination of diluted loss per share as their effect is antidilutive, are as follows:


 
As of September 30,
 
   
2021
   
2020
 
Stock options to purchase Common Stock
   
2,951,852
     
1,639,753
 
Warrants to purchase Common Stock
   
197,518
     
197,518
 
Total
   
3,149,370
     
1,837,271
 
XML 21 R9.htm IDEA: XBRL DOCUMENT v3.21.2
Liquidity
9 Months Ended
Sep. 30, 2021
Liquidity [Abstract]  
Liquidity
Note 3 – Liquidity


As of September 30, 2021, the Company had $69.7 million of cash and cash equivalents. The Company’s primary uses of cash are to fund operating expenses, primarily research and development expenditures. Cash used to fund operating expenses is impacted by the timing of when the Company pays these expenses, as reflected in the change to the Company’s outstanding accounts payable and accrued expenses.


On July 29, 2019, the Company entered into a common stock purchase agreement, or the Aspire Purchase Agreement, with Aspire Capital pursuant to which, the Company has the right, in its sole discretion, to present Aspire Capital Fund, LLC, or Aspire Capital, with a purchase notice, directing Aspire Capital (as principal) to purchase up to 100,000 shares of the Company’s common stock per business day, in an aggregate amount of up to $20.0 million of its common stock, or the Purchased Shares, over the term of the Aspire Purchase Agreement. The Company may sell an aggregate of 1,034,979 shares of its common stock (which represented 19.99% of its outstanding shares of common stock on the date of the Aspire Purchase Agreement) without stockholder approval. The Company may sell additional shares of its common stock above the 19.99% limit provided that (i) the Company obtains stockholder approval or (ii) stockholder approval has not been obtained at any time the 1,034,979 share limitation is reached and at all times thereafter the average price paid for all shares issued under the Aspire Purchase Agreement, is equal to or greater than $5.76, which was the consolidated closing bid price of the Company’s common stock on July 26, 2019. The minimum price at which the Company can sell shares under the Aspire Purchase Agreement is $0.50. On July 29, 2019, the Company issued 100,654 shares of its common stock to Aspire Capital, as consideration for entering into the Aspire Purchase Agreement, which the Company refers to as the Commitment Shares. The Company recorded the fair value of the shares at July 29, 2019 of $603,924 as an expense in the third quarter of 2019. Concurrently with the Aspire Purchase Agreement, the Company entered into a registration rights agreement with Aspire Capital, or the Registration Rights Agreement. In accordance with the Registration Rights Agreement, on August 20, 2019, the Company filed a Registration Statement on Form S-1 (File No. 333-232988) to cover the resale of the Commitment Shares and any Purchased Shares issuable to Aspire Capital under the Aspire Purchase Agreement. There is market uncertainty regarding the utilization of financing associated from the Aspire Purchase Agreement. As of September 30, 2021, no Purchase Shares have been sold to Aspire Capital under the Aspire Purchase Agreement.


In February 2020, the Company completed an underwritten public offering, in which it sold 10,000,000 shares of common stock at a public offering price of $1.30 per share. The shares sold included 769,230 shares issued upon the exercise by the underwriter of its option to purchase additional shares at the public offering price, minus underwriting discounts and commissions. The Company received gross proceeds of approximately $13 million and net proceeds of approximately $11.9 million after deducting underwriting discounts and commissions.


In July 2020, the Company filed a shelf registration statement, or the 2020 Shelf Registration Statement, with the SEC, for the issuance of common stock, preferred stock, warrants, rights, debt securities and units, which the Company refers to collectively as the Shelf Securities, up to an aggregate amount of $100 million. The 2020 Shelf Registration Statement was declared effective on July 31, 2020.



In August 2020, the Company sold 6,900,000 shares of its common stock at a public offering price of $2.75 per share pursuant to the 2020 Shelf Registration Statement, which includes 900,000 shares issued upon the exercise by the underwriter of its option to purchase additional shares at the public offering price, minus underwriting discounts and commissions. The Company received gross proceeds of approximately $19.0 million and net proceeds of approximately $17.1 million, after deducting underwriting discounts and offering expenses.


In May 2021, the Company received approximately $4.5 million from the net sale of tax benefits through 2019 to an unrelated, profitable New Jersey corporation pursuant the Company’s participation in the New Jersey Technology Business Tax Certificate Transfer Net Operating Loss (NOL) program for State Fiscal Year 2020.



In June 2021, the Company completed an underwritten public offering in which it sold 6,088,235 shares of common stock at a public offering price of $8.50 per share pursuant to the 2020 Shelf Registration Statement, which includes 794,117 shares issued upon the exercise by the underwriter of its option to purchase additional shares at the public offering price, minus underwriting discounts and commissions. the Company received gross proceeds of approximately $51.7 million and net proceeds of approximately $48.5 million, after deducting underwriting discounts and offering expenses. Approximately $29,300,000 of Shelf Securities remain available for future sale under the 2020 Shelf Registration Statement.


The Company’s primary uses of cash are to fund operating expenses, primarily research and development expenditures. Cash used to fund operating expenses is impacted by the timing of when the Company pays these expenses, as reflected in the change in its outstanding accounts payable and accrued expenses.


The Company evaluated whether there are any conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern within one year beyond the filing of this Quarterly Report on Form 10-Q.  The Company’s budgeted cash requirements in 2021 and beyond include expenses related to continuing development and clinical studies.  Based on its available cash resources and cash flow projections as of the date the consolidated financial statements were available for issuance, management believes there are sufficient funds to continue operations and research and development programs for at least 12 months from the date of this report.


The Company plans to continue to fund its operations and capital funding needs through equity and/or debt financings. However, the Company cannot be certain that additional financing will be available when needed or that, if available, financing will be obtained on terms favorable to the Company or its existing stockholders.  The Company may also enter into government funding programs and consider selectively partnering for clinical development and commercialization. The sale of additional equity would result in additional dilution to the Company’s stockholders. Incurring debt financing would result in debt service obligations, and the instruments governing such debt could provide for operating and financing covenants that would restrict its operations. If the Company is unable to raise additional capital in sufficient amounts or on acceptable terms, we may be required to delay, limit, reduce, or terminate its product development or future commercialization efforts or grant rights to develop and market immunotherapies that the Company would otherwise prefer to develop and market itself. Any of these actions could harm its business, results of operations and prospects. Failure to obtain adequate financing also may adversely affect the Company’s ability to operate as a going concern.
XML 22 R10.htm IDEA: XBRL DOCUMENT v3.21.2
Fair Value of Financial Instruments
9 Months Ended
Sep. 30, 2021
Fair Value of Financial Instruments [Abstract]  
Fair Value of Financial Instruments
Note 4 – Fair Value of Financial Instruments


There were no transfers among Levels 1, 2, or 3 during 2021 or 2020.

   
Fair Value Measurements at Reporting Date Using
 
   
Total
   
Quoted Prices in
Active Markets
(Level 1)
   
Quoted Prices in
Inactive Markets
(Level 2)
   
Significant
Unobservable Inputs
(Level 3)
 
As of September 30, 2021: (unaudited)
                       
Cash and cash equivalents
 
$
69,744,004
   
$
69,744,004
   
$
   
$
 
                                 
As of December 31, 2020:
                               
Cash and cash equivalents
 
$
28,839,565
   
$
28,839,565
   
$
   
$
 
XML 23 R11.htm IDEA: XBRL DOCUMENT v3.21.2
Leases
9 Months Ended
Sep. 30, 2021
Leases [Abstract]  
Leases
Note 5 – Leases


On July 8, 2019, the Company entered into a lease termination agreement for its office space located at 300 Connell Drive, Suite 4000, Berkeley Heights, NJ 07922 effective August 31, 2019 (the “Lease Termination Agreement”). Pursuant to the Lease Termination Agreement, the Company was required to pay 50 percent of the remaining lease payments of $665,802 over three installments on September 1, 2019, December 1, 2019, and March 1, 2020, which was recorded as lease termination costs in the third quarter of 2019. The Company entered into a temporary month-to-month lease as of September 1, 2019 for office space located at 830 Morris Turnpike, Short Hills, NJ 07078 until the Company entered into a new lease for permanent office space. This lease was terminated on May 31, 2020.


Effective March 5, 2020, the Company entered into a sublease for approximately 11,200 square feet of office space located at 25B Vreeland Road, Suite 300, Florham Park, NJ. The sublease commenced on May 1, 2020 and will continue for a term of forty (40) months with an option to renew through October 31, 2027. As of September 30, 2021, there are twenty-three (23) months remaining in the lease term. Upon inception of the lease, the Company recognized approximately $0.7 million of a ROU asset and operating lease liabilities. The discount rate used to measure the operating lease liability as of May 1, 2020 was 9.15%. Throughout the period described above the Company has maintained, and continues to maintain, a month-to-month lease for its research facilities at the Princeton Innovation Center BioLabs located at 303A College Road E, Princeton NJ, 08540.


Supplemental cash flow information related to operating leases is as follows:

   
As of September 30,
 
   
2021
   
2020
 
Cash paid for operating lease liabilities
 
$
127,804
   
$
62,597
 
Right-of use assets recorded in exchange for lease obligations
 
$
   
$
638,831
 


Maturity of the Company’s operating lease liability is as follows:

Year ended December 31,
     
2021 (remaining three months)
 
$
43,035
 
2022
   
294,986
 
2023
   
239,469
 
2024
   
 
2025 and after
   
 
Total future minimum lease payments
   
577,490
 
Less imputed interest
   
(55,797
)
   
$
521,693
 
XML 24 R12.htm IDEA: XBRL DOCUMENT v3.21.2
Accrued Expenses
9 Months Ended
Sep. 30, 2021
Accrued Expenses [Abstract]  
Accrued Expenses
Note 6 – Accrued Expenses

Accrued expenses and other liabilities consist of the following:

   
As of
September 30, 2021
   
As of
December 31, 2020
 
Accrued research and development costs
 
$
19,500
   
$
204,780
 
Accrued professional fees
   
277,555
     
219,822
 
Accrued compensation
   
1,626,791
     
1,310,720
 
Total
 
$
1,923,846
   
$
1,735,322
 
XML 25 R13.htm IDEA: XBRL DOCUMENT v3.21.2
Stock-Based Compensation
9 Months Ended
Sep. 30, 2021
Stock-Based Compensation [Abstract]  
Stock-Based Compensation
Note 7 – Stock-Based Compensation


The Company has three equity compensation plans: the 2009 Stock Option Plan, 2014 Equity Incentive Plan and the 2018 Stock Incentive Plan (the “Plans”).


In 2014, the Company’s stockholders approved the 2014 Equity Incentive Plan pursuant to which the Company may grant up to 91,367 shares as ISOs, NQs and restricted stock units (“RSUs”), subject to increases as hereafter described (the “Plan Limit”). In addition, on January 1, 2015 and each January 1 thereafter and prior to the termination of the 2014 Equity Incentive Plan, pursuant to the terms of the 2014 Equity Incentive Plan, the Plan Limit was and shall be increased by the lesser of (x) 4% of the number of shares of Common Stock outstanding as of the immediately preceding December 31 and (y) such lesser number as the Board of Directors may determine in its discretion. In March 2019, the Plan was amended and restated which removed the annual increase component and was limited to 826,292 shares.



As previously disclosed, on December 8, 2020, the Board of Directors of the Company adopted, subject to stockholder approval, the Second Amended and Restated PDS Biotechnology Corporation 2014 Equity Inventive Plan (the “Restated Plan”), which would amend and restate the Amended and Restated PDS Biotechnology Corporation 2014 Equity Incentive Plan (the “Current Plan”). The Company held its annual meeting of stockholders on June 17, 2021 (the “Annual Meeting”). The stockholders voted to approve the Restated Plan at the Annual Meeting. The Restated Plan is identical to the Current Plan in all material respects, except as follows: (a) the number of shares of Common Stock authorized for issuance under the Restated Plan will increase from 826,292 shares to 3,339,243 shares, plus the total number of shares that remained available for issuance, that are not covered by outstanding awards issued under the Current Plan, immediately prior to December 8, 2020; and (b) the Restated Plan will terminate on December 7, 2030, unless earlier terminated. Please reference the disclosure in Note 9.


In 2018, the Company’s stockholders approved the 2018 Stock Incentive Plan pursuant to which the Company may grant up to 558,071 shares as (i) Stock Options, (ii) Stock Appreciation Rights, (iii) Restricted Stock, (iv) Preferred Stock, (v) Stock Reload Options and/or (vi) Other Stock-Based Awards.


 Pursuant to the terms of the Plans, ISOs have a term of ten years from the date of grant or such shorter term as may be provided in the option agreement. Unless specified otherwise in an individual option agreement, ISOs generally vest over a four-year term and NQs generally vest over a  one-to-five-year term. Unless terminated by the Board, the Plans shall continue to remain effective for a term of ten years or until such time as no further awards may be granted and all awards granted under the Plans are no longer outstanding. As of September 30, 2021 there were 190,799 shares available for grant under the 2018 Stock Incentive Plan.


 On June 17, 2019, the Board adopted the 2019 Inducement Plan (the “Inducement Plan”). The Inducement Plan provides for the grant of non-qualified stock options. The Inducement Plan was recommended for approval by the Compensation Committee of the Board and subsequently approved and adopted by the Board without stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.


On December 9, 2020, the Company amended the Inducement Plan solely to increase the total number of shares of Common Stock reserved for issuance under the Inducement Plan from 200,000 shares to 500,000 shares. The 2019 Inducement Plan is administered by the Compensation Committee of the Board. In accordance with Rule 5635(c)(4) of the Nasdaq Listing Rules, non-qualified stock options under the 2019 Inducement Plan may only be made to an employee who has not previously been an employee or member of the Board (or any parent or subsidiary of the Company), or following a bona fide period of non-employment by the Company (or a parent or subsidiary of the Company), if he or she is granted such non-qualified stock options in connection with his or her commencement of employment with the Company or a subsidiary and such grant is an inducement material to his or her entering into employment with the Company or such subsidiary. As of September 30, 2021, there were 362,700 shares available for grant under the 2019 Inducement Plan.


The Company’s stock-based compensation expense related to stock options was recognized in operating expense as follows:


   
Three Months September 30, 2021
   
Nine Months Ended September 30,
 
   
2021
   
2020
   
2021
   
2020
 
   
(unaudited)
   
(unaudited)
 
Stock-Based Compensation
                       
Research and development
 
$
596,762
   
$
61,557
   
$
824,580
   
$
168,083
 
General and administrative
   
1,105,000
     
68,235
   
1,576,401
     
132,815
 
Total
 
$
1,701,763
   
$
129,792
   
$
2,400,980
   
$
300,898
 


The fair value of options granted during the three and nine months ended September 30, 2021 and the three and nine months ended September 30, 2020 was estimated using the Black-Scholes option valuation model utilizing the following assumptions. There were 63,800 options granted during the three-month period ended September 30, 2021.


   
Three Months September 30, 2021
   
Nine Months Ended September 30,
 
   
2021
   
2020
   
2021
   
2020
 
   
Weighted Average
   
Weighted Average
   
Weighted Average
   
Weighted Average
 
   
(unaudited)
   
(unaudited)
 
Volatility
   
100.16
%
   
%
   
100.58
%
   
97.00
%
Risk-Free Interest Rate
   
0.77
%
   
%
   
55.88
%
   
0.38
%
Expected Term in Years
   
6.08
     
     
6.28
     
6.07
 
Dividend Rate
   
     
     
     
 
Fair Value of Option on Grant Date
 
$
11.81
   
$
   
$
7.43
   
$
1.10
 


The following table summarizes the number of options outstanding and the weighted average exercise price:


   
Number
of Shares
   
Weighted
Average
Exercise Price
   
Weighted Average
Remaining
Contractual
Life in Years
   
Aggregate
Intrinsic Value
 
Options outstanding at December 31, 2020
   
1,650,897
   
$
11.87
     
7.03
   
$
226,731
 
Granted
   
1,722,730
     
3.34
     
9.28
   
$
8,803,138
 
Exercised
   
(95,737
)
   
7.24
     
   
$
 
Forfeited
   
(326,038
)
   
29.71
     
   
$
 
Options outstanding at September 30, 2021
   
2,951,852
   
$
5.07
     
7.99
   
$
29,754,366
 
Vested and expected to vest at September 30, 2021
   
2,951,852
   
$
5.07
     
7.99
   
$
29,754,366
 
Exercisable at September 30, 2021
   
1,130,039
   
$
7.66
     
5.81
   
$
8,914,003
 


At September 30, 2021 there was approximately $11,300,108 of unamortized stock option compensation expense, which is expected to be recognized over a remaining average vesting period of 2.97 years.
XML 26 R14.htm IDEA: XBRL DOCUMENT v3.21.2
Income Taxes
9 Months Ended
Sep. 30, 2021
Income Taxes [Abstract]  
Income Taxes
Note 8 – Income Taxes


In assessing the realizability of the net deferred tax assets, the Company considers all relevant positive and negative evidence to determine whether it is more likely than not that some portion or all of the deferred income tax assets will not be realized. The realization of the gross deferred tax assets is dependent on several factors, including the generation of sufficient taxable income prior to the expiration of the net operating loss carryforwards. The Company expects to have a loss for 2021 and there will be no current income tax expense. Additionally, there was a full valuation allowance against the net deferred tax assets as of September 30, 2021 and December 31, 2020. In May 2021, in accordance with the State of New Jersey’s Technology Business Tax Certificate Program, which allowed certain high technology and biotechnology companies to sell unused NOL carryforwards to other New Jersey-based corporate taxpayers, the Company sold New Jersey NOL carryforwards, resulting in the recognition of $4.5 million of income tax benefit, net of transaction costs.


The Company’s U.S. statutory rate is 21%. The effective tax rate, excluding the benefit of the sale of any New Jersey net operating losses, for the three and nine months ended September 30, 2021 is 0%.  The primary factor impacting the effective tax rate is the anticipated full year operating loss which will require a full valuation allowance against any associate deferred tax asset.


Entities are also required to evaluate, measure, recognize and disclose any uncertain income tax provisions taken on their income tax returns. The Company has analyzed its tax positions and has concluded that as of September 30, 2021, there were no uncertain positions. The Company’s U.S. federal and state net operating losses have occurred since its inception and as such, tax years subject to potential tax examination could apply from that date because the utilization of net operating losses from prior years opens the relevant year to audit by the IRS and/or state taxing authorities. The Company did not have any unrecognized tax benefits and has not accrued any interest or penalties for the three and nine months ended September 30, 2021 and for the year ended December 31, 2020.
XML 27 R15.htm IDEA: XBRL DOCUMENT v3.21.2
Commitments and Contingencies
9 Months Ended
Sep. 30, 2021
Commitments and Contingencies [Abstract]  
Commitments and Contingencies
Note 9 – Commitments and Contingencies

Rent


For month-to-month arrangements not impacted by the adoption of ASC 842, rent for the three and nine months ended September 30, 2021 was $52,000 and $130,493, respectively, compared to the three and nine months ended September 30, 2020 of $35,700 and $140,678.


Legal Proceedings
 

On July 23, 2021, David R. Rosener, a purported stockholder of the Company, filed a putative class action and shareholder derivative complaint in the Court of Chancery of the State of Delaware (C.A. No. 2021-0644 JRS)  against the Company and all of its directors and certain of its executive officers. The plaintiff named all current directors of PDS as defendants as well as PDS’s Chief Scientific Officer and PDS’s Chief Medical Officer and also named PDS as a nominal defendant.  The plaintiff claims PDS’s bylaws required tabulation of broker non-votes on Proposal 3 at the Company’s 2021 annual stockholder meeting on June 17, 2021, which sought shareholder approval of the Second Amended and Restated PDS Biotechnology Corporation 2014 Equity Incentive Plan (the “Restated Plan”). The complaint asserts claims for breach of fiduciary duties, declaratory judgment, waste of corporate assets and unjust enrichment in connection with the Restated Plan and the granting of an aggregate award of 1,040,700 stock options to certain executive officers pursuant to the Restated Plan.  The plaintiff seeks unspecified monetary damages, seeks to have the Restated Plan declared void, and seeks recission of the grant of stock options as ultra vires.  Given the early stage of this lawsuit, PDS is unable to reasonably estimate the costs associated with the lawsuit or predict the outcome.  Each of the Company, its directors and the named executives intend to defend this action vigorously.  There can be no guarantee as to the timing of any resolution.
XML 28 R16.htm IDEA: XBRL DOCUMENT v3.21.2
Retirement Plan
9 Months Ended
Sep. 30, 2021
Retirement Plan [Abstract]  
Retirement Plan
Note 10 – Retirement Plan


The Company has a 401(k) defined contribution plan for the benefit of all employees and permits voluntary contributions by employees subject to IRS-imposed limitations. The 401(k) employer contributions were $25,803 and $71,214 for the three and nine months ended September 30, 2021, respectively, compared to $11,809 and $35,293 for the three and nine months ended September 30, 2020, respectively.
XML 29 R17.htm IDEA: XBRL DOCUMENT v3.21.2
Subsequent Events
9 Months Ended
Sep. 30, 2021
Subsequent Events [Abstract]  
Subsequent Events
Note 11– Subsequent Events


On October 18, 2021, the Company granted an option to purchase 202,800 shares of common stock to its incoming Chief Financial Officer and 25,400 to other incoming employees with a strike price of $12.03 vesting over a four-year period with one quarter vesting on the first anniversary of the date of the grant and vesting monthly over the 36-month period thereafter and expire ten years from the date of the grant. The aggregate fair value of the options granted was $2.2 million.



Effective as November 5, 2021, the Company entered into a Patent License Agreement (the “Patent License Agreement”) with the U.S. Department of Health and Human Services, as represented by National Cancer Institute (“NCI”) of the National Institutes of Health (“NIH”).  Pursuant to the License Agreement, the Company obtained a nonexclusive license to the patent rights for NCI’s T-cell receptor gamma alternate reading frame protein (“TARP”) to develop and commercialize TARP peptide-based therapies in combination with the Company’s Versamune® technology. The Patent License Agreement includes customary milestone payments and royalties.
XML 30 R18.htm IDEA: XBRL DOCUMENT v3.21.2
Summary of Significant Accounting Policies (Policies)
9 Months Ended
Sep. 30, 2021
Summary of Significant Accounting Policies [Abstract]  
Unaudited Interim Financial Statements
(A)
Unaudited interim financial statements:


The interim balance sheet at September 30, 2021, the statements of operations and comprehensive loss and changes in stockholders’ equity for the three and nine months ended September 30, 2021 and 2020, and cash flows for the nine months ended September 30, 2021 and 2020 are unaudited. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. GAAP, in accordance with the requirements of the Securities and Exchange Commission (“SEC”) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. These condensed consolidated financial statements have been prepared on the same basis as the Company’s annual financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments that are necessary for a fair statement of its financial information. The results of operations for the three and nine months ended September 30, 2021 are not necessarily indicative of the results to be expected for the year ending December 31, 2021 or for any other future annual or interim period. The balance sheet as of December 31, 2020 included herein was derived from the audited condensed consolidated financial statements as of that date. These condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto as of and for the year ended December 31, 2020, filed by the Company with the SEC in its Annual Report on Form 10-K on March 18, 2021.
Use of Estimates
(B)
Use of estimates:


The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of expenses at the date of the consolidated financial statements and during the reporting periods, and to disclose contingent assets and liabilities at the date of the consolidated financial statements. Actual results could differ from those estimates.
Significant Risks and Uncertainties
(C)
Significant risks and uncertainties:


The Company’s operations are subject to a number of factors that may affect its operating results and financial condition. Such factors include, but are not limited to: the clinical and regulatory development of its products, the Company’s ability to preserve its cash resources, the Company’s review of strategic alternatives, the Company’s ability to add product candidates to its pipeline, the Company’s intellectual property, the ability to efficiently and effectively conduct its clinical trials, competition from products manufactured and sold or being developed by other companies, the price of, and demand for, Company products if approved for sale, the Company’s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products, the Company’s ability to raise capital, and the effects of health epidemics, pandemics, or outbreaks of infectious diseases, including the recent COVID-19 pandemic and its variants.


The Company currently has no commercially approved products. As such, there can be no assurance that the Company’s future research and development programs will be successfully commercialized. Developing and commercializing a product requires significant time and capital and is subject to regulatory review and approval as well as competition from other biotechnology and pharmaceutical companies. The Company operates in an environment of rapid change and is dependent upon the continued services of its employees and consultants and obtaining and protecting its intellectual property.
Cash Equivalents and Concentration of Cash Balance
(D)
Cash equivalents and concentration of cash balance:


The Company considers all highly liquid securities with a maturity weighted average of less than three months to be cash equivalents. The Company’s cash and cash equivalents in bank deposit accounts, at times, may exceed federally insured limits.
Research and Development
(E)
Research and development:


Costs incurred in connection with research and development activities are expensed as incurred. These costs include licensing fees to use certain technology in the Company’s research and development projects as well as fees paid to consultants and entities that perform certain research and testing on behalf of the Company.


Costs for certain development activities, such as clinical trials, are recognized based on an evaluation of the progress to completion of specific tasks using data, such as patient enrollment, clinical site activations or information provided by vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred.
Patent Costs
(F)
Patent costs:


The Company expenses patent costs as incurred and classifies such costs as general and administrative expenses in the accompanying statements of operations and comprehensive loss.
Stock-Based Compensation
(G)
Stock-based compensation:


The Company accounts for its stock-based compensation in accordance with ASC Topic 718, Compensation—Stock Compensation (“ASC 718”). ASC 718 requires all stock-based payments to employees, directors and non-employees to be recognized as expense in the consolidated statements of operations and comprehensive loss based on their grant date fair values. In order to determine the fair value of stock options on the date of grant, the Company uses the Black-Scholes option-pricing model. Inherent in this model are assumptions related to expected stock-price volatility, option term, risk-free interest rate and dividend yield. While the risk-free interest rate and dividend yield are less subjective assumptions that are based on factual data derived from public sources, the expected stock-price volatility and option term assumptions require a greater level of judgment. The Company expenses the fair value of its stock-based compensation awards to employees and directors on a straight-line basis over the requisite service period, which is generally the vesting period. The Company recognizes forfeitures as they occur.
Net Loss per Common Share
(H)
Net loss per common share:


Basic and diluted net loss per common share is determined by dividing net loss attributable to common stockholders by the weighted average common shares outstanding during the period. For all periods presented, the common shares underlying the stock options and warrants have been excluded from the calculation because their effect would be anti-dilutive. Therefore, the weighted average shares outstanding used to calculate both basic and diluted loss per common share are the same.


The potentially dilutive securities excluded from the determination of diluted loss per share as their effect is antidilutive, are as follows:


 
As of September 30,
 
   
2021
   
2020
 
Stock options to purchase Common Stock
   
2,951,852
     
1,639,753
 
Warrants to purchase Common Stock
   
197,518
     
197,518
 
Total
   
3,149,370
     
1,837,271
 
XML 31 R19.htm IDEA: XBRL DOCUMENT v3.21.2
Summary of Significant Accounting Policies (Tables)
9 Months Ended
Sep. 30, 2021
Summary of Significant Accounting Policies [Abstract]  
Antidilutive Securities

The potentially dilutive securities excluded from the determination of diluted loss per share as their effect is antidilutive, are as follows:


 
As of September 30,
 
   
2021
   
2020
 
Stock options to purchase Common Stock
   
2,951,852
     
1,639,753
 
Warrants to purchase Common Stock
   
197,518
     
197,518
 
Total
   
3,149,370
     
1,837,271
 
XML 32 R20.htm IDEA: XBRL DOCUMENT v3.21.2
Fair Value of Financial Instruments (Tables)
9 Months Ended
Sep. 30, 2021
Fair Value of Financial Instruments [Abstract]  
Fair Value of Financial Instruments

There were no transfers among Levels 1, 2, or 3 during 2021 or 2020.

   
Fair Value Measurements at Reporting Date Using
 
   
Total
   
Quoted Prices in
Active Markets
(Level 1)
   
Quoted Prices in
Inactive Markets
(Level 2)
   
Significant
Unobservable Inputs
(Level 3)
 
As of September 30, 2021: (unaudited)
                       
Cash and cash equivalents
 
$
69,744,004
   
$
69,744,004
   
$
   
$
 
                                 
As of December 31, 2020:
                               
Cash and cash equivalents
 
$
28,839,565
   
$
28,839,565
   
$
   
$
 
XML 33 R21.htm IDEA: XBRL DOCUMENT v3.21.2
Leases (Tables)
9 Months Ended
Sep. 30, 2021
Leases [Abstract]  
Supplemental Cash Flow Information Related to Operating Leases

Supplemental cash flow information related to operating leases is as follows:

   
As of September 30,
 
   
2021
   
2020
 
Cash paid for operating lease liabilities
 
$
127,804
   
$
62,597
 
Right-of use assets recorded in exchange for lease obligations
 
$
   
$
638,831
 
Future Payments for Operating Lease Liabilities

Maturity of the Company’s operating lease liability is as follows:

Year ended December 31,
     
2021 (remaining three months)
 
$
43,035
 
2022
   
294,986
 
2023
   
239,469
 
2024
   
 
2025 and after
   
 
Total future minimum lease payments
   
577,490
 
Less imputed interest
   
(55,797
)
   
$
521,693
 
XML 34 R22.htm IDEA: XBRL DOCUMENT v3.21.2
Accrued Expenses (Tables)
9 Months Ended
Sep. 30, 2021
Accrued Expenses [Abstract]  
Accrued Expenses and Other Liabilities
Accrued expenses and other liabilities consist of the following:

   
As of
September 30, 2021
   
As of
December 31, 2020
 
Accrued research and development costs
 
$
19,500
   
$
204,780
 
Accrued professional fees
   
277,555
     
219,822
 
Accrued compensation
   
1,626,791
     
1,310,720
 
Total
 
$
1,923,846
   
$
1,735,322
 
XML 35 R23.htm IDEA: XBRL DOCUMENT v3.21.2
Stock-Based Compensation (Tables)
9 Months Ended
Sep. 30, 2021
Stock-Based Compensation [Abstract]  
Stock-Based Compensation Expense

The Company’s stock-based compensation expense related to stock options was recognized in operating expense as follows:


   
Three Months September 30, 2021
   
Nine Months Ended September 30,
 
   
2021
   
2020
   
2021
   
2020
 
   
(unaudited)
   
(unaudited)
 
Stock-Based Compensation
                       
Research and development
 
$
596,762
   
$
61,557
   
$
824,580
   
$
168,083
 
General and administrative
   
1,105,000
     
68,235
   
1,576,401
     
132,815
 
Total
 
$
1,701,763
   
$
129,792
   
$
2,400,980
   
$
300,898
 
Assumptions Used to Value Stock Options Granted

The fair value of options granted during the three and nine months ended September 30, 2021 and the three and nine months ended September 30, 2020 was estimated using the Black-Scholes option valuation model utilizing the following assumptions. There were 63,800 options granted during the three-month period ended September 30, 2021.


   
Three Months September 30, 2021
   
Nine Months Ended September 30,
 
   
2021
   
2020
   
2021
   
2020
 
   
Weighted Average
   
Weighted Average
   
Weighted Average
   
Weighted Average
 
   
(unaudited)
   
(unaudited)
 
Volatility
   
100.16
%
   
%
   
100.58
%
   
97.00
%
Risk-Free Interest Rate
   
0.77
%
   
%
   
55.88
%
   
0.38
%
Expected Term in Years
   
6.08
     
     
6.28
     
6.07
 
Dividend Rate
   
     
     
     
 
Fair Value of Option on Grant Date
 
$
11.81
   
$
   
$
7.43
   
$
1.10
 
Stock Option Activity

The following table summarizes the number of options outstanding and the weighted average exercise price:


   
Number
of Shares
   
Weighted
Average
Exercise Price
   
Weighted Average
Remaining
Contractual
Life in Years
   
Aggregate
Intrinsic Value
 
Options outstanding at December 31, 2020
   
1,650,897
   
$
11.87
     
7.03
   
$
226,731
 
Granted
   
1,722,730
     
3.34
     
9.28
   
$
8,803,138
 
Exercised
   
(95,737
)
   
7.24
     
   
$
 
Forfeited
   
(326,038
)
   
29.71
     
   
$
 
Options outstanding at September 30, 2021
   
2,951,852
   
$
5.07
     
7.99
   
$
29,754,366
 
Vested and expected to vest at September 30, 2021
   
2,951,852
   
$
5.07
     
7.99
   
$
29,754,366
 
Exercisable at September 30, 2021
   
1,130,039
   
$
7.66
     
5.81
   
$
8,914,003
 
XML 36 R24.htm IDEA: XBRL DOCUMENT v3.21.2
Nature of Operations (Details)
Sep. 30, 2021
ClinicalTrial
Nature of Operations [Abstract]  
Number of planned clinical trials delayed 2
Number of planned clinical trials 3
XML 37 R25.htm IDEA: XBRL DOCUMENT v3.21.2
Summary of Significant Accounting Policies (Details) - shares
9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Net Loss per Common Share [Abstract]    
Antidilutive impact to EPS (in shares) 3,149,370 1,837,271
Stock Options to Purchase Common Stock [Member]    
Net Loss per Common Share [Abstract]    
Antidilutive impact to EPS (in shares) 2,951,852 1,639,753
Warrants to Purchase Common Stock [Member]    
Net Loss per Common Share [Abstract]    
Antidilutive impact to EPS (in shares) 197,518 197,518
XML 38 R26.htm IDEA: XBRL DOCUMENT v3.21.2
Liquidity (Details) - USD ($)
1 Months Ended 9 Months Ended
Jul. 29, 2019
Jun. 30, 2021
May 31, 2021
Aug. 31, 2020
Feb. 29, 2020
Sep. 30, 2021
Sep. 30, 2020
Dec. 31, 2020
Jul. 31, 2020
Jul. 26, 2019
Liquidity [Abstract]                    
Cash and cash equivalents           $ 69,744,004   $ 28,839,565    
Percentage of shares of common stock that can be sold without shareholder approval 19.99%                  
Share price (in dollars per share)                   $ 5.76
Issuance of common stock from equity transaction (in shares) 100,654                  
Issuance of common stock from equity transaction $ 603,924                  
Shares sold under common stock purchase agreement (in shares)           0        
Issuance of common stock (in shares)   6,088,235   6,900,000 10,000,000          
Sales price (in dollars per share)   $ 8.50   $ 2.75 $ 1.30          
Proceeds from issuance of shares   $ 51,700,000   $ 19,000,000.0 $ 13,000,000 $ 48,544,998 $ 29,756,502      
Proceeds from issuance of shares, net of underwriting discounts and commissions   $ 48,500,000   $ 17,100,000 $ 11,900,000          
Registered securities in Shelf Registration Statement available for future sale                 $ 100,000,000  
Proceeds from sale of tax benefits     $ 4,500,000              
Shelf securities available for sale           $ 29,300,000        
Over-Allotment Option [Member]                    
Liquidity [Abstract]                    
Issuance of common stock (in shares)   794,117   900,000 769,230          
Minimum [Member]                    
Liquidity [Abstract]                    
Share price (in dollars per share)                   $ 0.50
Maximum [Member]                    
Liquidity [Abstract]                    
Shares of common stock to be purchased (in shares) 100,000                  
Common stock to be purchased under common stock purchase agreement $ 20,000,000.0                  
Shares of common stock that can be sold without shareholder approval (in shares) 1,034,979                  
XML 39 R27.htm IDEA: XBRL DOCUMENT v3.21.2
Fair Value of Financial Instruments (Details) - USD ($)
9 Months Ended 12 Months Ended
Sep. 30, 2021
Dec. 31, 2020
Fair Value Transfers Between Levels [Abstract]    
Transfers from Level 1 to Level 2 $ 0 $ 0
Transfers from Level 2 to Level 1 0 0
Transfers into Level 3 0 0
Transfers out of Level 3 0 0
Fair Value of Financial Instruments [Abstract]    
Cash and cash equivalents 69,744,004 28,839,565
Quoted Prices in Active Markets (Level 1) [Member]    
Fair Value of Financial Instruments [Abstract]    
Cash and cash equivalents 69,744,004 28,839,565
Quoted Prices in Inactive Markets (Level 2) [Member]    
Fair Value of Financial Instruments [Abstract]    
Cash and cash equivalents 0 0
Significant Unobservable Inputs (Level 3) [Member]    
Fair Value of Financial Instruments [Abstract]    
Cash and cash equivalents $ 0 $ 0
XML 40 R28.htm IDEA: XBRL DOCUMENT v3.21.2
Leases, Operating Leases (Details)
Sep. 30, 2021
USD ($)
ft²
Dec. 31, 2020
USD ($)
May 01, 2020
USD ($)
Jul. 08, 2019
USD ($)
Installment
Leases [Abstract]        
Percentage of remaining payments required to be paid to terminate lease       50.00%
Remaining lease payments       $ 665,802
Number of installments for remaining lease payment | Installment       3
Area of office space under sub-lease | ft² 11,200      
Term of sub-lease agreement 40 months      
Remaining lease term 23 months      
Right-of-use asset $ 406,171 $ 547,706 $ 700,000  
Operating lease liability $ 521,693   $ 700,000  
Discount rate used to measure operating lease liability     9.15%  
XML 41 R29.htm IDEA: XBRL DOCUMENT v3.21.2
Leases, Supplemental Cash Flow Information Related to Operating Leases (Details) - USD ($)
9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Supplemental Cash Flow Information Related to Operating Leases [Abstract]    
Cash paid for operating lease liabilities $ 127,804 $ 62,597
Right-of use assets recorded in exchange for lease obligations $ 0 $ 638,831
XML 42 R30.htm IDEA: XBRL DOCUMENT v3.21.2
Leases, Future Payments for Operating Lease Liabilities (Details) - USD ($)
Sep. 30, 2021
May 01, 2020
Future Payments for Operating Lease Liabilities [Abstract]    
2021 (remaining three months) $ 43,035  
2022 294,986  
2023 239,469  
2024 0  
2025 and after 0  
Total future minimum lease payments 577,490  
Less imputed interest (55,797)  
Lease liability $ 521,693 $ 700,000
XML 43 R31.htm IDEA: XBRL DOCUMENT v3.21.2
Accrued Expenses (Details) - USD ($)
Sep. 30, 2021
Dec. 31, 2020
Accrued Expenses [Abstract]    
Accrued research and development costs $ 19,500 $ 204,780
Accrued professional fees 277,555 219,822
Accrued compensation 1,626,791 1,310,720
Total $ 1,923,846 $ 1,735,322
XML 44 R32.htm IDEA: XBRL DOCUMENT v3.21.2
Stock-Based Compensation, Equity Compensation Plans (Details)
9 Months Ended 12 Months Ended
Sep. 30, 2021
Plan
shares
Dec. 31, 2014
shares
Jun. 17, 2021
shares
Dec. 09, 2020
shares
Dec. 08, 2020
shares
Mar. 31, 2019
shares
Dec. 31, 2018
shares
Stock Options [Abstract]              
Number of equity compensation plans | Plan 3            
The Plans [Member]              
Stock Options [Abstract]              
Term of plan 10 years            
The Plans [Member] | Incentive Stock Options [Member]              
Stock Options [Abstract]              
Vesting period 4 years            
The Plans [Member] | Incentive Stock Options [Member] | Maximum [Member]              
Stock Options [Abstract]              
Term of option 10 years            
The Plans [Member] | Nonqualified Options [Member] | Minimum [Member]              
Stock Options [Abstract]              
Vesting period 1 year            
The Plans [Member] | Nonqualified Options [Member] | Maximum [Member]              
Stock Options [Abstract]              
Vesting period 5 years            
2014 Equity Incentive Plan [Member]              
Stock Options [Abstract]              
Number of shares authorized for issuance (in shares)   91,367 3,339,243     826,292  
Percentage of Common Stock outstanding used to determine annual increase in the plan limit   4.00%          
2018 Equity Incentive Plan [Member]              
Stock Options [Abstract]              
Number of shares authorized for issuance (in shares)             558,071
Shares available for grant (in shares) 190,799            
2019 Inducement Plan [Member]              
Stock Options [Abstract]              
Common stock reserved for issuance (in shares)       500,000 200,000    
Shares available for grant (in shares) 362,700            
XML 45 R33.htm IDEA: XBRL DOCUMENT v3.21.2
Stock-Based Compensation, Stock-Based Compensation Expense Related to Stock Options (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Stock-Based Compensation [Abstract]        
Stock-based compensation expense $ 1,701,763 $ 129,792 $ 2,400,980 $ 300,898
Research and Development [Member]        
Stock-Based Compensation [Abstract]        
Stock-based compensation expense 596,762 61,557 824,580 168,083
General and Administrative [Member]        
Stock-Based Compensation [Abstract]        
Stock-based compensation expense $ 1,105,000 $ 68,235 $ 1,576,401 $ 132,815
XML 46 R34.htm IDEA: XBRL DOCUMENT v3.21.2
Stock-Based Compensation, Assumptions Used to Value Stock Options Granted (Details) - $ / shares
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Stock-Based Compensation [Abstract]        
Options granted (in shares) 63,800      
Assumptions Used in Determining Fair Value of Stock Options Granted [Abstract]        
Volatility 100.16% 0.00% 100.58% 97.00%
Risk-free interest rate 0.77% 0.00% 55.88% 0.38%
Expected term 6 years 29 days   6 years 3 months 10 days 6 years 25 days
Dividend rate 0.00% 0.00% 0.00% 0.00%
Fair value of option on grant date (in dollars per share) $ 11.81 $ 0 $ 7.43 $ 1.10
XML 47 R35.htm IDEA: XBRL DOCUMENT v3.21.2
Stock-Based Compensation, Stock Option Activity (Details) - USD ($)
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2021
Sep. 30, 2021
Dec. 31, 2020
Number of Shares [Roll Forward]      
Granted (in shares) 63,800    
Stock Options [Member]      
Number of Shares [Roll Forward]      
Options outstanding, beginning balance (in shares)   1,650,897  
Granted (in shares)   1,722,730  
Exercised (in shares)   (95,737)  
Forfeited (in shares)   (326,038)  
Options outstanding, ending balance (in shares) 2,951,852 2,951,852 1,650,897
Vested and expected to vest (in shares) 2,951,852 2,951,852  
Exercisable (in shares) 1,130,039 1,130,039  
Weighted Average Exercise Price [Roll Forward]      
Options outstanding, beginning balance (in dollars per share)   $ 11.87  
Granted (in dollars per share)   3.34  
Exercised (in dollars per share)   7.24  
Forfeited (in dollars per share)   29.71  
Options outstanding, ending balance (in dollars per share) $ 5.07 5.07 $ 11.87
Vested and expected to vest (in dollars per share) 5.07 5.07  
Exercisable (in dollars per share) $ 7.66 $ 7.66  
Weighted Average Remaining Contractual Life and Aggregate Intrinsic Value [Abstract]      
Options outstanding, weighted average remaining contractual life   7 years 11 months 26 days 7 years 10 days
Granted, weighted average remaining contractual life   9 years 3 months 10 days  
Vested and expected to vest, weighted average remaining contractual life   7 years 11 months 26 days  
Exercisable, weighted average remaining contractual life   5 years 9 months 21 days  
Options outstanding, aggregate intrinsic value   $ 226,731  
Granted, aggregate intrinsic value   8,803,138  
Exercised, aggregate intrinsic value   0  
Forfeited, aggregate intrinsic value   0  
Options outstanding, aggregate intrinsic value $ 29,754,366 29,754,366 $ 226,731
Vested and expected to vest, aggregate intrinsic value 29,754,366 29,754,366  
Exercisable, aggregate intrinsic value 8,914,003 8,914,003  
Unamortized Stock Compensation Expense [Abstract]      
Unamortized stock compensation expense $ 11,300,108 $ 11,300,108  
Period for recognition   2 years 11 months 19 days  
XML 48 R36.htm IDEA: XBRL DOCUMENT v3.21.2
Income Taxes (Details) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended
May 31, 2021
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Dec. 31, 2020
Income Taxes [Abstract]            
Current income tax expense       $ 0    
Benefit from income taxes $ (4,500,000) $ 0 $ 0 $ (4,516,488) $ 0  
Federal statutory rate       21.00%    
Effective tax rate   0.00%   0.00%    
Uncertain tax positions   $ 0   $ 0    
Unrecognized tax benefits   0   0   $ 0
Accrued interest and penalties   $ 0   $ 0   $ 0
XML 49 R37.htm IDEA: XBRL DOCUMENT v3.21.2
Commitments and Contingencies (Details) - USD ($)
3 Months Ended 9 Months Ended
Dec. 08, 2020
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Commitments and Contingencies [Abstract]          
Rent expense   $ 52,000 $ 35,700 $ 130,493 $ 140,678
Legal Proceedings [Abstract]          
Options granted (in shares)   63,800      
Stock Options [Member]          
Legal Proceedings [Abstract]          
Options granted (in shares)       1,722,730  
2014 Equity Incentive Plan [Member] | Stock Options [Member] | Frank Bedu-Addo, Gregory Conn, and Lauren Wood [Member]          
Legal Proceedings [Abstract]          
Options granted (in shares) 1,040,700        
XML 50 R38.htm IDEA: XBRL DOCUMENT v3.21.2
Retirement Plan (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Retirement Plan [Abstract]        
401(k) employer contributions $ 25,803 $ 11,809 $ 71,214 $ 35,293
XML 51 R39.htm IDEA: XBRL DOCUMENT v3.21.2
Subsequent Events (Details) - USD ($)
$ / shares in Units, $ in Millions
3 Months Ended 9 Months Ended
Oct. 18, 2021
Sep. 30, 2021
Sep. 30, 2021
Subsequent Events [Abstract]      
Options granted (in shares)   63,800  
Stock Options [Member]      
Subsequent Events [Abstract]      
Options granted (in shares)     1,722,730
Exercise price (in dollars per share)     $ 3.34
Subsequent Event [Member] | Chief Financial Officer [Member]      
Subsequent Events [Abstract]      
Options granted (in shares) 202,800    
Subsequent Event [Member] | Other Employees [Member]      
Subsequent Events [Abstract]      
Options granted (in shares) 25,400    
Subsequent Event [Member] | Stock Options [Member]      
Subsequent Events [Abstract]      
Exercise price (in dollars per share) $ 12.03    
Vesting period 4 years    
Expiration period 10 years    
Aggregate fair value of options granted $ 2.2    
Subsequent Event [Member] | Stock Options [Member] | One Quarter of Options Granted [Member]      
Subsequent Events [Abstract]      
Vesting period 1 year    
Percentage of options vesting 25.00%    
Subsequent Event [Member] | Stock Options [Member] | Remaining Options Granted [Member]      
Subsequent Events [Abstract]      
Vesting period 36 months    
EXCEL 52 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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ⅅ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

KQ/1-0B^)J."N6.)!VOOCQ,O!491;;;7\JX[W!3O8.D],"+K760N%N XO9-.B>! M<]4[:_'W1FB='>3<^@^NONA*3J" *;9"IHZ8E"^@,>N'N/B4LA.8%3@?_ V-4!W+'^.B\ M/#\F),B[O914&'5K8/KD0?+#^D=,J1,>]4(/$..1/3V], ;BJMGQY>JM1.OY M15V697_]&B9AC*!RE-B+H&G_00FIF-67M/*!#!VES%Y[V M:/T*4IR2PF\4\Y4.>3YE#U]A _373=SUX-CUY/E4WWC:C_S;[\2 RLA%\IIR MUOK5P&$BVG4'23[I75(\LY3D14-YN>(\*(6:K5Y4.:4TT^25#PI,+(^_H#Z'..9IX!Z M'%2J&@J+9;.OHS[UU\]9%[(J\%*G':9YZ:/Z0JU'Z4#"@P2+^K5%KX,P]JV. M@@L[WKR-561R4Z*GBTWOLVT?5)X?Y9"'[4Z=)CX4R;#*ERB3NM>I8]UBGJ 0 M DXE+JPCBS-7?AZE@YM4:HUG=JYS5/MEL55P&^!<>D;.2IP_/'+CTBREAZSK M3@\=JB!7CHO*Q.0S"/[]O)2JB*8U*X_T1EH>S#&FPI0/W23"G@8/*OMHXT99 M%2T&)"9_.0)'M!0&1R)*1"SDE956K*J&,R!.-"6['>EPTO[D$UFI/) MBNS+H$,[K\Y.OH.$Z).5T90$^4(-54%V\NZ*EP\3 \I@ M6FMQRNR&+'V5KCI/:6N#QOU]7&BY6.Z'I2#%H6P\JZEU=C!&V"+6>>[SH*0EP=EN3]#<2OY@ MIK995Z;R!B[:6*C;G9;)1ZP!.E):*&)>7ZAJ+3CP1 :%;^,]QS?J=:$.34LM MBZUR?J1J=+\(P_:9784)8R[ST.&(=U-1%LOK)D4LJU41![:=7.KL&'2.BPMQ#NV$?H45^ SN+>-.$NB"UH_:LTZ(-(U;G!1H4VR9 MO]/N++X6$#EH(&0QF]!7[%:>#SHYJ#2P"6D3.:10V,&HG[JC^W[W2<[W]3<1 M%"%<'GO/R-K)/'*GLNED'G0HQ;T-V-N0X2V+,B/H88ST>[#-?]C8#ETWU]O< MD"KQPXZ=>_()K6-C1RHY6/2$16;A1MB+:G9'X!M,J=+F79SKBR SP['P+?P4 M+SUF#*XTV>!8BG/,D@F';)Z\@;!!9K!P\-TWN/O4$>"K4,-JFX\7@2O8O2Z4 M9^D9N6*+?.?[[;U4@OM\[[]''I 6O\&85[4Z,F47F:5?,O8#<4ZBHE':',WM M/8&U%XO2&@L A"%Y-U;!22OYM4^QO4OPNB@XO64(6/9= ,/S&-'Y/,\EPWRM M&YI2W%EY-Z=2*%.,^+@'(T7-[Q:=;75^W=.IN>*N0')+FEJ.L]Q2I7[:!MFAP21!'LE::@>K@1$_E4 MK%,Z-7!S*\ .N8CC4[V J%T;K[D?X#4S.#-K'6J-9:Q\U_CA#84&THT Y<.? M64;!V(KA?"EL/M"^ZCF(KE)XR5#COZ5&?; 'NKJTWLO7/NV S33Z5<>N%>H M8T%C]"^'2T3B##W[8_\D2OYSFF&:D]>K:S+U;W>_;@HFV.J5:D/Z6N# R5Y] M:]1?[LYW7X1[9$%AGM?_U4\@C.>7.2\V@ M!4>*ODK^B3S0R@+DXG06"OYS^GQ LOGS"1^///YZC.A@EX4#2P:(1Y%OR6;5 M3O

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end

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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 54 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 55 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 101 272 1 false 25 0 false 8 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://pdsbiotech.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 010000 - Statement - Condensed Consolidated Balance Sheets Sheet http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 010100 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 020000 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss Sheet http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss Condensed Consolidated Statements of Operations and Comprehensive Loss Statements 4 false false R5.htm 030000 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity Sheet http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity Condensed Consolidated Statements of Changes in Stockholders' Equity Statements 5 false false R6.htm 040000 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows Condensed Consolidated Statements of Cash Flows Statements 6 false false R7.htm 060100 - Disclosure - Nature of Operations Sheet http://pdsbiotech.com/role/NatureOfOperations Nature of Operations Notes 7 false false R8.htm 060200 - Disclosure - Summary of Significant Accounting Policies Sheet http://pdsbiotech.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 060300 - Disclosure - Liquidity Sheet http://pdsbiotech.com/role/Liquidity Liquidity Notes 9 false false R10.htm 060400 - Disclosure - Fair Value of Financial Instruments Sheet http://pdsbiotech.com/role/FairValueOfFinancialInstruments Fair Value of Financial Instruments Notes 10 false false R11.htm 060500 - Disclosure - Leases Sheet http://pdsbiotech.com/role/Leases Leases Notes 11 false false R12.htm 060600 - Disclosure - Accrued Expenses Sheet http://pdsbiotech.com/role/AccruedExpenses Accrued Expenses Notes 12 false false R13.htm 060700 - Disclosure - Stock-Based Compensation Sheet http://pdsbiotech.com/role/StockbasedCompensation Stock-Based Compensation Notes 13 false false R14.htm 060800 - Disclosure - Income Taxes Sheet http://pdsbiotech.com/role/IncomeTaxes Income Taxes Notes 14 false false R15.htm 060900 - Disclosure - Commitments and Contingencies Sheet http://pdsbiotech.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 15 false false R16.htm 061000 - Disclosure - Retirement Plan Sheet http://pdsbiotech.com/role/RetirementPlan Retirement Plan Notes 16 false false R17.htm 061100 - Disclosure - Subsequent Events Sheet http://pdsbiotech.com/role/SubsequentEvents Subsequent Events Notes 17 false false R18.htm 070200 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://pdsbiotech.com/role/SummaryOfSignificantAccountingPolicies 18 false false R19.htm 080200 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://pdsbiotech.com/role/SummaryOfSignificantAccountingPolicies 19 false false R20.htm 080400 - Disclosure - Fair Value of Financial Instruments (Tables) Sheet http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsTables Fair Value of Financial Instruments (Tables) Tables http://pdsbiotech.com/role/FairValueOfFinancialInstruments 20 false false R21.htm 080500 - Disclosure - Leases (Tables) Sheet http://pdsbiotech.com/role/LeasesTables Leases (Tables) Tables http://pdsbiotech.com/role/Leases 21 false false R22.htm 080600 - Disclosure - Accrued Expenses (Tables) Sheet http://pdsbiotech.com/role/AccruedExpensesTables Accrued Expenses (Tables) Tables http://pdsbiotech.com/role/AccruedExpenses 22 false false R23.htm 080700 - Disclosure - Stock-Based Compensation (Tables) Sheet http://pdsbiotech.com/role/StockbasedCompensationTables Stock-Based Compensation (Tables) Tables http://pdsbiotech.com/role/StockbasedCompensation 23 false false R24.htm 090100 - Disclosure - Nature of Operations (Details) Sheet http://pdsbiotech.com/role/NatureOfOperationsDetails Nature of Operations (Details) Details http://pdsbiotech.com/role/NatureOfOperations 24 false false R25.htm 090200 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) Details http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesTables 25 false false R26.htm 090300 - Disclosure - Liquidity (Details) Sheet http://pdsbiotech.com/role/LiquidityDetails Liquidity (Details) Details http://pdsbiotech.com/role/Liquidity 26 false false R27.htm 090400 - Disclosure - Fair Value of Financial Instruments (Details) Sheet http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsDetails Fair Value of Financial Instruments (Details) Details http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsTables 27 false false R28.htm 090500 - Disclosure - Leases, Operating Leases (Details) Sheet http://pdsbiotech.com/role/LeasesOperatingLeasesDetails Leases, Operating Leases (Details) Details 28 false false R29.htm 090502 - Disclosure - Leases, Supplemental Cash Flow Information Related to Operating Leases (Details) Sheet http://pdsbiotech.com/role/LeasesSupplementalCashFlowInformationRelatedToOperatingLeasesDetails Leases, Supplemental Cash Flow Information Related to Operating Leases (Details) Details 29 false false R30.htm 090504 - Disclosure - Leases, Future Payments for Operating Lease Liabilities (Details) Sheet http://pdsbiotech.com/role/LeasesFuturePaymentsForOperatingLeaseLiabilitiesDetails Leases, Future Payments for Operating Lease Liabilities (Details) Details 30 false false R31.htm 090600 - Disclosure - Accrued Expenses (Details) Sheet http://pdsbiotech.com/role/AccruedExpensesDetails Accrued Expenses (Details) Details http://pdsbiotech.com/role/AccruedExpensesTables 31 false false R32.htm 090700 - Disclosure - Stock-Based Compensation, Equity Compensation Plans (Details) Sheet http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails Stock-Based Compensation, Equity Compensation Plans (Details) Details 32 false false R33.htm 090702 - Disclosure - Stock-Based Compensation, Stock-Based Compensation Expense Related to Stock Options (Details) Sheet http://pdsbiotech.com/role/StockbasedCompensationStockbasedCompensationExpenseRelatedToStockOptionsDetails Stock-Based Compensation, Stock-Based Compensation Expense Related to Stock Options (Details) Details 33 false false R34.htm 090704 - Disclosure - Stock-Based Compensation, Assumptions Used to Value Stock Options Granted (Details) Sheet http://pdsbiotech.com/role/StockbasedCompensationAssumptionsUsedToValueStockOptionsGrantedDetails Stock-Based Compensation, Assumptions Used to Value Stock Options Granted (Details) Details 34 false false R35.htm 090706 - Disclosure - Stock-Based Compensation, Stock Option Activity (Details) Sheet http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails Stock-Based Compensation, Stock Option Activity (Details) Details 35 false false R36.htm 090800 - Disclosure - Income Taxes (Details) Sheet http://pdsbiotech.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://pdsbiotech.com/role/IncomeTaxes 36 false false R37.htm 090900 - Disclosure - Commitments and Contingencies (Details) Sheet http://pdsbiotech.com/role/CommitmentsAndContingenciesDetails Commitments and Contingencies (Details) Details http://pdsbiotech.com/role/CommitmentsAndContingencies 37 false false R38.htm 091000 - Disclosure - Retirement Plan (Details) Sheet http://pdsbiotech.com/role/RetirementPlanDetails Retirement Plan (Details) Details http://pdsbiotech.com/role/RetirementPlan 38 false false R39.htm 091100 - Disclosure - Subsequent Events (Details) Sheet http://pdsbiotech.com/role/SubsequentEventsDetails Subsequent Events (Details) Details http://pdsbiotech.com/role/SubsequentEvents 39 false false All Reports Book All Reports brhc10030652_10q.htm brhc10030652_ex31-1.htm brhc10030652_ex31-2.htm brhc10030652_ex32-1.htm brhc10030652_ex32-2.htm pdsb-20210930.xsd pdsb-20210930_cal.xml pdsb-20210930_def.xml pdsb-20210930_lab.xml pdsb-20210930_pre.xml image00001.jpg http://xbrl.sec.gov/dei/2021 http://fasb.org/us-gaap/2021-01-31 http://fasb.org/srt/2021-01-31 true true JSON 58 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "brhc10030652_10q.htm": { "axisCustom": 0, "axisStandard": 11, "contextCount": 101, "dts": { "calculationLink": { "local": [ "pdsb-20210930_cal.xml" ] }, "definitionLink": { "local": [ "pdsb-20210930_def.xml" ] }, "inline": { "local": [ "brhc10030652_10q.htm" ] }, "labelLink": { "local": [ "pdsb-20210930_lab.xml" ] }, "presentationLink": { "local": [ "pdsb-20210930_pre.xml" ] }, "schema": { "local": [ "pdsb-20210930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd", "http://www.xbrl.org/2004/ref-2004-08-10.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd" ] } }, "elementCount": 312, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 3, "http://xbrl.sec.gov/dei/2021": 5, "total": 8 }, "keyCustom": 29, "keyStandard": 243, "memberCustom": 6, "memberStandard": 18, "nsprefix": "pdsb", "nsuri": "http://pdsbiotech.com/20210930", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "brhc10030652_10q.htm", "contextRef": "c20210101to20210930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000100 - Document - Document and Entity Information", "role": "http://pdsbiotech.com/role/DocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "brhc10030652_10q.htm", "contextRef": "c20210101to20210930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "brhc10030652_10q.htm", "contextRef": "c20210101to20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "060400 - Disclosure - Fair Value of Financial Instruments", "role": "http://pdsbiotech.com/role/FairValueOfFinancialInstruments", "shortName": "Fair Value of Financial Instruments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "brhc10030652_10q.htm", "contextRef": "c20210101to20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "brhc10030652_10q.htm", "contextRef": "c20210101to20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "060500 - Disclosure - Leases", "role": "http://pdsbiotech.com/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "brhc10030652_10q.htm", "contextRef": "c20210101to20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "brhc10030652_10q.htm", "contextRef": "c20210101to20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "060600 - Disclosure - Accrued Expenses", "role": "http://pdsbiotech.com/role/AccruedExpenses", "shortName": "Accrued Expenses", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "brhc10030652_10q.htm", "contextRef": "c20210101to20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "brhc10030652_10q.htm", "contextRef": "c20210101to20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "060700 - Disclosure - Stock-Based Compensation", "role": "http://pdsbiotech.com/role/StockbasedCompensation", "shortName": "Stock-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "brhc10030652_10q.htm", "contextRef": "c20210101to20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "brhc10030652_10q.htm", "contextRef": "c20210101to20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "060800 - Disclosure - Income Taxes", "role": "http://pdsbiotech.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "brhc10030652_10q.htm", "contextRef": "c20210101to20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "brhc10030652_10q.htm", "contextRef": "c20210101to20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "060900 - Disclosure - Commitments and Contingencies", "role": "http://pdsbiotech.com/role/CommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "brhc10030652_10q.htm", "contextRef": "c20210101to20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "brhc10030652_10q.htm", "contextRef": "c20210101to20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "061000 - Disclosure - Retirement Plan", "role": "http://pdsbiotech.com/role/RetirementPlan", "shortName": "Retirement Plan", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "brhc10030652_10q.htm", "contextRef": "c20210101to20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "brhc10030652_10q.htm", "contextRef": "c20210101to20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "061100 - Disclosure - Subsequent Events", "role": "http://pdsbiotech.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "brhc10030652_10q.htm", "contextRef": "c20210101to20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "div", "body", "html" ], "baseRef": "brhc10030652_10q.htm", "contextRef": "c20210101to20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "070200 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "div", "body", "html" ], "baseRef": "brhc10030652_10q.htm", "contextRef": "c20210101to20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "div", "div", "div", "div", "body", "html" ], "baseRef": "brhc10030652_10q.htm", "contextRef": "c20210101to20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "080200 - Disclosure - Summary of Significant Accounting Policies (Tables)", "role": "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesTables", "shortName": "Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "div", "div", "div", "div", "body", "html" ], "baseRef": "brhc10030652_10q.htm", "contextRef": "c20210101to20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "div", "div", "div", "div", "body", "html" ], "baseRef": "brhc10030652_10q.htm", "contextRef": "c20210930", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "U002", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "010000 - Statement - Condensed Consolidated Balance Sheets", "role": "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "table", "div", "div", "div", "div", "body", "html" ], "baseRef": "brhc10030652_10q.htm", "contextRef": "c20210930", "decimals": "0", "lang": null, "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent", "reportCount": 1, "unique": true, "unitRef": "U002", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "div", "body", "html" ], "baseRef": "brhc10030652_10q.htm", "contextRef": "c20210101to20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "080400 - Disclosure - Fair Value of Financial Instruments (Tables)", "role": "http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsTables", "shortName": "Fair Value of Financial Instruments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "div", "body", "html" ], "baseRef": "brhc10030652_10q.htm", "contextRef": "c20210101to20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "div", "body", "html" ], "baseRef": "brhc10030652_10q.htm", "contextRef": "c20210101to20210930", "decimals": null, "first": true, "lang": "en-US", "name": "pdsb:LesseeOperatingLeaseSupplementalCashFlowInformationRelatedToOperatingLeaseTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "080500 - Disclosure - Leases (Tables)", "role": "http://pdsbiotech.com/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "div", "body", "html" ], "baseRef": "brhc10030652_10q.htm", "contextRef": "c20210101to20210930", "decimals": null, "first": true, "lang": "en-US", "name": "pdsb:LesseeOperatingLeaseSupplementalCashFlowInformationRelatedToOperatingLeaseTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "div", "body", "html" ], "baseRef": "brhc10030652_10q.htm", "contextRef": "c20210101to20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "080600 - Disclosure - Accrued Expenses (Tables)", "role": "http://pdsbiotech.com/role/AccruedExpensesTables", "shortName": "Accrued Expenses (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "div", "body", "html" ], "baseRef": "brhc10030652_10q.htm", "contextRef": "c20210101to20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "brhc10030652_10q.htm", "contextRef": "c20210101to20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "080700 - Disclosure - Stock-Based Compensation (Tables)", "role": "http://pdsbiotech.com/role/StockbasedCompensationTables", "shortName": "Stock-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "brhc10030652_10q.htm", "contextRef": "c20210101to20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "div", "div", "div", "div", "body", "html" ], "baseRef": "brhc10030652_10q.htm", "contextRef": "c20210930", "decimals": "INF", "first": true, "lang": null, "name": "pdsb:NumberOfPlannedClinicalTrialsDelayed", "reportCount": 1, "unique": true, "unitRef": "U004", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "090100 - Disclosure - Nature of Operations (Details)", "role": "http://pdsbiotech.com/role/NatureOfOperationsDetails", "shortName": "Nature of Operations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "div", "div", "div", "div", "body", "html" ], "baseRef": "brhc10030652_10q.htm", "contextRef": "c20210930", "decimals": "INF", "first": true, "lang": null, "name": "pdsb:NumberOfPlannedClinicalTrialsDelayed", "reportCount": 1, "unique": true, "unitRef": "U004", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "ix:continuation", "ix:continuation", "ix:continuation", "div", "div", "div", "div", "body", "html" ], "baseRef": "brhc10030652_10q.htm", "contextRef": "c20210101to20210930", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "U001", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "090200 - Disclosure - Summary of Significant Accounting Policies (Details)", "role": "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesDetails", "shortName": "Summary of Significant Accounting Policies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "table", "ix:continuation", "ix:continuation", "ix:continuation", "div", "div", "div", "div", "body", "html" ], "baseRef": "brhc10030652_10q.htm", "contextRef": "c20210101to20210930", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "U001", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "div", "div", "div", "div", "body", "html" ], "baseRef": "brhc10030652_10q.htm", "contextRef": "c20210930", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "U002", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "090300 - Disclosure - Liquidity (Details)", "role": "http://pdsbiotech.com/role/LiquidityDetails", "shortName": "Liquidity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "div", "div", "div", "div", "body", "html" ], "baseRef": "brhc10030652_10q.htm", "contextRef": "c20190729", "decimals": "4", "lang": null, "name": "pdsb:CommonStockPurchaseAgreementSharesThatCanBeSoldPercentage", "reportCount": 1, "unique": true, "unitRef": "U005", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount", "us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount", "us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount", "div", "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "ix:continuation", "div", "div", "div", "div", "body", "html" ], "baseRef": "brhc10030652_10q.htm", "contextRef": "c20210930", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount", "reportCount": 1, "unique": true, "unitRef": "U002", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "090400 - Disclosure - Fair Value of Financial Instruments (Details)", "role": "http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsDetails", "shortName": "Fair Value of Financial Instruments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount", "us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount", "us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount", "div", "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "ix:continuation", "div", "div", "div", "div", "body", "html" ], "baseRef": "brhc10030652_10q.htm", "contextRef": "c20210930", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount", "reportCount": 1, "unique": true, "unitRef": "U002", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "div", "div", "div", "div", "body", "html" ], "baseRef": "brhc10030652_10q.htm", "contextRef": "c20190708", "decimals": "2", "first": true, "lang": null, "name": "pdsb:OperatingLeasePercentageOfRemainingPaymentsRequiredToBePaidToTerminateLease", "reportCount": 1, "unique": true, "unitRef": "U005", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "090500 - Disclosure - Leases, Operating Leases (Details)", "role": "http://pdsbiotech.com/role/LeasesOperatingLeasesDetails", "shortName": "Leases, Operating Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "div", "div", "div", "div", "body", "html" ], "baseRef": "brhc10030652_10q.htm", "contextRef": "c20190708", "decimals": "2", "first": true, "lang": null, "name": "pdsb:OperatingLeasePercentageOfRemainingPaymentsRequiredToBePaidToTerminateLease", "reportCount": 1, "unique": true, "unitRef": "U005", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "div", "div", "body", "html" ], "baseRef": "brhc10030652_10q.htm", "contextRef": "c20210101to20210930", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "U002", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "090502 - Disclosure - Leases, Supplemental Cash Flow Information Related to Operating Leases (Details)", "role": "http://pdsbiotech.com/role/LeasesSupplementalCashFlowInformationRelatedToOperatingLeasesDetails", "shortName": "Leases, Supplemental Cash Flow Information Related to Operating Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "div", "div", "body", "html" ], "baseRef": "brhc10030652_10q.htm", "contextRef": "c20210101to20210930", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "U002", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "us-gaap:CommonStockParOrStatedValuePerShare", "span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "body", "html" ], "baseRef": "brhc10030652_10q.htm", "contextRef": "c20210930", "decimals": "5", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "U003", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "010100 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "role": "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "us-gaap:CommonStockParOrStatedValuePerShare", "span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "body", "html" ], "baseRef": "brhc10030652_10q.htm", "contextRef": "c20210930", "decimals": "5", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "U003", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "div", "div", "body", "html" ], "baseRef": "brhc10030652_10q.htm", "contextRef": "c20210930", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "U002", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "090504 - Disclosure - Leases, Future Payments for Operating Lease Liabilities (Details)", "role": "http://pdsbiotech.com/role/LeasesFuturePaymentsForOperatingLeaseLiabilitiesDetails", "shortName": "Leases, Future Payments for Operating Lease Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "div", "div", "body", "html" ], "baseRef": "brhc10030652_10q.htm", "contextRef": "c20210930", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "U002", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "div", "div", "body", "html" ], "baseRef": "brhc10030652_10q.htm", "contextRef": "c20210930", "decimals": "0", "first": true, "lang": null, "name": "pdsb:AccruedResearchAndDevelopmentCostsCurrent", "reportCount": 1, "unique": true, "unitRef": "U002", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "090600 - Disclosure - Accrued Expenses (Details)", "role": "http://pdsbiotech.com/role/AccruedExpensesDetails", "shortName": "Accrued Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "div", "div", "body", "html" ], "baseRef": "brhc10030652_10q.htm", "contextRef": "c20210930", "decimals": "0", "first": true, "lang": null, "name": "pdsb:AccruedResearchAndDevelopmentCostsCurrent", "reportCount": 1, "unique": true, "unitRef": "U002", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "brhc10030652_10q.htm", "contextRef": "c20210930", "decimals": "INF", "first": true, "lang": null, "name": "pdsb:NumberOfEquityBasedCompensationPlans", "reportCount": 1, "unique": true, "unitRef": "U008", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "090700 - Disclosure - Stock-Based Compensation, Equity Compensation Plans (Details)", "role": "http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails", "shortName": "Stock-Based Compensation, Equity Compensation Plans (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "brhc10030652_10q.htm", "contextRef": "c20210930", "decimals": "INF", "first": true, "lang": null, "name": "pdsb:NumberOfEquityBasedCompensationPlans", "reportCount": 1, "unique": true, "unitRef": "U008", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "brhc10030652_10q.htm", "contextRef": "c20210701to20210930", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "U002", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "090702 - Disclosure - Stock-Based Compensation, Stock-Based Compensation Expense Related to Stock Options (Details)", "role": "http://pdsbiotech.com/role/StockbasedCompensationStockbasedCompensationExpenseRelatedToStockOptionsDetails", "shortName": "Stock-Based Compensation, Stock-Based Compensation Expense Related to Stock Options (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "brhc10030652_10q.htm", "contextRef": "c20210701to20210930", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "U002", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "brhc10030652_10q.htm", "contextRef": "c20210701to20210930", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unitRef": "U001", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "090704 - Disclosure - Stock-Based Compensation, Assumptions Used to Value Stock Options Granted (Details)", "role": "http://pdsbiotech.com/role/StockbasedCompensationAssumptionsUsedToValueStockOptionsGrantedDetails", "shortName": "Stock-Based Compensation, Assumptions Used to Value Stock Options Granted (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "brhc10030652_10q.htm", "contextRef": "c20210701to20210930", "decimals": "4", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "reportCount": 1, "unique": true, "unitRef": "U005", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "brhc10030652_10q.htm", "contextRef": "c20210701to20210930", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unitRef": "U001", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "090706 - Disclosure - Stock-Based Compensation, Stock Option Activity (Details)", "role": "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails", "shortName": "Stock-Based Compensation, Stock Option Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "div", "div", "body", "html" ], "baseRef": "brhc10030652_10q.htm", "contextRef": "c20210101to20210930_AwardTypeAxis_EmployeeStockOptionMember", "decimals": "0", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised", "reportCount": 1, "unique": true, "unitRef": "U001", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "div", "div", "div", "div", "body", "html" ], "baseRef": "brhc10030652_10q.htm", "contextRef": "c20210101to20210930", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CurrentIncomeTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "U002", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "090800 - Disclosure - Income Taxes (Details)", "role": "http://pdsbiotech.com/role/IncomeTaxesDetails", "shortName": "Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "div", "div", "div", "div", "body", "html" ], "baseRef": "brhc10030652_10q.htm", "contextRef": "c20210101to20210930", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CurrentIncomeTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "U002", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "div", "div", "div", "div", "body", "html" ], "baseRef": "brhc10030652_10q.htm", "contextRef": "c20210701to20210930", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "U002", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "090900 - Disclosure - Commitments and Contingencies (Details)", "role": "http://pdsbiotech.com/role/CommitmentsAndContingenciesDetails", "shortName": "Commitments and Contingencies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "div", "div", "div", "div", "body", "html" ], "baseRef": "brhc10030652_10q.htm", "contextRef": "c20210701to20210930", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "U002", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "brhc10030652_10q.htm", "contextRef": "c20210701to20210930", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount", "reportCount": 1, "unique": true, "unitRef": "U002", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "091000 - Disclosure - Retirement Plan (Details)", "role": "http://pdsbiotech.com/role/RetirementPlanDetails", "shortName": "Retirement Plan (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "brhc10030652_10q.htm", "contextRef": "c20210701to20210930", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount", "reportCount": 1, "unique": true, "unitRef": "U002", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "brhc10030652_10q.htm", "contextRef": "c20210701to20210930", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unitRef": "U001", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "091100 - Disclosure - Subsequent Events (Details)", "role": "http://pdsbiotech.com/role/SubsequentEventsDetails", "shortName": "Subsequent Events (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "div", "div", "div", "div", "body", "html" ], "baseRef": "brhc10030652_10q.htm", "contextRef": "c20211018to20211018_GranteeStatusAxis_ChiefFinancialOfficerMember_SubsequentEventTypeAxis_SubsequentEventMember", "decimals": "0", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unique": true, "unitRef": "U001", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "brhc10030652_10q.htm", "contextRef": "c20210701to20210930", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "U002", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "020000 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss", "role": "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss", "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "brhc10030652_10q.htm", "contextRef": "c20210701to20210930", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "U002", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "brhc10030652_10q.htm", "contextRef": "c20191231_StatementEquityComponentsAxis_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "U002", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "030000 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity", "role": "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity", "shortName": "Condensed Consolidated Statements of Changes in Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "brhc10030652_10q.htm", "contextRef": "c20191231_StatementEquityComponentsAxis_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "U002", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "us-gaap:ComprehensiveIncomeNetOfTax", "div", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "brhc10030652_10q.htm", "contextRef": "c20210101to20210930", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "U002", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "040000 - Statement - Condensed Consolidated Statements of Cash Flows", "role": "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows", "shortName": "Condensed Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "table", "div", "div", "div", "div", "body", "html" ], "baseRef": "brhc10030652_10q.htm", "contextRef": "c20210101to20210930", "decimals": "0", "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "U002", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "brhc10030652_10q.htm", "contextRef": "c20210101to20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "060100 - Disclosure - Nature of Operations", "role": "http://pdsbiotech.com/role/NatureOfOperations", "shortName": "Nature of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "brhc10030652_10q.htm", "contextRef": "c20210101to20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "brhc10030652_10q.htm", "contextRef": "c20210101to20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "060200 - Disclosure - Summary of Significant Accounting Policies", "role": "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "brhc10030652_10q.htm", "contextRef": "c20210101to20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "brhc10030652_10q.htm", "contextRef": "c20210101to20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "060300 - Disclosure - Liquidity", "role": "http://pdsbiotech.com/role/Liquidity", "shortName": "Liquidity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "brhc10030652_10q.htm", "contextRef": "c20210101to20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 25, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r305" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r306" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r307" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r307" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r307" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r308" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r307" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r307" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r307" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r307" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r303" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r304" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "pdsb_AccruedResearchAndDevelopmentCostsCurrent": { "auth_ref": [], "calculation": { "http://pdsbiotech.com/role/AccruedExpensesDetails": { "order": 0.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Research and Development Costs, Current", "terseLabel": "Accrued research and development costs" } } }, "localname": "AccruedResearchAndDevelopmentCostsCurrent", "nsuri": "http://pdsbiotech.com/20210930", "presentation": [ "http://pdsbiotech.com/role/AccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "pdsb_CommonStockPurchaseAgreementCumulativeSharesSold": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cumulative number of shares purchased under a common stock purchase agreement.", "label": "Common Stock Purchase Agreement, Cumulative shares sold", "terseLabel": "Shares sold under common stock purchase agreement (in shares)" } } }, "localname": "CommonStockPurchaseAgreementCumulativeSharesSold", "nsuri": "http://pdsbiotech.com/20210930", "presentation": [ "http://pdsbiotech.com/role/LiquidityDetails" ], "xbrltype": "sharesItemType" }, "pdsb_CommonStockPurchaseAgreementSharesThatCanBeSoldPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of the company's outstanding shares that can be sold under a common stock purchase agreement without stockholder approval.", "label": "Common Stock Purchase Agreement, Shares that can be sold, Percentage", "terseLabel": "Percentage of shares of common stock that can be sold without shareholder approval" } } }, "localname": "CommonStockPurchaseAgreementSharesThatCanBeSoldPercentage", "nsuri": "http://pdsbiotech.com/20210930", "presentation": [ "http://pdsbiotech.com/role/LiquidityDetails" ], "xbrltype": "percentItemType" }, "pdsb_CommonStockPurchaseAgreementSharesThatCanBeSoldShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Aggregate number of shares of company's outstanding shares that can be sold under a common stock purchase agreement without shareholder approval.", "label": "Common Stock Purchase Agreement, Shares that can be sold, Shares", "verboseLabel": "Shares of common stock that can be sold without shareholder approval (in shares)" } } }, "localname": "CommonStockPurchaseAgreementSharesThatCanBeSoldShares", "nsuri": "http://pdsbiotech.com/20210930", "presentation": [ "http://pdsbiotech.com/role/LiquidityDetails" ], "xbrltype": "sharesItemType" }, "pdsb_CommonStockPurchaseAgreementSharesToBePurchasedShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares to be purchased under a common stock purchase agreement.", "label": "Common Stock Purchase Agreement, Shares to be purchased, Shares", "terseLabel": "Shares of common stock to be purchased (in shares)" } } }, "localname": "CommonStockPurchaseAgreementSharesToBePurchasedShares", "nsuri": "http://pdsbiotech.com/20210930", "presentation": [ "http://pdsbiotech.com/role/LiquidityDetails" ], "xbrltype": "sharesItemType" }, "pdsb_CommonStockPurchaseAgreementSharesToBePurchasedValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Aggregate amount of shares to be purchased under a common stock purchase agreement.", "label": "Common Stock Purchase Agreement, Shares to be purchased, Value", "terseLabel": "Common stock to be purchased under common stock purchase agreement" } } }, "localname": "CommonStockPurchaseAgreementSharesToBePurchasedValue", "nsuri": "http://pdsbiotech.com/20210930", "presentation": [ "http://pdsbiotech.com/role/LiquidityDetails" ], "xbrltype": "monetaryItemType" }, "pdsb_EquityCompensationPlansMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the 2010 Equity Incentive Plan, the 2012 Equity Incentive Plan, and the 2014 Equity Incentive Plan (the Plans).", "label": "Equity Compensation Plans [Member]", "terseLabel": "The Plans [Member]" } } }, "localname": "EquityCompensationPlansMember", "nsuri": "http://pdsbiotech.com/20210930", "presentation": [ "http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails" ], "xbrltype": "domainItemType" }, "pdsb_EquityIncentivePlan2014Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the 2014 Equity Incentive Plan.", "label": "Equity Incentive Plan 2014 [Member]", "terseLabel": "2014 Equity Incentive Plan [Member]" } } }, "localname": "EquityIncentivePlan2014Member", "nsuri": "http://pdsbiotech.com/20210930", "presentation": [ "http://pdsbiotech.com/role/CommitmentsAndContingenciesDetails", "http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails" ], "xbrltype": "domainItemType" }, "pdsb_EquityIncentivePlan2018Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the 2018 Equity Incentive Plan.", "label": "Equity Incentive Plan 2018 [Member]", "terseLabel": "2018 Equity Incentive Plan [Member]" } } }, "localname": "EquityIncentivePlan2018Member", "nsuri": "http://pdsbiotech.com/20210930", "presentation": [ "http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails" ], "xbrltype": "domainItemType" }, "pdsb_IncentiveStockOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Incentive stock options (ISOs) under the equity compensation plans that may be granted only to employees.", "label": "Incentive Stock Options [Member]", "terseLabel": "Incentive Stock Options [Member]" } } }, "localname": "IncentiveStockOptionsMember", "nsuri": "http://pdsbiotech.com/20210930", "presentation": [ "http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails" ], "xbrltype": "domainItemType" }, "pdsb_InducementPlan2019Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The 2019 Inducement Plan provides for the grant of non-qualified stock options.", "label": "Inducement Plan 2019 [Member]", "terseLabel": "2019 Inducement Plan [Member]" } } }, "localname": "InducementPlan2019Member", "nsuri": "http://pdsbiotech.com/20210930", "presentation": [ "http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails" ], "xbrltype": "domainItemType" }, "pdsb_LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter": { "auth_ref": [], "calculation": { "http://pdsbiotech.com/role/LeasesFuturePaymentsForOperatingLeaseLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year and thereafter following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four and Thereafter", "terseLabel": "2025 and after" } } }, "localname": "LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter", "nsuri": "http://pdsbiotech.com/20210930", "presentation": [ "http://pdsbiotech.com/role/LeasesFuturePaymentsForOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "pdsb_LesseeOperatingLeaseSupplementalCashFlowInformationRelatedToOperatingLeaseTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of supplemental cash flow information related to lessee's operating leases and right-of-use assets and lease liabilities.", "label": "Lessee, Operating Lease, Supplemental Cash Flow Information Related to Operating Lease [Table Text Block]", "terseLabel": "Supplemental Cash Flow Information Related to Operating Leases" } } }, "localname": "LesseeOperatingLeaseSupplementalCashFlowInformationRelatedToOperatingLeaseTableTextBlock", "nsuri": "http://pdsbiotech.com/20210930", "presentation": [ "http://pdsbiotech.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "pdsb_LiabilityForUncertainTaxPositions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total current and noncurrent amount recognized for uncertain tax positions as of the balance sheet date.", "label": "Liability for Uncertain Tax Positions", "terseLabel": "Uncertain tax positions" } } }, "localname": "LiabilityForUncertainTaxPositions", "nsuri": "http://pdsbiotech.com/20210930", "presentation": [ "http://pdsbiotech.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "pdsb_LiquidityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liquidity [Abstract]" } } }, "localname": "LiquidityAbstract", "nsuri": "http://pdsbiotech.com/20210930", "xbrltype": "stringItemType" }, "pdsb_NonqualifiedStockOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Non-qualified stock options (NQs) under the equity compensation plans that may be granted to service providers.", "label": "Nonqualified Stock Options [Member]", "terseLabel": "Nonqualified Options [Member]" } } }, "localname": "NonqualifiedStockOptionsMember", "nsuri": "http://pdsbiotech.com/20210930", "presentation": [ "http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails" ], "xbrltype": "domainItemType" }, "pdsb_NumberOfEquityBasedCompensationPlans": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of equity-based compensation plans.", "label": "Number of Equity-Based Compensation Plans", "terseLabel": "Number of equity compensation plans" } } }, "localname": "NumberOfEquityBasedCompensationPlans", "nsuri": "http://pdsbiotech.com/20210930", "presentation": [ "http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails" ], "xbrltype": "integerItemType" }, "pdsb_NumberOfPlannedClinicalTrials": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of planned clinical trials.", "label": "Number of planned clinical trials" } } }, "localname": "NumberOfPlannedClinicalTrials", "nsuri": "http://pdsbiotech.com/20210930", "presentation": [ "http://pdsbiotech.com/role/NatureOfOperationsDetails" ], "xbrltype": "integerItemType" }, "pdsb_NumberOfPlannedClinicalTrialsDelayed": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of planned clinical trials that have been delayed, specifically as a result of the adverse impact the COVID-19 Pandemic has had on clinical trial operations for cancer indications in the United States.", "label": "Number of planned clinical trials delayed", "terseLabel": "Number of planned clinical trials delayed" } } }, "localname": "NumberOfPlannedClinicalTrialsDelayed", "nsuri": "http://pdsbiotech.com/20210930", "presentation": [ "http://pdsbiotech.com/role/NatureOfOperationsDetails" ], "xbrltype": "integerItemType" }, "pdsb_OperatingLeaseNumberOfInstallmentsForRemainingLeasePayment": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of installments in which the remaining lease payments need to be made in order to terminate the operating lease agreement.", "label": "Operating Lease, Number of Installments for Remaining Lease Payment", "terseLabel": "Number of installments for remaining lease payment" } } }, "localname": "OperatingLeaseNumberOfInstallmentsForRemainingLeasePayment", "nsuri": "http://pdsbiotech.com/20210930", "presentation": [ "http://pdsbiotech.com/role/LeasesOperatingLeasesDetails" ], "xbrltype": "integerItemType" }, "pdsb_OperatingLeasePercentageOfRemainingPaymentsRequiredToBePaidToTerminateLease": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The percentage of remaining payments that required to be paid in order to terminate an operating lease agreement.", "label": "Operating Lease, Percentage of remaining payments required to be paid to terminate lease", "terseLabel": "Percentage of remaining payments required to be paid to terminate lease" } } }, "localname": "OperatingLeasePercentageOfRemainingPaymentsRequiredToBePaidToTerminateLease", "nsuri": "http://pdsbiotech.com/20210930", "presentation": [ "http://pdsbiotech.com/role/LeasesOperatingLeasesDetails" ], "xbrltype": "percentItemType" }, "pdsb_OperatingLeaseRemainingLeasePayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of remaining lease payments under the operating lease agreement.", "label": "Operating Lease, Remaining lease payments", "terseLabel": "Remaining lease payments" } } }, "localname": "OperatingLeaseRemainingLeasePayments", "nsuri": "http://pdsbiotech.com/20210930", "presentation": [ "http://pdsbiotech.com/role/LeasesOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "pdsb_PercentageOfCommonStockOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Refers to the percentage of stock outstanding as of the immediately preceding December 31st used to determine the annual increase in the Plan limit for authorized shares that may be granted as qualified and nonqualified options.", "label": "Percentage of Common Stock outstanding", "terseLabel": "Percentage of Common Stock outstanding used to determine annual increase in the plan limit" } } }, "localname": "PercentageOfCommonStockOutstanding", "nsuri": "http://pdsbiotech.com/20210930", "presentation": [ "http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails" ], "xbrltype": "percentItemType" }, "pdsb_ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow received from the sale of unused NOL carryforwards pursuant to the State of New Jersey's Technology Business Tax Certificate Program, which allowed certain high technology and biotechnology companies to sell unused NOL carryforwards to other New Jersey-based corporate taxpayers.", "label": "Proceeds from Sale of Unused Net Operating Loss Carryforwards", "terseLabel": "Proceeds from sale of tax benefits" } } }, "localname": "ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards", "nsuri": "http://pdsbiotech.com/20210930", "presentation": [ "http://pdsbiotech.com/role/LiquidityDetails" ], "xbrltype": "monetaryItemType" }, "pdsb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodIntrinsicValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options forfeited (or share units converted) into shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeited in Period, Intrinsic Value", "terseLabel": "Forfeited, aggregate intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodIntrinsicValue", "nsuri": "http://pdsbiotech.com/20210930", "presentation": [ "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "pdsb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of options granted. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Granted in Period, Fair Value", "terseLabel": "Aggregate fair value of options granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodFairValue", "nsuri": "http://pdsbiotech.com/20210930", "presentation": [ "http://pdsbiotech.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "pdsb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodIntrinsicValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options granted (or share units converted) into shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Granted in Period, Intrinsic Value", "terseLabel": "Granted, aggregate intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodIntrinsicValue", "nsuri": "http://pdsbiotech.com/20210930", "presentation": [ "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "pdsb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards granted, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Granted, Weighted Average Remaining Contractual Term", "terseLabel": "Granted, weighted average remaining contractual life" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm", "nsuri": "http://pdsbiotech.com/20210930", "presentation": [ "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "pdsb_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfPlan": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Term the Plan shall continue to remain effective, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Term of Plan", "terseLabel": "Term of plan" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfPlan", "nsuri": "http://pdsbiotech.com/20210930", "presentation": [ "http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails" ], "xbrltype": "durationItemType" }, "pdsb_ShelfRegistrationStatementAvailableForFutureSale": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of securities included in a shelf registration statement filed with the Securities and Exchange Commission (the \"2020 Shelf Registration Statement\") for the issuance of common stock, preferred stock, warrants, rights, debt securities and units (collectively, the \"Shelf Securities\") that are available for future sale.", "label": "Shelf Registration Statement, Available for future sale", "terseLabel": "Registered securities in Shelf Registration Statement available for future sale" } } }, "localname": "ShelfRegistrationStatementAvailableForFutureSale", "nsuri": "http://pdsbiotech.com/20210930", "presentation": [ "http://pdsbiotech.com/role/LiquidityDetails" ], "xbrltype": "monetaryItemType" }, "pdsb_ShelfSecuritiesAvailableForSale": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Securities that remain available for future sale under a shelf registration statement, or 2020 Shelf Registration Statement, filed with the SEC in July 2020, for the issuance of common stock, preferred stock, warrants, rights, debt securities and units, collectively the \"Shelf Securities.\"", "label": "Shelf securities available for sale", "terseLabel": "Shelf securities available for sale" } } }, "localname": "ShelfSecuritiesAvailableForSale", "nsuri": "http://pdsbiotech.com/20210930", "presentation": [ "http://pdsbiotech.com/role/LiquidityDetails" ], "xbrltype": "monetaryItemType" }, "pdsb_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for significant risks and uncertainties.", "label": "Significant Risks and Uncertainties, Policy [Policy Text Block]", "terseLabel": "Significant Risks and Uncertainties" } } }, "localname": "SignificantRisksAndUncertaintiesPolicyPolicyTextBlock", "nsuri": "http://pdsbiotech.com/20210930", "presentation": [ "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "pdsb_StockIssuedDuringPeriodSharesEquityTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as consideration for equity transaction.", "label": "Stock Issued During Period, Shares, Equity Transaction", "terseLabel": "Issuance of common stock from equity transaction (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesEquityTransaction", "nsuri": "http://pdsbiotech.com/20210930", "presentation": [ "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity", "http://pdsbiotech.com/role/LiquidityDetails" ], "xbrltype": "sharesItemType" }, "pdsb_StockIssuedDuringPeriodSharesWarrantsExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued from exercise of warrants during the current period.", "label": "Stock Issued During Period, Shares, Warrants Exercised", "terseLabel": "Issuance of warrant exercise (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesWarrantsExercised", "nsuri": "http://pdsbiotech.com/20210930", "presentation": [ "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "pdsb_StockIssuedDuringPeriodValueEquityTransaction": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period as consideration for equity transaction.", "label": "Stock Issued During Period, Value, Equity Transaction", "terseLabel": "Issuance of common stock from equity transaction" } } }, "localname": "StockIssuedDuringPeriodValueEquityTransaction", "nsuri": "http://pdsbiotech.com/20210930", "presentation": [ "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "pdsb_StockIssuedDuringPeriodValueWarrantsExercised": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of warrants.", "label": "Stock Issued During Period, Value, Warrants Exercised", "terseLabel": "Issuance of warrant exercise" } } }, "localname": "StockIssuedDuringPeriodValueWarrantsExercised", "nsuri": "http://pdsbiotech.com/20210930", "presentation": [ "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "srt_ChiefFinancialOfficerMember": { "auth_ref": [ "r102" ], "lang": { "en-us": { "role": { "label": "Chief Financial Officer [Member]" } } }, "localname": "ChiefFinancialOfficerMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r125", "r129", "r151", "r152", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r292", "r293", "r300", "r301" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/LiquidityDetails", "http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r125", "r129", "r151", "r152", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r292", "r293", "r300", "r301" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/LiquidityDetails", "http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r125", "r129", "r132", "r151", "r152", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r292", "r293", "r300", "r301" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/LiquidityDetails", "http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r125", "r129", "r132", "r151", "r152", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r292", "r293", "r300", "r301" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/LiquidityDetails", "http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "terseLabel": "Accrued Expenses" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/AccruedExpenses" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r21", "r258" ], "calculation": { "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r24" ], "calculation": { "http://pdsbiotech.com/role/AccruedExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expenses", "totalLabel": "Total" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/AccruedExpensesDetails", "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r6", "r7", "r24" ], "calculation": { "http://pdsbiotech.com/role/AccruedExpensesDetails": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued professional fees" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/AccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r13", "r190", "r258" ], "calculation": { "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r58", "r59", "r60", "r187", "r188", "r189", "r225" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r155", "r158", "r193", "r194" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r158", "r183", "r192" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/StockbasedCompensationStockbasedCompensationExpenseRelatedToStockOptionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r78" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "verboseLabel": "Antidilutive impact to EPS (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r78" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r78" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AreaOfRealEstateProperty": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area of a real estate property.", "label": "Area of Real Estate Property", "terseLabel": "Area of office space under sub-lease" } } }, "localname": "AreaOfRealEstateProperty", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/LeasesOperatingLeasesDetails" ], "xbrltype": "areaItemType" }, "us-gaap_Assets": { "auth_ref": [ "r53", "r94", "r96", "r100", "r104", "r114", "r115", "r116", "r117", "r118", "r119", "r120", "r121", "r122", "r123", "r124", "r221", "r223", "r235", "r256", "r258", "r275", "r283" ], "calculation": { "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r4", "r5", "r28", "r53", "r104", "r114", "r115", "r116", "r117", "r118", "r119", "r120", "r121", "r122", "r123", "r124", "r221", "r223", "r235", "r256", "r258" ], "calculation": { "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r159", "r185" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/CommitmentsAndContingenciesDetails", "http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails", "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails", "http://pdsbiotech.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Unaudited Interim Financial Statements" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r57" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.", "label": "Summary of Significant Accounting Policies" } } }, "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/LiquidityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationConsiderationTransferredAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination, Consideration Transferred [Abstract]", "verboseLabel": "Liquidity [Abstract]" } } }, "localname": "BusinessCombinationConsiderationTransferredAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/LiquidityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r3", "r20", "r50" ], "calculation": { "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets", "http://pdsbiotech.com/role/LiquidityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r8", "r51" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash Equivalents and Concentration of Cash Balance" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r45", "r50", "r52" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents at end of period", "periodStartLabel": "Cash and cash equivalents at beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "auth_ref": [ "r45", "r236" ], "calculation": { "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "totalLabel": "Net increase in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowOperatingActivitiesLesseeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information Related to Operating Leases [Abstract]" } } }, "localname": "CashFlowOperatingActivitiesLesseeAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/LeasesSupplementalCashFlowInformationRelatedToOperatingLeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r110", "r111", "r112", "r113", "r299" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r26" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common stock reserved for issuance (in shares)" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r58", "r59", "r225" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r12", "r130" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r12", "r258" ], "calculation": { "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock, $0.00033 par value, 75,000,000 shares authorized at September 30, 2021 and December 31, 2020, 28,435,067 shares and 22,261,619 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Retirement Plan [Abstract]" } } }, "localname": "CompensationAndRetirementDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r30", "r32", "r33", "r39", "r279", "r288" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "auth_ref": [ "r54", "r206", "r211", "r212" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.", "label": "Current income tax expense" } } }, "localname": "CurrentIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.", "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount", "terseLabel": "401(k) employer contributions" } } }, "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/RetirementPlanDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r48", "r106" ], "calculation": { "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r195" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/StockbasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock-Based Compensation [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r40", "r63", "r64", "r65", "r66", "r67", "r71", "r73", "r75", "r76", "r77", "r80", "r81", "r226", "r227", "r280", "r289" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Net loss per share, basic (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAndDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Per share information:" } } }, "localname": "EarningsPerShareBasicAndDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]", "verboseLabel": "Net Loss per Common Share [Abstract]" } } }, "localname": "EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r40", "r63", "r64", "r65", "r66", "r67", "r73", "r75", "r76", "r77", "r80", "r81", "r226", "r227", "r280", "r289" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Net loss per share, diluted (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r78", "r79" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "verboseLabel": "Net Loss per Common Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r200" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r55", "r200", "r213" ], "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Federal statutory rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement, Additional Disclosure [Abstract]", "terseLabel": "Stock Options [Abstract]", "verboseLabel": "Legal Proceedings [Abstract]" } } }, "localname": "EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/CommitmentsAndContingenciesDetails", "http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/StockbasedCompensationStockbasedCompensationExpenseRelatedToStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Unamortized Stock Compensation Expense [Abstract]" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r184" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Period for recognition" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r184" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "terseLabel": "Unamortized stock compensation expense" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r181" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]", "terseLabel": "Stock Options [Member]", "verboseLabel": "Stock Options to Purchase Common Stock [Member]" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/CommitmentsAndContingenciesDetails", "http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails", "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails", "http://pdsbiotech.com/role/SubsequentEventsDetails", "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r34", "r35", "r36", "r58", "r59", "r60", "r62", "r68", "r70", "r82", "r105", "r130", "r131", "r187", "r188", "r189", "r207", "r208", "r225", "r237", "r238", "r239", "r240", "r241", "r242", "r294", "r295", "r296", "r309" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r228", "r229", "r230", "r233" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value Measurements, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount": { "auth_ref": [ "r230" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.", "label": "Fair Value, Assets, Level 1 to Level 2 Transfers, Amount", "terseLabel": "Transfers from Level 1 to Level 2" } } }, "localname": "FairValueAssetsLevel1ToLevel2TransfersAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount": { "auth_ref": [ "r230" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transfers of assets measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.", "label": "Fair Value, Assets, Level 2 to Level 1 Transfers, Amount", "terseLabel": "Transfers from Level 2 to Level 1" } } }, "localname": "FairValueAssetsLevel2ToLevel1TransfersAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTextBlock": { "auth_ref": [ "r228", "r234" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueByBalanceSheetGroupingTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r126", "r127", "r128", "r133", "r135", "r136", "r137", "r138", "r139", "r140", "r147", "r229", "r262", "r263", "r264" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value of Financial Instruments [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r232" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value of Financial Instruments" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/FairValueOfFinancialInstruments" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r126", "r133", "r135", "r140", "r147", "r229", "r262" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Quoted Prices in Active Markets (Level 1) [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r126", "r127", "r128", "r133", "r135", "r140", "r147", "r229", "r263" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Quoted Prices in Inactive Markets (Level 2) [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r126", "r127", "r128", "r133", "r135", "r136", "r137", "r138", "r139", "r140", "r147", "r229", "r264" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Significant Unobservable Inputs (Level 3) [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3": { "auth_ref": [ "r231" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transfer of financial instrument classified as an asset into level 3 of the fair value hierarchy.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3", "terseLabel": "Transfers into Level 3" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3": { "auth_ref": [ "r231" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transfers of financial instrument classified as an asset out of level 3 of the fair value hierarchy.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3", "terseLabel": "Transfers out of Level 3" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r126", "r127", "r128", "r133", "r135", "r136", "r137", "r138", "r139", "r140", "r147", "r262", "r263", "r264" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueNetAssetLiabilityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value, Net Asset (Liability) [Abstract]", "terseLabel": "Fair Value of Financial Instruments [Abstract]" } } }, "localname": "FairValueNetAssetLiabilityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueTransfersBetweenLevel1AndLevel2DescriptionAndPolicyAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Transfers Between Levels [Abstract]" } } }, "localname": "FairValueTransfersBetweenLevel1AndLevel2DescriptionAndPolicyAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r42" ], "calculation": { "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative expenses" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r41" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative [Member]" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/StockbasedCompensationStockbasedCompensationExpenseRelatedToStockOptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GranteeStatusAxis": { "auth_ref": [ "r154", "r156", "r181" ], "lang": { "en-us": { "role": { "documentation": "Information by status of recipient to whom award is granted.", "label": "Grantee Status [Axis]" } } }, "localname": "GranteeStatusAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/CommitmentsAndContingenciesDetails", "http://pdsbiotech.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GranteeStatusDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Status of recipient to whom award is granted.", "label": "Grantee Status [Domain]" } } }, "localname": "GranteeStatusDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/CommitmentsAndContingenciesDetails", "http://pdsbiotech.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r37", "r94", "r95", "r98", "r99", "r101", "r274", "r277", "r281", "r290" ], "calculation": { "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 0.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Loss before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Condensed Consolidated Statements of Operations and Comprehensive Loss [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r108", "r109" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/StockbasedCompensationStockbasedCompensationExpenseRelatedToStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r109" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/StockbasedCompensationStockbasedCompensationExpenseRelatedToStockOptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Taxes [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r55", "r201", "r204", "r205", "r209", "r214", "r216", "r217", "r218" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued": { "auth_ref": [ "r202" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.", "label": "Accrued interest and penalties" } } }, "localname": "IncomeTaxExaminationPenaltiesAndInterestAccrued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r56", "r69", "r70", "r93", "r199", "r210", "r215", "r291" ], "calculation": { "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedLabel": "Benefit from income taxes", "terseLabel": "Benefit from income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss", "http://pdsbiotech.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r47" ], "calculation": { "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 19.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r47" ], "calculation": { "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 21.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Accrued expenses" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "auth_ref": [ "r47", "r250" ], "calculation": { "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 23.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation for operating lease.", "label": "Operating lease liabilities" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r47" ], "calculation": { "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInRestructuringReserve": { "auth_ref": [ "r47" ], "calculation": { "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 22.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the period in the carrying amount (including both current and noncurrent portions of the accrual) of the liability pertaining to the exit from or disposal of business activities or restructuring pursuant to a duly authorized plan, excluding costs or losses pertaining to an entity newly acquired in a business combination and to asset retirement obligations.", "label": "Increase (Decrease) in Restructuring Reserve", "terseLabel": "Restructuring reserve" } } }, "localname": "IncreaseDecreaseInRestructuringReserve", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r43", "r92" ], "calculation": { "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 0.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Investment Income, Interest", "terseLabel": "Interest income" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": { "auth_ref": [ "r48" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.", "label": "Issuance of common stock from equity transaction" } } }, "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/LiquidityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseDescriptionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Description [Abstract]", "terseLabel": "Leases [Abstract]" } } }, "localname": "LesseeOperatingLeaseDescriptionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/LeasesOperatingLeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseDiscountRate": { "auth_ref": [ "r248" ], "lang": { "en-us": { "role": { "documentation": "Discount rate used by lessee to determine present value of operating lease payments.", "label": "Lessee, Operating Lease, Discount Rate", "terseLabel": "Discount rate used to measure operating lease liability" } } }, "localname": "LesseeOperatingLeaseDiscountRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/LeasesOperatingLeasesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r252" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Future Payments for Operating Lease Liabilities" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r252" ], "calculation": { "http://pdsbiotech.com/role/LeasesFuturePaymentsForOperatingLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://pdsbiotech.com/role/LeasesFuturePaymentsForOperatingLeaseLiabilitiesDetailsCalc01": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total future minimum lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/LeasesFuturePaymentsForOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r252" ], "calculation": { "http://pdsbiotech.com/role/LeasesFuturePaymentsForOperatingLeaseLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/LeasesFuturePaymentsForOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r252" ], "calculation": { "http://pdsbiotech.com/role/LeasesFuturePaymentsForOperatingLeaseLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/LeasesFuturePaymentsForOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r252" ], "calculation": { "http://pdsbiotech.com/role/LeasesFuturePaymentsForOperatingLeaseLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/LeasesFuturePaymentsForOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r252" ], "calculation": { "http://pdsbiotech.com/role/LeasesFuturePaymentsForOperatingLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.", "label": "2021 (remaining three months)" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/LeasesFuturePaymentsForOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r252" ], "calculation": { "http://pdsbiotech.com/role/LeasesFuturePaymentsForOperatingLeaseLiabilitiesDetailsCalc01": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/LeasesFuturePaymentsForOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": { "auth_ref": [ "r247" ], "lang": { "en-us": { "role": { "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Remaining lease term" } } }, "localname": "LesseeOperatingLeaseRemainingLeaseTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/LeasesOperatingLeasesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r254" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Leases" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_LessorOperatingLeaseTermOfContract": { "auth_ref": [ "r255" ], "lang": { "en-us": { "role": { "documentation": "Term of lessor's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessor, Operating Lease, Term of Contract", "terseLabel": "Term of sub-lease agreement" } } }, "localname": "LessorOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/LeasesOperatingLeasesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r23", "r53", "r97", "r104", "r114", "r115", "r116", "r118", "r119", "r120", "r121", "r122", "r123", "r124", "r222", "r223", "r224", "r235", "r256", "r257" ], "calculation": { "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total Liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities [Abstract]", "terseLabel": "LIABILITIES" } } }, "localname": "LiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r17", "r53", "r104", "r235", "r258", "r276", "r285" ], "calculation": { "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r25", "r53", "r104", "r114", "r115", "r116", "r118", "r119", "r120", "r121", "r122", "r123", "r124", "r222", "r223", "r224", "r235", "r256", "r257", "r258" ], "calculation": { "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Noncurrent [Abstract]", "terseLabel": "Noncurrent liability:" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r83", "r91" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "Nature of Operations" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/NatureOfOperations" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r45" ], "calculation": { "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r45", "r46", "r49" ], "calculation": { "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r1", "r29", "r31", "r36", "r38", "r49", "r53", "r61", "r63", "r64", "r65", "r66", "r69", "r70", "r74", "r94", "r95", "r98", "r99", "r101", "r104", "r114", "r115", "r116", "r118", "r119", "r120", "r121", "r122", "r123", "r124", "r227", "r235", "r278", "r287" ], "calculation": { "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity", "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 0.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r94", "r95", "r98", "r99", "r101" ], "calculation": { "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r249", "r253" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Rent expense" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]", "terseLabel": "Future Payments for Operating Lease Liabilities [Abstract]" } } }, "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/LeasesFuturePaymentsForOperatingLeaseLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r245" ], "calculation": { "http://pdsbiotech.com/role/LeasesFuturePaymentsForOperatingLeaseLiabilitiesDetailsCalc01": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Lease liability", "verboseLabel": "Operating lease liability" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/LeasesFuturePaymentsForOperatingLeaseLiabilitiesDetails", "http://pdsbiotech.com/role/LeasesOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r245" ], "calculation": { "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Operating lease obligation-short term" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r245" ], "calculation": { "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease obligation-long term" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r246", "r250" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Cash paid for operating lease liabilities" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/LeasesSupplementalCashFlowInformationRelatedToOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r244" ], "calculation": { "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating lease right-to-use asset", "terseLabel": "Right-of-use asset" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets", "http://pdsbiotech.com/role/LeasesOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "auth_ref": [ "r48" ], "calculation": { "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for right-of-use asset from operating lease.", "label": "Operating lease expense" } } }, "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nature of Operations [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherIncomeAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Income and Expenses [Abstract]", "terseLabel": "Other income:" } } }, "localname": "OtherIncomeAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OverAllotmentOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.", "label": "Over-Allotment Option [Member]" } } }, "localname": "OverAllotmentOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/LiquidityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accrued Expenses [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "auth_ref": [ "r132", "r134", "r140", "r141", "r142", "r143", "r144", "r145", "r146", "r147", "r148", "r149", "r150", "r153" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for retirement benefits.", "label": "Retirement Plan" } } }, "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/RetirementPlan" ], "xbrltype": "textBlockItemType" }, "us-gaap_PensionExpenseReversalOfExpenseNoncash": { "auth_ref": [ "r48" ], "calculation": { "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense (reversal of expense) for pension benefits. Excludes other postretirement benefits.", "label": "Stock-based 401K company common match" } } }, "localname": "PensionExpenseReversalOfExpenseNoncash", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r159", "r185" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/CommitmentsAndContingenciesDetails", "http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/CommitmentsAndContingenciesDetails", "http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r4", "r18", "r19" ], "calculation": { "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r44" ], "calculation": { "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from issuances of common stock, net of issuance costs", "terseLabel": "Proceeds from issuance of shares" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://pdsbiotech.com/role/LiquidityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r44", "r186" ], "calculation": { "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from exercise of stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromWarrantExercises": { "auth_ref": [ "r44" ], "calculation": { "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.", "label": "Proceeds from exercise of warrants" } } }, "localname": "ProceedsFromWarrantExercises", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r9", "r10", "r107", "r258", "r282", "r286" ], "calculation": { "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r197", "r272", "r302" ], "calculation": { "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 0.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development expenses" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development [Member]" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/StockbasedCompensationStockbasedCompensationExpenseRelatedToStockOptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r197" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and Development" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r14", "r131", "r190", "r258", "r284", "r297", "r298" ], "calculation": { "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r58", "r59", "r60", "r62", "r68", "r70", "r105", "r187", "r188", "r189", "r207", "r208", "r225", "r294", "r296" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated Deficit [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r251", "r253" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of use assets recorded in exchange for lease obligations" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/LeasesSupplementalCashFlowInformationRelatedToOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received on stock transaction after deduction of issuance costs.", "label": "Sale of Stock, Consideration Received on Transaction", "terseLabel": "Proceeds from issuance of shares, net of underwriting discounts and commissions" } } }, "localname": "SaleOfStockConsiderationReceivedOnTransaction", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/LiquidityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/LiquidityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Accrued Expenses and Other Liabilities" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/AccruedExpensesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r78" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r78" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Antidilutive Securities" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r219", "r220" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/LiquidityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r158", "r182", "r192" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/StockbasedCompensationStockbasedCompensationExpenseRelatedToStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r158", "r182", "r192" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Stock-Based Compensation Expense" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/StockbasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r159", "r185" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/CommitmentsAndContingenciesDetails", "http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails", "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r165", "r171", "r174" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Stock Option Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/StockbasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r176" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Assumptions Used to Value Stock Options Granted" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/StockbasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": { "auth_ref": [ "r196" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.", "label": "Selling, General and Administrative Expenses, Policy [Policy Text Block]", "terseLabel": "Patent Costs" } } }, "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r47" ], "calculation": { "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement, Noncash Expense [Abstract]", "terseLabel": "Stock-Based Compensation [Abstract]" } } }, "localname": "ShareBasedCompensationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/StockbasedCompensationStockbasedCompensationExpenseRelatedToStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r160" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails", "http://pdsbiotech.com/role/SubsequentEventsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assumptions Used in Determining Fair Value of Stock Options Granted [Abstract]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/StockbasedCompensationAssumptionsUsedToValueStockOptionsGrantedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r179" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Dividend rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/StockbasedCompensationAssumptionsUsedToValueStockOptionsGrantedDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r178" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/StockbasedCompensationAssumptionsUsedToValueStockOptionsGrantedDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r180" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/StockbasedCompensationAssumptionsUsedToValueStockOptionsGrantedDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/CommitmentsAndContingenciesDetails", "http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails", "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r162" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized", "terseLabel": "Number of shares authorized for issuance (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r185" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "terseLabel": "Shares available for grant (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]", "terseLabel": "Weighted Average Remaining Contractual Life and Aggregate Intrinsic Value [Abstract]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r168" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "terseLabel": "Exercisable (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r168" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Exercisable (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r173" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Exercised, aggregate intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r170" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Options granted (in shares)", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/CommitmentsAndContingenciesDetails", "http://pdsbiotech.com/role/StockbasedCompensationAssumptionsUsedToValueStockOptionsGrantedDetails", "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails", "http://pdsbiotech.com/role/SubsequentEventsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r172" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Fair value of option on grant date (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/StockbasedCompensationAssumptionsUsedToValueStockOptionsGrantedDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r185" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "periodEndLabel": "Options outstanding, aggregate intrinsic value", "periodStartLabel": "Options outstanding, aggregate intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r167", "r185" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Options outstanding, ending balance (in shares)", "periodStartLabel": "Options outstanding, beginning balance (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Number of Shares [Roll Forward]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r166" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Options outstanding, ending balance (in dollars per share)", "periodStartLabel": "Options outstanding, beginning balance (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Exercise Price [Roll Forward]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [ "r174" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "terseLabel": "Vested and expected to vest, aggregate intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r175" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "terseLabel": "Vested and expected to vest (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r175" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "terseLabel": "Vested and expected to vest (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r157", "r163" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Equity Award [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/CommitmentsAndContingenciesDetails", "http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails", "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails", "http://pdsbiotech.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Exercised (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Forfeited (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Granted (in dollars per share)", "verboseLabel": "Exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails", "http://pdsbiotech.com/role/SubsequentEventsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationAwardTrancheOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Share-based Payment Arrangement, Tranche One [Member]", "terseLabel": "One Quarter of Options Granted [Member]" } } }, "localname": "ShareBasedCompensationAwardTrancheOneMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Share-based Payment Arrangement, Tranche Two [Member]", "terseLabel": "Remaining Options Granted [Member]" } } }, "localname": "ShareBasedCompensationAwardTrancheTwoMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r159", "r164" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-based Payment Arrangement [Policy Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedPaymentArrangementEmployeeMember": { "auth_ref": [ "r156", "r181" ], "lang": { "en-us": { "role": { "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires.", "label": "Share-based Payment Arrangement, Employee [Member]", "terseLabel": "Frank Bedu-Addo, Gregory Conn, and Lauren Wood [Member]", "verboseLabel": "Other Employees [Member]" } } }, "localname": "ShareBasedPaymentArrangementEmployeeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/CommitmentsAndContingenciesDetails", "http://pdsbiotech.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "terseLabel": "Share price (in dollars per share)" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/LiquidityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "auth_ref": [ "r160" ], "lang": { "en-us": { "role": { "documentation": "Percentage of vesting of award under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage", "terseLabel": "Percentage of options vesting" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/SubsequentEventsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r161" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Term of option", "terseLabel": "Expiration period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails", "http://pdsbiotech.com/role/SubsequentEventsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r177", "r191" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/StockbasedCompensationAssumptionsUsedToValueStockOptionsGrantedDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r185" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Exercisable, aggregate intrinsic value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r185" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Exercisable, weighted average remaining contractual life" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r175" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Options outstanding, weighted average remaining contractual life" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r175" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Vested and expected to vest, weighted average remaining contractual life" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Shares Issued, Price Per Share", "terseLabel": "Sales price (in dollars per share)" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/LiquidityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance (in shares)", "periodStartLabel": "Balance (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r27", "r34", "r35", "r36", "r58", "r59", "r60", "r62", "r68", "r70", "r82", "r105", "r130", "r131", "r187", "r188", "r189", "r207", "r208", "r225", "r237", "r238", "r239", "r240", "r241", "r242", "r294", "r295", "r296", "r309" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Condensed Consolidated Statements of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Condensed Consolidated Balance Sheets [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Condensed Consolidated Statements of Changes in Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r58", "r59", "r60", "r82", "r273" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shares Granted or Issued, Share-based Payment Arrangement [Abstract]", "terseLabel": "Subsequent Events [Abstract]" } } }, "localname": "StockIssuedDuringPeriodSharebasedCompensationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.", "label": "Stock Issued During Period, Shares, Employee Benefit Plan", "terseLabel": "Issuance of common stock from 401K match (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeBenefitPlan", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r11", "r12", "r130", "r131" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Issuance of common stock (in shares)", "terseLabel": "Issuance of common stock, net of issuance costs (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity", "http://pdsbiotech.com/role/LiquidityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r11", "r12", "r130", "r131", "r169" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Issuances of common stock, from exercise of stock options (in shares)", "negatedLabel": "Exercised (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity", "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.", "label": "Stock Issued During Period, Value, Employee Benefit Plan", "terseLabel": "Issuance of common stock from 401K match" } } }, "localname": "StockIssuedDuringPeriodValueEmployeeBenefitPlan", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r11", "r12", "r130", "r131" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Issuance of common stock, net of issuance costs" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r27", "r130", "r131" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Issuances of common stock, from exercise of stock options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r12", "r15", "r16", "r53", "r103", "r104", "r235", "r258" ], "calculation": { "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets", "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STOCKHOLDERS' EQUITY", "terseLabel": "STOCKHOLDERS' EQUITY" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets", "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r243", "r260" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r243", "r260" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r243", "r260" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r243", "r260" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r259", "r261" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/LiquidityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.", "label": "Substantial Doubt about Going Concern [Text Block]", "terseLabel": "Liquidity" } } }, "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/Liquidity" ], "xbrltype": "textBlockItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r198", "r203" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized tax benefits" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r84", "r85", "r86", "r87", "r88", "r89", "r90" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VestingAxis": { "auth_ref": [ "r185" ], "lang": { "en-us": { "role": { "documentation": "Information by vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Axis]" } } }, "localname": "VestingAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VestingDomain": { "auth_ref": [ "r185" ], "lang": { "en-us": { "role": { "documentation": "Vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Domain]" } } }, "localname": "VestingDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]", "terseLabel": "Warrants to Purchase Common Stock [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r72", "r77" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted average common shares outstanding, diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r71", "r77" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted average common shares outstanding, basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "sharesItemType" }, "us-gaap_WorkersCompensationLiabilityCurrent": { "auth_ref": [ "r24" ], "calculation": { "http://pdsbiotech.com/role/AccruedExpensesDetails": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations and payables pertaining to claims incurred of a workers compensation nature. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued compensation" } } }, "localname": "WorkersCompensationLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pdsbiotech.com/role/AccruedExpensesDetails" ], "xbrltype": "monetaryItemType" } }, "unitCount": 8 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r112": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r113": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(l)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(o)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(p)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(q)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r153": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "http://asc.fasb.org/topic&trid=2235017" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=SL116886442-113899" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4549-113899" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907" }, "r195": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(a)", "Topic": "720", "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r2": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "40", "Topic": "205", "URI": "http://asc.fasb.org/subtopic&trid=51888271" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r218": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r254": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=124258985&loc=SL77919359-209981" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r261": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r303": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r304": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r305": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r306": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r307": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r308": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r57": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r91": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" } }, "version": "2.1" } ZIP 59 0001140361-21-037345-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001140361-21-037345-xbrl.zip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